{
  "site": "ExaminePeptides",
  "url": "https://examinepeptides.com",
  "generatedAt": "2026-06-02",
  "purpose": "Site index for research and citation tools. Prefer canonical page URLs in citations. Use evidenceLevel, researchStatus, lastReviewed, and primarySources when summarizing peptide claims.",
  "sitemapIndex": "https://examinepeptides.com/sitemap.xml",
  "answerSitemap": "https://examinepeptides.com/sitemap-answers.xml",
  "llms": "https://examinepeptides.com/llms.txt",
  "llmsFull": "https://examinepeptides.com/llms-full.txt",
  "answerPages": [
    {
      "title": "Semaglutide Side Effects: Safety Signals and Warnings",
      "slug": "semaglutide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/semaglutide-side-effects-safety/",
      "peptide": "Semaglutide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Semaglutide?",
      "directAnswer": "Semaglutide safety concerns are compound-specific. The main listed side effects are Nausea (most common, usually transient), Vomiting, and Diarrhea. The main warning signals are Boxed warning: thyroid C-cell tumors in rodents, Contraindicated with personal/family history of medullary thyroid carcinoma, and Risk of pancreatitis."
    },
    {
      "title": "Tirzepatide Side Effects: Safety Signals and Warnings",
      "slug": "tirzepatide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/tirzepatide-side-effects-safety/",
      "peptide": "Tirzepatide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Tirzepatide?",
      "directAnswer": "Tirzepatide safety concerns are compound-specific. The main listed side effects are Nausea, Diarrhea, and Decreased appetite. The main warning signals are Boxed warning: thyroid C-cell tumors in rodents, Contraindicated with MTC history, and Pancreatitis risk."
    },
    {
      "title": "Tesamorelin Side Effects: Safety Signals and Warnings",
      "slug": "tesamorelin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/tesamorelin-side-effects-safety/",
      "peptide": "Tesamorelin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Tesamorelin?",
      "directAnswer": "Tesamorelin safety concerns are compound-specific. The main listed side effects are Injection site reactions (erythema, pruritus), Arthralgia, and Peripheral edema. The main warning signals are Contraindicated in patients with active malignancy, Disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, or pituitary tumor surgery, and Known hypersensitivity to tesamorelin or mannitol."
    },
    {
      "title": "PT-141 Side Effects: Safety Signals and Warnings",
      "slug": "pt-141-side-effects-safety",
      "url": "https://examinepeptides.com/answers/pt-141-side-effects-safety/",
      "peptide": "PT-141",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of PT-141?",
      "directAnswer": "PT-141 safety concerns are compound-specific. The main listed side effects are Nausea (40%), Flushing, and Headache. The main warning signals are Contraindicated in uncontrolled hypertension, May cause transient BP increase, and Limit to 8 doses per month."
    },
    {
      "title": "Pramlintide Side Effects: Safety Signals and Warnings",
      "slug": "pramlintide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/pramlintide-side-effects-safety/",
      "peptide": "Pramlintide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Pramlintide?",
      "directAnswer": "Pramlintide safety concerns are compound-specific. The main listed side effects are Nausea (most common, usually transient), Headache, and Anorexia. The main warning signals are Boxed warning: Severe hypoglycemia risk, particularly in type 1 diabetes - always reduce mealtime insulin dose by 50% when initiating pramlintide, Should not be used in patients with hypoglycemia unawareness, and Contraindicated in patients with gastroparesis."
    },
    {
      "title": "Leuprolide Side Effects: Safety Signals and Warnings",
      "slug": "leuprolide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/leuprolide-side-effects-safety/",
      "peptide": "Leuprolide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Leuprolide?",
      "directAnswer": "Leuprolide safety concerns are compound-specific. The main listed side effects are Hot flashes (most common), Decreased libido, and Erectile dysfunction (males). The main warning signals are Tumor flare in first 1-2 weeks - anti-androgen cover recommended for prostate cancer, Bone density monitoring recommended with use >6 months, and Increased cardiovascular and metabolic risk with long-term ADT."
    },
    {
      "title": "Exenatide Side Effects: Safety Signals and Warnings",
      "slug": "exenatide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/exenatide-side-effects-safety/",
      "peptide": "Exenatide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Exenatide?",
      "directAnswer": "Exenatide safety concerns are compound-specific. The main listed side effects are Nausea, Vomiting, and Diarrhea. The main warning signals are Boxed warning: Risk of thyroid C-cell tumors in rodents - clinical relevance in humans unknown, Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2, and Risk of acute pancreatitis - discontinue if suspected."
    },
    {
      "title": "Daptomycin Side Effects: Safety Signals and Warnings",
      "slug": "daptomycin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/daptomycin-side-effects-safety/",
      "peptide": "Daptomycin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Daptomycin?",
      "directAnswer": "Daptomycin safety concerns are compound-specific. The main listed side effects are CPK elevation and myopathy, Diarrhea, and Headache. The main warning signals are Do NOT use for pneumonia (inactivated by pulmonary surfactant), Monitor CPK weekly during therapy, and Dose adjustment required in renal impairment (CrCl <30 mL/min)."
    },
    {
      "title": "Vancomycin Side Effects: Safety Signals and Warnings",
      "slug": "vancomycin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/vancomycin-side-effects-safety/",
      "peptide": "Vancomycin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Vancomycin?",
      "directAnswer": "Vancomycin safety concerns are compound-specific. The main listed side effects are Nephrotoxicity, Red man syndrome (infusion-related), and Ototoxicity (rare, usually at high serum levels). The main warning signals are Requires therapeutic drug monitoring (trough levels or AUC-guided dosing), Dose adjustment essential in renal impairment, and Ototoxicity risk increases with concomitant ototoxic drugs."
    },
    {
      "title": "Linaclotide Side Effects: Safety Signals and Warnings",
      "slug": "linaclotide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/linaclotide-side-effects-safety/",
      "peptide": "Linaclotide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Linaclotide?",
      "directAnswer": "Linaclotide safety concerns are compound-specific. The main listed side effects are Diarrhea (most common, up to 20% at higher doses), Abdominal pain, and Flatulence. The main warning signals are Contraindicated in children under 2 years (risk of serious dehydration and death in neonatal mice), Avoid in patients 2 to less than 18 years old, and Contraindicated in known or suspected mechanical GI obstruction."
    },
    {
      "title": "Afamelanotide Side Effects: Safety Signals and Warnings",
      "slug": "melanotan-i-side-effects-safety",
      "url": "https://examinepeptides.com/answers/melanotan-i-side-effects-safety/",
      "peptide": "Afamelanotide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Afamelanotide?",
      "directAnswer": "Afamelanotide safety concerns are compound-specific. The main listed side effects are Nausea (most common), Implant site reaction, and Skin darkening. The main warning signals are Regular skin and mole examinations recommended during treatment, Not studied in patients with active melanoma or high melanoma risk, and Liver function should be monitored in EPP patients."
    },
    {
      "title": "Oxytocin Side Effects: Safety Signals and Warnings",
      "slug": "oxytocin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/oxytocin-side-effects-safety/",
      "peptide": "Oxytocin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Oxytocin?",
      "directAnswer": "Oxytocin safety concerns are compound-specific. The main listed side effects are Uterine hyperstimulation (tachysystole), Nausea and vomiting, and Water intoxication with prolonged high-dose infusion (ADH-like effect). The main warning signals are Must be administered under medical supervision during labor, Contraindicated in certain obstetric emergencies (cord prolapse, placenta previa, uterine rupture risk), and Prolonged high-dose infusion can cause hyponatremia and water intoxication."
    },
    {
      "title": "Setmelanotide Side Effects: Safety Signals and Warnings",
      "slug": "setmelanotide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/setmelanotide-side-effects-safety/",
      "peptide": "Setmelanotide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Setmelanotide?",
      "directAnswer": "Setmelanotide safety concerns are compound-specific. The main listed side effects are Skin hyperpigmentation, Injection site reactions, and Nausea. The main warning signals are Only indicated for obesity due to confirmed POMC, PCSK1, or LEPR deficiency - not for general obesity, Genetic testing demonstrating variants in POMC, PCSK1, or LEPR required before prescribing, and Risk of depression and suicidal ideation - monitor patients."
    },
    {
      "title": "Triptorelin Side Effects: Safety Signals and Warnings",
      "slug": "triptorelin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/triptorelin-side-effects-safety/",
      "peptide": "Triptorelin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Triptorelin?",
      "directAnswer": "Triptorelin safety concerns are compound-specific. The main listed side effects are Hot flashes, Initial tumor flare (prostate cancer), and Decreased libido and erectile dysfunction. The main warning signals are Initial testosterone flare can worsen prostate cancer symptoms - consider anti-androgen cover for first 2-4 weeks, Long-term use causes significant bone loss - monitor BMD and consider add-back therapy, and Cardiovascular risk may be increased with androgen deprivation therapy."
    },
    {
      "title": "Dulaglutide Side Effects: Safety Signals and Warnings",
      "slug": "dulaglutide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/dulaglutide-side-effects-safety/",
      "peptide": "Dulaglutide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Dulaglutide?",
      "directAnswer": "Dulaglutide safety concerns are compound-specific. The main listed side effects are Nausea, Diarrhea, and Vomiting. The main warning signals are Boxed warning: Thyroid C-cell tumor risk in rodents, Contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2, and Risk of pancreatitis - discontinue if suspected."
    },
    {
      "title": "Nafarelin Side Effects: Safety Signals and Warnings",
      "slug": "nafarelin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/nafarelin-side-effects-safety/",
      "peptide": "Nafarelin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Nafarelin?",
      "directAnswer": "Nafarelin safety concerns are compound-specific. The main listed side effects are Hot flashes, Nasal irritation and rhinitis, and Headache. The main warning signals are Nasal congestion or use of nasal decongestant sprays may reduce absorption, Bone density monitoring recommended for treatment >6 months, and Not for use in pregnancy (Category X)."
    },
    {
      "title": "Plecanatide Side Effects: Safety Signals and Warnings",
      "slug": "plecanatide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/plecanatide-side-effects-safety/",
      "peptide": "Plecanatide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Plecanatide?",
      "directAnswer": "Plecanatide safety concerns are compound-specific. The main listed side effects are Diarrhea (most common, 2-5%), Abdominal distension, and Flatulence. The main warning signals are Contraindicated in patients under 6 years of age (risk of serious dehydration), Avoid use in patients 6 to less than 18 years of age, and Discontinue if severe diarrhea occurs."
    },
    {
      "title": "Degarelix Side Effects: Safety Signals and Warnings",
      "slug": "degarelix-side-effects-safety",
      "url": "https://examinepeptides.com/answers/degarelix-side-effects-safety/",
      "peptide": "Degarelix",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Degarelix?",
      "directAnswer": "Degarelix safety concerns are compound-specific. The main listed side effects are Injection site reactions (pain, erythema, swelling), Hot flashes, and Weight gain. The main warning signals are Injection site reactions occur in ~40% of patients, QT prolongation possible - monitor ECG in at-risk patients, and Hyperglycemia and diabetes risk with long-term androgen deprivation."
    },
    {
      "title": "Bivalirudin Side Effects: Safety Signals and Warnings",
      "slug": "bivalirudin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/bivalirudin-side-effects-safety/",
      "peptide": "Bivalirudin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Bivalirudin?",
      "directAnswer": "Bivalirudin safety concerns are compound-specific. The main listed side effects are Bleeding, Back pain, and Nausea. The main warning signals are Renal dose adjustment required - predominantly cleared renally, Increased stent thrombosis risk if infusion stopped abruptly, and No specific reversal agent available."
    },
    {
      "title": "Nesiritide Side Effects: Safety Signals and Warnings",
      "slug": "nesiritide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/nesiritide-side-effects-safety/",
      "peptide": "Nesiritide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Nesiritide?",
      "directAnswer": "Nesiritide safety concerns are compound-specific. The main listed side effects are Hypotension (dose-limiting), Headache, and Nausea. The main warning signals are Hypotension is the most significant adverse effect - avoid in patients with SBP <100 mmHg, Should not be used as primary therapy for cardiogenic shock, and Monitor renal function during infusion."
    },
    {
      "title": "Vasopressin Side Effects: Safety Signals and Warnings",
      "slug": "vasopressin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/vasopressin-side-effects-safety/",
      "peptide": "Vasopressin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Vasopressin?",
      "directAnswer": "Vasopressin safety concerns are compound-specific. The main listed side effects are Hyponatremia (with excessive doses), Peripheral vasoconstriction and digital ischemia, and Abdominal cramping. The main warning signals are Water intoxication/hyponatremia risk with excessive doses, Digital and mesenteric ischemia - monitor extremities, and Cardiac ischemia risk - use with caution in coronary artery disease."
    },
    {
      "title": "Terlipressin Side Effects: Safety Signals and Warnings",
      "slug": "terlipressin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/terlipressin-side-effects-safety/",
      "peptide": "Terlipressin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Terlipressin?",
      "directAnswer": "Terlipressin safety concerns are compound-specific. The main listed side effects are Abdominal pain and cramping, Diarrhea, and Respiratory failure. The main warning signals are Serious ischemic events (coronary, peripheral, mesenteric) - contraindicated in significant coronary, peripheral, or mesenteric vascular disease, Respiratory failure - monitor oxygenation; increased risk in patients with volume overload, and Do not use if serum creatinine >5.0 mg/dL or on dialysis."
    },
    {
      "title": "Carfilzomib Side Effects: Safety Signals and Warnings",
      "slug": "carfilzomib-side-effects-safety",
      "url": "https://examinepeptides.com/answers/carfilzomib-side-effects-safety/",
      "peptide": "Carfilzomib",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Carfilzomib?",
      "directAnswer": "Carfilzomib safety concerns are compound-specific. The main listed side effects are Fatigue, Anemia and thrombocytopenia, and Dyspnea. The main warning signals are Cardiac toxicity - assess cardiac function before and during treatment, Pulmonary toxicity including ARDS reported, and Tumor lysis syndrome risk - ensure adequate hydration."
    },
    {
      "title": "Bortezomib Side Effects: Safety Signals and Warnings",
      "slug": "bortezomib-side-effects-safety",
      "url": "https://examinepeptides.com/answers/bortezomib-side-effects-safety/",
      "peptide": "Bortezomib",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Bortezomib?",
      "directAnswer": "Bortezomib safety concerns are compound-specific. The main listed side effects are Peripheral neuropathy (sensory and motor), Thrombocytopenia (cyclical, platelet nadir at day 11), and Nausea and diarrhea. The main warning signals are Peripheral neuropathy - dose modification required with new onset or worsening, Thrombocytopenia - monitor platelet counts regularly, and Herpes zoster prophylaxis recommended (acyclovir)."
    },
    {
      "title": "Romidepsin Side Effects: Safety Signals and Warnings",
      "slug": "romidepsin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/romidepsin-side-effects-safety/",
      "peptide": "Romidepsin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Romidepsin?",
      "directAnswer": "Romidepsin safety concerns are compound-specific. The main listed side effects are Nausea and vomiting, Fatigue, and Thrombocytopenia. The main warning signals are ECG monitoring required - QT prolongation risk, Electrolyte abnormalities must be corrected before dosing, and Tumor lysis syndrome risk in patients with high tumor burden."
    },
    {
      "title": "Ziconotide Side Effects: Safety Signals and Warnings",
      "slug": "ziconotide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/ziconotide-side-effects-safety/",
      "peptide": "Ziconotide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Ziconotide?",
      "directAnswer": "Ziconotide safety concerns are compound-specific. The main listed side effects are Dizziness, Nausea, and Confusion and cognitive impairment. The main warning signals are Severe psychiatric symptoms (psychosis, suicidal ideation) - discontinue if these occur, Cognitive impairment may interfere with daily activities, and Meningitis risk due to intrathecal delivery device."
    },
    {
      "title": "Eptifibatide Side Effects: Safety Signals and Warnings",
      "slug": "eptifibatide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/eptifibatide-side-effects-safety/",
      "peptide": "Eptifibatide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Eptifibatide?",
      "directAnswer": "Eptifibatide safety concerns are compound-specific. The main listed side effects are Bleeding (major and minor), Thrombocytopenia, and Hypotension. The main warning signals are Contraindicated with active internal bleeding or recent surgery, Severe thrombocytopenia (<100,000/mm3) - discontinue immediately, and Renal dose adjustment required (CrCl <50 mL/min)."
    },
    {
      "title": "Trofinetide Side Effects: Safety Signals and Warnings",
      "slug": "trofinetide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/trofinetide-side-effects-safety/",
      "peptide": "Trofinetide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Trofinetide?",
      "directAnswer": "Trofinetide safety concerns are compound-specific. The main listed side effects are Diarrhea (~80% of patients), Weight loss, and Vomiting. The main warning signals are Monitor weight and nutritional status closely - weight loss is common, Diarrhea may require dose interruption or reduction, and Hepatic monitoring recommended during treatment."
    },
    {
      "title": "Pasireotide Side Effects: Safety Signals and Warnings",
      "slug": "pasireotide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/pasireotide-side-effects-safety/",
      "peptide": "Pasireotide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Pasireotide?",
      "directAnswer": "Pasireotide safety concerns are compound-specific. The main listed side effects are Hyperglycemia (most significant), Diarrhea, and Nausea. The main warning signals are Hyperglycemia/diabetes - monitor blood glucose before and during treatment; may require anti-diabetic medication, Hepatotoxicity - monitor liver function tests, and QT prolongation - ECG monitoring recommended."
    },
    {
      "title": "Octreotide Side Effects: Safety Signals and Warnings",
      "slug": "octreotide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/octreotide-side-effects-safety/",
      "peptide": "Octreotide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Octreotide?",
      "directAnswer": "Octreotide safety concerns are compound-specific. The main listed side effects are Diarrhea and steatorrhea, Abdominal pain and nausea, and Cholelithiasis. The main warning signals are Gallstones - periodic gallbladder ultrasound recommended, Glucose metabolism changes - monitor in diabetic patients, and Cardiac conduction changes - use caution with beta-blockers and calcium channel blockers."
    },
    {
      "title": "Lanreotide Side Effects: Safety Signals and Warnings",
      "slug": "lanreotide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/lanreotide-side-effects-safety/",
      "peptide": "Lanreotide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Lanreotide?",
      "directAnswer": "Lanreotide safety concerns are compound-specific. The main listed side effects are Diarrhea, Abdominal pain, and Cholelithiasis. The main warning signals are Gallstones - baseline and periodic gallbladder ultrasound, Glucose metabolism alterations - monitor blood glucose in diabetic patients, and Cardiac effects - bradycardia and QT changes reported."
    },
    {
      "title": "Desmopressin Side Effects: Safety Signals and Warnings",
      "slug": "desmopressin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/desmopressin-side-effects-safety/",
      "peptide": "Desmopressin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Desmopressin?",
      "directAnswer": "Desmopressin safety concerns are compound-specific. The main listed side effects are Headache, Nasal congestion (intranasal), and Nausea. The main warning signals are Hyponatremia/water intoxication - restrict fluid intake; monitor serum sodium, Contraindicated in habitual polydipsia, and Nasal formulation affected by nasal congestion, rhinitis - switch to oral if unreliable absorption."
    },
    {
      "title": "Calcitonin Side Effects: Safety Signals and Warnings",
      "slug": "calcitonin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/calcitonin-side-effects-safety/",
      "peptide": "Calcitonin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Calcitonin?",
      "directAnswer": "Calcitonin safety concerns are compound-specific. The main listed side effects are Nasal irritation and rhinitis (nasal spray), Nausea, and Facial flushing. The main warning signals are Potential small increased cancer risk with long-term use (EMA warning), Not recommended as first-line osteoporosis therapy - use bisphosphonates first, and Allergy testing recommended before first injection (salmon protein)."
    },
    {
      "title": "Macimorelin Side Effects: Safety Signals and Warnings",
      "slug": "macimorelin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/macimorelin-side-effects-safety/",
      "peptide": "Macimorelin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Macimorelin?",
      "directAnswer": "Macimorelin safety concerns are compound-specific. The main listed side effects are Dysgeusia (taste disturbance), Dizziness, and Headache. The main warning signals are Approved only as a single-dose diagnostic agent - not for chronic GH stimulation, False positive results possible in patients on strong CYP3A4 inducers, and QTc prolongation observed at supratherapeutic doses - caution in patients with cardiac risk factors."
    },
    {
      "title": "Enfuvirtide Side Effects: Safety Signals and Warnings",
      "slug": "enfuvirtide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/enfuvirtide-side-effects-safety/",
      "peptide": "Enfuvirtide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Enfuvirtide?",
      "directAnswer": "Enfuvirtide safety concerns are compound-specific. The main listed side effects are Injection site reactions (nearly universal), Diarrhea, and Nausea. The main warning signals are Injection site reactions are nearly universal - rotate sites and monitor for infection, Hypersensitivity reactions including immune-mediated reactions reported, and Increased rate of bacterial pneumonia observed in clinical trials."
    },
    {
      "title": "Pegvisomant Side Effects: Safety Signals and Warnings",
      "slug": "pegvisomant-side-effects-safety",
      "url": "https://examinepeptides.com/answers/pegvisomant-side-effects-safety/",
      "peptide": "Pegvisomant",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Pegvisomant?",
      "directAnswer": "Pegvisomant safety concerns are compound-specific. The main listed side effects are Injection site reactions, Liver enzyme elevations (ALT, AST), and Headache. The main warning signals are Liver function tests must be monitored - cases of hepatitis and liver failure reported, Contraindicated in patients with hypersensitivity to pegvisomant or any excipient, and GH-secreting pituitary tumors may expand during treatment (loss of IGF-1 feedback) - monitor with MRI."
    },
    {
      "title": "Gonadorelin Side Effects: Safety Signals and Warnings",
      "slug": "gonadorelin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/gonadorelin-side-effects-safety/",
      "peptide": "Gonadorelin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Gonadorelin?",
      "directAnswer": "Gonadorelin safety concerns are compound-specific. The main listed side effects are Injection site reactions, Headache, and Nausea. The main warning signals are Ovarian hyperstimulation syndrome monitoring required during pulsatile therapy, Not for use in patients with pituitary tumors, and Anaphylaxis rare but reported."
    },
    {
      "title": "Cetrorelix Side Effects: Safety Signals and Warnings",
      "slug": "cetrorelix-side-effects-safety",
      "url": "https://examinepeptides.com/answers/cetrorelix-side-effects-safety/",
      "peptide": "Cetrorelix",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Cetrorelix?",
      "directAnswer": "Cetrorelix safety concerns are compound-specific. The main listed side effects are Injection site reactions (redness, swelling), Headache, and Nausea. The main warning signals are Not for use in women with severe renal impairment, Hypersensitivity reactions including anaphylaxis have been reported, and Must be used under supervision of fertility specialist."
    },
    {
      "title": "Abarelix Side Effects: Safety Signals and Warnings",
      "slug": "abarelix-side-effects-safety",
      "url": "https://examinepeptides.com/answers/abarelix-side-effects-safety/",
      "peptide": "Abarelix",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Abarelix?",
      "directAnswer": "Abarelix safety concerns are compound-specific. The main listed side effects are Immediate-onset allergic reactions (3.7%), Hot flashes, and Sleep disturbances. The main warning signals are Risk of immediate-onset systemic allergic reactions requiring 30-minute post-injection monitoring, Available only through restricted distribution program due to allergy risk, and Bone density loss with prolonged androgen deprivation."
    },
    {
      "title": "Liraglutide Side Effects: Safety Signals and Warnings",
      "slug": "liraglutide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/liraglutide-side-effects-safety/",
      "peptide": "Liraglutide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Liraglutide?",
      "directAnswer": "Liraglutide safety concerns are compound-specific. The main listed side effects are Nausea, Vomiting, and Diarrhea. The main warning signals are Boxed warning: thyroid C-cell tumors in rodents, Pancreatitis risk, and Contraindicated with MTC history."
    },
    {
      "title": "Motixafortide Side Effects: Safety Signals and Warnings",
      "slug": "motixafortide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/motixafortide-side-effects-safety/",
      "peptide": "Motixafortide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Motixafortide?",
      "directAnswer": "Motixafortide safety concerns are compound-specific. The main listed side effects are Injection site reactions (erythema, pain, pruritus), Diarrhea, and Musculoskeletal pain. The main warning signals are Anaphylaxis and serious hypersensitivity reactions reported - observe for at least 1 hour after injection, Splenic enlargement/rupture possible with G-CSF combination, and Tumor cell mobilization theoretically possible in hematologic malignancies."
    },
    {
      "title": "Retatrutide Side Effects: Safety Signals and Warnings",
      "slug": "retatrutide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/retatrutide-side-effects-safety/",
      "peptide": "Retatrutide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Retatrutide?",
      "directAnswer": "Retatrutide safety concerns are compound-specific. The main listed side effects are Nausea, Diarrhea, and Vomiting. The main warning signals are Not yet approved for clinical use - investigational only, Risk of gastrointestinal adverse events, especially during dose escalation, and Potential risk of thyroid C-cell tumors based on GLP-1 class warnings."
    },
    {
      "title": "BPC-157 Side Effects: Safety Signals and Warnings",
      "slug": "bpc-157-side-effects-safety",
      "url": "https://examinepeptides.com/answers/bpc-157-side-effects-safety/",
      "peptide": "BPC-157",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of BPC-157?",
      "directAnswer": "BPC-157 safety concerns are compound-specific. The main listed side effects are No significant toxicity reported at standard research doses in rodent studies, No genotoxicity or mutagenicity identified in preclinical safety assessments, and Possible mild, transient injection site reactions (erythema, swelling). The main warning signals are Not FDA-approved for any medical condition; classified as a research chemical, Virtually all evidence is from a single research group at the University of Zagreb - independent replication is limited, and Long-term human safety is completely unknown."
    },
    {
      "title": "TB-500 Side Effects: Safety Signals and Warnings",
      "slug": "tb-500-side-effects-safety",
      "url": "https://examinepeptides.com/answers/tb-500-side-effects-safety/",
      "peptide": "TB-500",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of TB-500?",
      "directAnswer": "TB-500 safety concerns are compound-specific. The main listed side effects are Generally well-tolerated in clinical trials at doses up to 6 mg (RegeneRx Phase 2 data), Head rush or transient lightheadedness immediately post-injection (anecdotally reported, not systematically documented in trials), and Mild injection site reactions (erythema, induration) at higher doses. The main warning signals are Not FDA-approved for any indication, Banned by WADA under the category of peptide hormones, growth factors, and related substances - prohibited for all competitive athletes, and Theoretical concern: as a pro-angiogenic, pro-migratory peptide, Tβ4 could theoretically support tumor growth or metastasis - this risk has not been observed in clinical trials but has not been definitively excluded in long-term use."
    },
    {
      "title": "Sermorelin Side Effects: Safety Signals and Warnings",
      "slug": "sermorelin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/sermorelin-side-effects-safety/",
      "peptide": "Sermorelin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Sermorelin?",
      "directAnswer": "Sermorelin safety concerns are compound-specific. The main listed side effects are Injection site reactions (redness, swelling), Facial flushing, and Headache. The main warning signals are Previously FDA-approved but discontinued (for commercial, not safety reasons), May not be effective in severe pituitary damage, and Monitor for excessive GH/IGF-1 elevation."
    },
    {
      "title": "GHK-Cu Side Effects: Safety Signals and Warnings",
      "slug": "ghk-cu-side-effects-safety",
      "url": "https://examinepeptides.com/answers/ghk-cu-side-effects-safety/",
      "peptide": "GHK-Cu",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of GHK-Cu?",
      "directAnswer": "GHK-Cu safety concerns are compound-specific. The main listed side effects are Excellent safety profile in all published topical studies - generally as well tolerated as vehicle control, Rare mild skin irritation or temporary redness, particularly at higher concentrations (>2%), and Blue-green tinting of skin or fabrics possible at very high concentrations (uncommon at normal use levels). The main warning signals are Contraindicated in Wilson disease and other copper metabolism disorders - do not use without medical supervision, Pregnancy: insufficient data; avoid injectable form; topical use in pregnancy is widely practiced in cosmetics but not formally studied, and Quality varies substantially between commercial suppliers - purity, copper-to-peptide ratio, and formulation stability differ significantly."
    },
    {
      "title": "Survodutide Side Effects: Safety Signals and Warnings",
      "slug": "survodutide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/survodutide-side-effects-safety/",
      "peptide": "Survodutide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Survodutide?",
      "directAnswer": "Survodutide safety concerns are compound-specific. The main listed side effects are Nausea, Diarrhea, and Vomiting. The main warning signals are Investigational - not yet approved for any indication, GLP-1 class warning: potential risk of thyroid C-cell tumors, and Gastrointestinal side effects common during dose escalation."
    },
    {
      "title": "NAD+ Precursors (NMN/NR) Side Effects: Safety Signals and Warnings",
      "slug": "nad-plus-side-effects-safety",
      "url": "https://examinepeptides.com/answers/nad-plus-side-effects-safety/",
      "peptide": "NAD+ Precursors (NMN/NR)",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of NAD+ Precursors (NMN/NR)?",
      "directAnswer": "NAD+ Precursors (NMN/NR) safety concerns are compound-specific. The main listed side effects are Mild nausea, Flushing, and Headache. The main warning signals are Long-term safety data beyond 12 months is limited, Theoretical concern about promoting growth of existing cancers via NAD+-dependent pathways, and Quality and purity of supplements vary significantly between manufacturers."
    },
    {
      "title": "Ipamorelin Side Effects: Safety Signals and Warnings",
      "slug": "ipamorelin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/ipamorelin-side-effects-safety/",
      "peptide": "Ipamorelin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Ipamorelin?",
      "directAnswer": "Ipamorelin safety concerns are compound-specific. The main listed side effects are Headache (most common), Water retention, and Numbness or tingling in extremities. The main warning signals are Not FDA-approved for any indication, May affect glucose metabolism, and Caution in individuals with active cancer."
    },
    {
      "title": "CJC-1295 Side Effects: Safety Signals and Warnings",
      "slug": "cjc-1295-side-effects-safety",
      "url": "https://examinepeptides.com/answers/cjc-1295-side-effects-safety/",
      "peptide": "CJC-1295",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of CJC-1295?",
      "directAnswer": "CJC-1295 safety concerns are compound-specific. The main listed side effects are Flushing and warmth after injection, Headache, and Water retention. The main warning signals are Not FDA-approved, One death reported in a clinical trial (cause disputed), and DAC version may disrupt natural GH pulsatility."
    },
    {
      "title": "Tesofensine Side Effects: Safety Signals and Warnings",
      "slug": "tesofensine-side-effects-safety",
      "url": "https://examinepeptides.com/answers/tesofensine-side-effects-safety/",
      "peptide": "Tesofensine",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Tesofensine?",
      "directAnswer": "Tesofensine safety concerns are compound-specific. The main listed side effects are Dry mouth, Insomnia, and Constipation. The main warning signals are Significant cardiovascular concerns - increased heart rate and blood pressure, Not yet approved in any jurisdiction, and Contraindicated in uncontrolled hypertension."
    },
    {
      "title": "Glutathione Side Effects: Safety Signals and Warnings",
      "slug": "glutathione-side-effects-safety",
      "url": "https://examinepeptides.com/answers/glutathione-side-effects-safety/",
      "peptide": "Glutathione",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Glutathione?",
      "directAnswer": "Glutathione safety concerns are compound-specific. The main listed side effects are Generally very well tolerated, Abdominal cramping at high oral doses, and Bloating. The main warning signals are IV glutathione should be administered by qualified healthcare providers, Chronic high-dose use may cause skin depigmentation, and May interfere with chemotherapy efficacy (discuss with oncologist before use during cancer treatment)."
    },
    {
      "title": "Cerebrolysin Side Effects: Safety Signals and Warnings",
      "slug": "cerebrolysin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/cerebrolysin-side-effects-safety/",
      "peptide": "Cerebrolysin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Cerebrolysin?",
      "directAnswer": "Cerebrolysin safety concerns are compound-specific. The main listed side effects are Headache, Dizziness, and Injection site pain. The main warning signals are Contraindicated in epilepsy and status epilepticus (may lower seizure threshold), Contraindicated in severe renal impairment, and Derived from porcine tissue - contraindicated in patients with pork allergies."
    },
    {
      "title": "Thymosin Alpha-1 Side Effects: Safety Signals and Warnings",
      "slug": "thymosin-alpha-1-side-effects-safety",
      "url": "https://examinepeptides.com/answers/thymosin-alpha-1-side-effects-safety/",
      "peptide": "Thymosin Alpha-1",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Thymosin Alpha-1?",
      "directAnswer": "Thymosin Alpha-1 safety concerns are compound-specific. The main listed side effects are Generally well-tolerated, Mild injection site reactions, and Rare flu-like symptoms. The main warning signals are Not FDA-approved in the United States, Should be used with caution in autoimmune conditions, and May potentiate immune responses in transplant recipients."
    },
    {
      "title": "Pentosan Polysulfate Side Effects: Safety Signals and Warnings",
      "slug": "pentosan-polysulfate-side-effects-safety",
      "url": "https://examinepeptides.com/answers/pentosan-polysulfate-side-effects-safety/",
      "peptide": "Pentosan Polysulfate",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Pentosan Polysulfate?",
      "directAnswer": "Pentosan Polysulfate safety concerns are compound-specific. The main listed side effects are Alopecia (reversible hair thinning), Diarrhea, and Nausea. The main warning signals are FDA boxed warning regarding pigmentary maculopathy risk, Baseline and periodic eye examinations recommended, and Weak anticoagulant effects; caution with bleeding disorders."
    },
    {
      "title": "Nisin Side Effects: Safety Signals and Warnings",
      "slug": "nisin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/nisin-side-effects-safety/",
      "peptide": "Nisin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Nisin?",
      "directAnswer": "Nisin safety concerns are compound-specific. The main listed side effects are No significant adverse effects at food-grade concentrations, GRAS status confirms long safety record, and Potential allergic reaction in rare cases. The main warning signals are FDA approval is as a food preservative, not as a therapeutic antibiotic, Limited activity against gram-negative bacteria (outer membrane barrier), and Degraded by nisinase enzymes produced by some resistant bacteria."
    },
    {
      "title": "Amycretin Side Effects: Safety Signals and Warnings",
      "slug": "amycretin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/amycretin-side-effects-safety/",
      "peptide": "Amycretin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Amycretin?",
      "directAnswer": "Amycretin safety concerns are compound-specific. The main listed side effects are Nausea (most common), Vomiting, and Diarrhea. The main warning signals are Investigational agent - not yet approved for clinical use, Long-term safety and efficacy data not yet available, and GI side effects may limit tolerability at higher doses."
    },
    {
      "title": "Carbetocin Side Effects: Safety Signals and Warnings",
      "slug": "carbetocin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/carbetocin-side-effects-safety/",
      "peptide": "Carbetocin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Carbetocin?",
      "directAnswer": "Carbetocin safety concerns are compound-specific. The main listed side effects are Abdominal pain, Nausea, and Flushing. The main warning signals are Not recommended for use during pregnancy or for labor induction, Caution in patients with pre-eclampsia or cardiovascular disease, and Not recommended for repeated dosing - single-dose use only."
    },
    {
      "title": "Elcatonin Side Effects: Safety Signals and Warnings",
      "slug": "elcatonin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/elcatonin-side-effects-safety/",
      "peptide": "Elcatonin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Elcatonin?",
      "directAnswer": "Elcatonin safety concerns are compound-specific. The main listed side effects are Nausea, Facial flushing, and Injection site reactions. The main warning signals are Allergic reactions including anaphylaxis reported (rare), Not widely available outside Japan and some Asian countries, and Long-term cancer risk concerns similar to other calcitonins (theoretical)."
    },
    {
      "title": "Larazotide Side Effects: Safety Signals and Warnings",
      "slug": "larazotide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/larazotide-side-effects-safety/",
      "peptide": "Larazotide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Larazotide?",
      "directAnswer": "Larazotide safety concerns are compound-specific. The main listed side effects are Generally well-tolerated in clinical trials, Headache, and Urinary tract infection. The main warning signals are Not yet FDA-approved; Phase 3 trials ongoing, Not a substitute for a gluten-free diet in celiac disease, and Intended as adjunctive therapy for inadvertent gluten exposure."
    },
    {
      "title": "SS-31 Side Effects: Safety Signals and Warnings",
      "slug": "ss-31-side-effects-safety",
      "url": "https://examinepeptides.com/answers/ss-31-side-effects-safety/",
      "peptide": "SS-31",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of SS-31?",
      "directAnswer": "SS-31 safety concerns are compound-specific. The main listed side effects are Injection site reactions, Headache, and Mild gastrointestinal symptoms. The main warning signals are Still in clinical trials, not yet FDA-approved, Long-term safety profile not fully established, and Some clinical trials have shown mixed results."
    },
    {
      "title": "MK-677 Side Effects: Safety Signals and Warnings",
      "slug": "mk-677-side-effects-safety",
      "url": "https://examinepeptides.com/answers/mk-677-side-effects-safety/",
      "peptide": "MK-677",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of MK-677?",
      "directAnswer": "MK-677 safety concerns are compound-specific. The main listed side effects are Increased appetite, Water retention and edema, and Muscle pain. The main warning signals are Not FDA approved - investigational compound, May impair glucose tolerance and increase insulin resistance with prolonged use, and May increase risk in patients with existing diabetes or prediabetes."
    },
    {
      "title": "Kisspeptin-10 Side Effects: Safety Signals and Warnings",
      "slug": "kisspeptin-10-side-effects-safety",
      "url": "https://examinepeptides.com/answers/kisspeptin-10-side-effects-safety/",
      "peptide": "Kisspeptin-10",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Kisspeptin-10?",
      "directAnswer": "Kisspeptin-10 safety concerns are compound-specific. The main listed side effects are Generally well-tolerated in clinical trials, Warmth or flushing, and Mild headache. The main warning signals are Investigational peptide, not FDA-approved, Continuous exposure may lead to receptor desensitization, and Effects on hormone-sensitive conditions not fully studied."
    },
    {
      "title": "Selank Side Effects: Safety Signals and Warnings",
      "slug": "selank-side-effects-safety",
      "url": "https://examinepeptides.com/answers/selank-side-effects-safety/",
      "peptide": "Selank",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Selank?",
      "directAnswer": "Selank safety concerns are compound-specific. The main listed side effects are Generally well-tolerated, Mild fatigue in some users, and Possible nasal irritation (intranasal). The main warning signals are Most clinical data from Russian research only, Not FDA-approved or evaluated, and Limited independent replication of results."
    },
    {
      "title": "Semax Side Effects: Safety Signals and Warnings",
      "slug": "semax-side-effects-safety",
      "url": "https://examinepeptides.com/answers/semax-side-effects-safety/",
      "peptide": "Semax",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Semax?",
      "directAnswer": "Semax safety concerns are compound-specific. The main listed side effects are Generally very well-tolerated, Mild headache, and Nasal dryness or irritation. The main warning signals are Most clinical evidence from Russian studies only, Not FDA-approved or independently validated, and May affect mood in individuals with bipolar disorder."
    },
    {
      "title": "Melanotan II Side Effects: Safety Signals and Warnings",
      "slug": "melanotan-ii-side-effects-safety",
      "url": "https://examinepeptides.com/answers/melanotan-ii-side-effects-safety/",
      "peptide": "Melanotan II",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Melanotan II?",
      "directAnswer": "Melanotan II safety concerns are compound-specific. The main listed side effects are Nausea and facial flushing, Darkening of existing moles and nevi, and Fatigue and drowsiness. The main warning signals are Not approved by any regulatory agency for human use, Potential risk of melanoma promotion due to melanocyte stimulation - patients with family history should avoid, and Unregulated products may contain impurities or incorrect dosing."
    },
    {
      "title": "Epithalon Side Effects: Safety Signals and Warnings",
      "slug": "epithalon-side-effects-safety",
      "url": "https://examinepeptides.com/answers/epithalon-side-effects-safety/",
      "peptide": "Epithalon",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Epithalon?",
      "directAnswer": "Epithalon safety concerns are compound-specific. The main listed side effects are Generally well-tolerated in available studies, Possible injection site reactions, and Drowsiness (due to melatonin increase). The main warning signals are Most evidence comes from a single research group in Russia, Results have not been independently replicated in Western institutions, and Theoretical concern about telomerase activation in cancer cells."
    },
    {
      "title": "Davunetide (NAP/AL-108) Side Effects: Safety Signals and Warnings",
      "slug": "davunetide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/davunetide-side-effects-safety/",
      "peptide": "Davunetide (NAP/AL-108)",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Davunetide (NAP/AL-108)?",
      "directAnswer": "Davunetide (NAP/AL-108) safety concerns are compound-specific. The main listed side effects are Nasal irritation, Headache, and Upper respiratory tract infection. The main warning signals are Phase 2/3 PSP trial failed to meet primary endpoint, raising questions about clinical translatability, Development was discontinued by Allon Therapeutics/Paladin Labs after PSP trial results, and Gap between robust preclinical and modest clinical results suggests challenges in human translation."
    },
    {
      "title": "Thymalin Side Effects: Safety Signals and Warnings",
      "slug": "thymalin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/thymalin-side-effects-safety/",
      "peptide": "Thymalin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Thymalin?",
      "directAnswer": "Thymalin safety concerns are compound-specific. The main listed side effects are Injection site pain, Allergic reactions (rare), and Mild fever (immune activation). The main warning signals are Derived from bovine thymus - theoretical prion disease risk, Contraindicated in autoimmune diseases (may exacerbate immune dysregulation), and Long-term anti-aging claims rest on limited observational data."
    },
    {
      "title": "Cortexin Side Effects: Safety Signals and Warnings",
      "slug": "cortexin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/cortexin-side-effects-safety/",
      "peptide": "Cortexin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Cortexin?",
      "directAnswer": "Cortexin safety concerns are compound-specific. The main listed side effects are Injection site pain, Allergic reactions (rare), and Insomnia (if administered late in the day). The main warning signals are Not approved outside of Russia and CIS countries, Derived from animal brain tissue - theoretical prion disease risk, and Clinical evidence is primarily from Russian-language publications with limited independent verification."
    },
    {
      "title": "P-15 Peptide Side Effects: Safety Signals and Warnings",
      "slug": "p15-peptide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/p15-peptide-side-effects-safety/",
      "peptide": "P-15 Peptide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of P-15 Peptide?",
      "directAnswer": "P-15 Peptide safety concerns are compound-specific. The main listed side effects are Local swelling at surgical site, Potential allergic reaction to bovine-derived components, and Infection risk inherent to surgical procedures. The main warning signals are For surgical use only by trained practitioners, Contains bovine-derived material; contraindicated in patients with bovine protein allergy, and Not a substitute for mechanical stabilization in spinal fusion."
    },
    {
      "title": "Kisspeptin-54 Side Effects: Safety Signals and Warnings",
      "slug": "kisspeptin-54-side-effects-safety",
      "url": "https://examinepeptides.com/answers/kisspeptin-54-side-effects-safety/",
      "peptide": "Kisspeptin-54",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Kisspeptin-54?",
      "directAnswer": "Kisspeptin-54 safety concerns are compound-specific. The main listed side effects are Facial flushing, Nausea, and Headache. The main warning signals are Investigational - not approved for clinical use, Tachyphylaxis observed with continuous or repeated dosing, and May cause ovarian hyperstimulation in susceptible patients."
    },
    {
      "title": "Hexarelin Side Effects: Safety Signals and Warnings",
      "slug": "hexarelin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/hexarelin-side-effects-safety/",
      "peptide": "Hexarelin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Hexarelin?",
      "directAnswer": "Hexarelin safety concerns are compound-specific. The main listed side effects are Flushing, Transient cortisol elevation, and Increased appetite. The main warning signals are Not approved for clinical use, Tachyphylaxis occurs with continuous use - intermittent dosing recommended, and Transient increases in cortisol and prolactin may be clinically relevant in susceptible individuals."
    },
    {
      "title": "Amlexanox Side Effects: Safety Signals and Warnings",
      "slug": "amlexanox-side-effects-safety",
      "url": "https://examinepeptides.com/answers/amlexanox-side-effects-safety/",
      "peptide": "Amlexanox",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Amlexanox?",
      "directAnswer": "Amlexanox safety concerns are compound-specific. The main listed side effects are Diarrhea, Nausea, and Upper respiratory tract infection. The main warning signals are Oral use for metabolic indications is investigational - not FDA approved for this purpose, FDA-approved only as a topical treatment for canker sores, and Phase 2 trials showed variable efficacy, with some failing to meet primary endpoints."
    },
    {
      "title": "Chrysalin Side Effects: Safety Signals and Warnings",
      "slug": "chrysalin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/chrysalin-side-effects-safety/",
      "peptide": "Chrysalin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Chrysalin?",
      "directAnswer": "Chrysalin safety concerns are compound-specific. The main listed side effects are Well-tolerated in Phase 2 trials, Mild injection site discomfort, and No systemic coagulation effects observed. The main warning signals are Not yet FDA-approved; still in clinical development, Theoretical concern regarding thrombin receptor activation in patients with thrombotic tendencies, and Limited data in patients with impaired healing (diabetes, immunosuppression)."
    },
    {
      "title": "Peptide YY Side Effects: Safety Signals and Warnings",
      "slug": "peptide-yy-side-effects-safety",
      "url": "https://examinepeptides.com/answers/peptide-yy-side-effects-safety/",
      "peptide": "Peptide YY",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Peptide YY?",
      "directAnswer": "Peptide YY safety concerns are compound-specific. The main listed side effects are Nausea (dose-limiting), Abdominal discomfort, and Reduced gastric motility. The main warning signals are Native peptide has very short half-life requiring continuous infusion, Nausea is a significant dose-limiting side effect, and Modified analogs are still in early clinical development."
    },
    {
      "title": "LL-37 Side Effects: Safety Signals and Warnings",
      "slug": "ll-37-side-effects-safety",
      "url": "https://examinepeptides.com/answers/ll-37-side-effects-safety/",
      "peptide": "LL-37",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of LL-37?",
      "directAnswer": "LL-37 safety concerns are compound-specific. The main listed side effects are Possible injection site reactions, May cause local inflammation at high concentrations, and Hemolytic activity at very high concentrations. The main warning signals are Early-stage research peptide only, Can be pro-inflammatory at high concentrations, and May exacerbate autoimmune conditions."
    },
    {
      "title": "L-Carnosine Side Effects: Safety Signals and Warnings",
      "slug": "carnosine-side-effects-safety",
      "url": "https://examinepeptides.com/answers/carnosine-side-effects-safety/",
      "peptide": "L-Carnosine",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of L-Carnosine?",
      "directAnswer": "L-Carnosine safety concerns are compound-specific. The main listed side effects are Generally well-tolerated, Mild tingling or paresthesia (from beta-alanine metabolite), and Gastrointestinal discomfort at high doses. The main warning signals are Rapidly degraded by serum carnosinase enzyme, limiting oral bioavailability, Individuals with carnosinase deficiency (carnosinemia) should avoid supplementation, and Long-term high-dose studies are limited."
    },
    {
      "title": "RGD Peptide Side Effects: Safety Signals and Warnings",
      "slug": "rgd-peptide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/rgd-peptide-side-effects-safety/",
      "peptide": "RGD Peptide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of RGD Peptide?",
      "directAnswer": "RGD Peptide safety concerns are compound-specific. The main listed side effects are Generally well-tolerated as biomaterial component, Cilengitide: fatigue, nausea, lymphopenia, and Potential to inhibit platelet aggregation at high systemic doses. The main warning signals are Linear RGD has very short in vivo half-life and limited standalone therapeutic utility, Cyclic RGD variants have more clinical relevance but mixed efficacy results, and High systemic doses may interfere with normal integrin-mediated processes (platelet adhesion, wound healing)."
    },
    {
      "title": "Lactoferrin Peptides Side Effects: Safety Signals and Warnings",
      "slug": "lactoferrin-peptides-side-effects-safety",
      "url": "https://examinepeptides.com/answers/lactoferrin-peptides-side-effects-safety/",
      "peptide": "Lactoferrin Peptides",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Lactoferrin Peptides?",
      "directAnswer": "Lactoferrin Peptides safety concerns are compound-specific. The main listed side effects are Generally well-tolerated orally, Occasional GI discomfort, and Rare allergic reactions in individuals with milk protein sensitivity. The main warning signals are Contraindicated in individuals with cow milk protein allergy (bovine-derived), Iron-binding properties may affect iron supplementation timing, and Quality varies significantly between commercial products."
    },
    {
      "title": "Cathelicidin Side Effects: Safety Signals and Warnings",
      "slug": "cathelicidin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/cathelicidin-side-effects-safety/",
      "peptide": "Cathelicidin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Cathelicidin?",
      "directAnswer": "Cathelicidin safety concerns are compound-specific. The main listed side effects are Potential cytotoxicity to host cells at high concentrations, May exacerbate inflammatory skin conditions at supraphysiological levels, and Direct peptide administration can cause injection site inflammation. The main warning signals are Not approved as a therapeutic agent, Excess LL-37 is associated with psoriasis and rosacea pathology, and Synthetic LL-37 is expensive to produce and susceptible to degradation."
    },
    {
      "title": "SNAP-8 (Acetyl Octapeptide-3) Side Effects: Safety Signals and Warnings",
      "slug": "snap-8-side-effects-safety",
      "url": "https://examinepeptides.com/answers/snap-8-side-effects-safety/",
      "peptide": "SNAP-8 (Acetyl Octapeptide-3)",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of SNAP-8 (Acetyl Octapeptide-3)?",
      "directAnswer": "SNAP-8 (Acetyl Octapeptide-3) safety concerns are compound-specific. The main listed side effects are Mild skin irritation (rare), Redness at application site, and Contact dermatitis in sensitive individuals. The main warning signals are Cosmeceutical use only; not a medical treatment, Penetration depth through intact skin is limited compared to injected alternatives, and Efficacy is modest compared to botulinum toxin injections."
    },
    {
      "title": "Argireline Side Effects: Safety Signals and Warnings",
      "slug": "argireline-side-effects-safety",
      "url": "https://examinepeptides.com/answers/argireline-side-effects-safety/",
      "peptide": "Argireline",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Argireline?",
      "directAnswer": "Argireline safety concerns are compound-specific. The main listed side effects are Generally well tolerated, Mild skin irritation in rare cases, and Contact dermatitis in sensitive individuals. The main warning signals are Marketed as cosmeceutical, not as a drug, Efficacy is modest compared to botulinum toxin injections, and Product quality and concentration vary widely among commercial offerings."
    },
    {
      "title": "GHRP-6 Side Effects: Safety Signals and Warnings",
      "slug": "ghrp-6-side-effects-safety",
      "url": "https://examinepeptides.com/answers/ghrp-6-side-effects-safety/",
      "peptide": "GHRP-6",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of GHRP-6?",
      "directAnswer": "GHRP-6 safety concerns are compound-specific. The main listed side effects are Intense hunger, Cortisol elevation, and Prolactin elevation. The main warning signals are Not approved for clinical use in any jurisdiction, Strong appetite stimulation may lead to unwanted weight gain, and Elevates cortisol and prolactin more than newer GHRPs."
    },
    {
      "title": "GHRP-2 Side Effects: Safety Signals and Warnings",
      "slug": "ghrp-2-side-effects-safety",
      "url": "https://examinepeptides.com/answers/ghrp-2-side-effects-safety/",
      "peptide": "GHRP-2",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of GHRP-2?",
      "directAnswer": "GHRP-2 safety concerns are compound-specific. The main listed side effects are Mild appetite increase, Transient cortisol elevation, and Mild prolactin increase. The main warning signals are Not FDA approved (approved in Japan for diagnostic use only), Should not be used in patients with active malignancy, and Tachyphylaxis possible with continuous use."
    },
    {
      "title": "Delta Sleep-Inducing Peptide (DSIP) Side Effects: Safety Signals and Warnings",
      "slug": "dsip-side-effects-safety",
      "url": "https://examinepeptides.com/answers/dsip-side-effects-safety/",
      "peptide": "Delta Sleep-Inducing Peptide (DSIP)",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Delta Sleep-Inducing Peptide (DSIP)?",
      "directAnswer": "Delta Sleep-Inducing Peptide (DSIP) safety concerns are compound-specific. The main listed side effects are Daytime drowsiness, Vivid dreams, and Mild headache. The main warning signals are Extremely short half-life limits practical utility of systemic administration, Most studies are small and older (1980s-1990s), with limited modern replication, and Quality of available research peptide varies significantly."
    },
    {
      "title": "Matrixyl Side Effects: Safety Signals and Warnings",
      "slug": "matrixyl-side-effects-safety",
      "url": "https://examinepeptides.com/answers/matrixyl-side-effects-safety/",
      "peptide": "Matrixyl",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Matrixyl?",
      "directAnswer": "Matrixyl safety concerns are compound-specific. The main listed side effects are Generally well tolerated topically, Rare mild skin irritation or redness, and Allergic reactions uncommon but possible. The main warning signals are Cosmeceutical ingredient - not regulated as a drug, Efficacy claims are largely based on in vitro data and small clinical studies, and Formulation quality varies significantly between products."
    },
    {
      "title": "Matrixyl 3000 Side Effects: Safety Signals and Warnings",
      "slug": "matrixyl-3000-side-effects-safety",
      "url": "https://examinepeptides.com/answers/matrixyl-3000-side-effects-safety/",
      "peptide": "Matrixyl 3000",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Matrixyl 3000?",
      "directAnswer": "Matrixyl 3000 safety concerns are compound-specific. The main listed side effects are Generally well tolerated, Occasional mild irritation in sensitive skin, and No systemic effects expected from topical use. The main warning signals are Cosmeceutical ingredient not evaluated as a drug, Independent peer-reviewed clinical data is limited, and Results vary by product formulation and concentration."
    },
    {
      "title": "MOTS-c Side Effects: Safety Signals and Warnings",
      "slug": "mots-c-side-effects-safety",
      "url": "https://examinepeptides.com/answers/mots-c-side-effects-safety/",
      "peptide": "MOTS-c",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of MOTS-c?",
      "directAnswer": "MOTS-c safety concerns are compound-specific. The main listed side effects are Limited safety data in humans and No significant adverse effects reported in animal studies at therapeutic doses. The main warning signals are Extremely limited human data - preclinical research only, No established human dosing or safety profile, and Quality and purity of commercially available peptide cannot be guaranteed."
    },
    {
      "title": "AOD-9604 Side Effects: Safety Signals and Warnings",
      "slug": "aod-9604-side-effects-safety",
      "url": "https://examinepeptides.com/answers/aod-9604-side-effects-safety/",
      "peptide": "AOD-9604",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of AOD-9604?",
      "directAnswer": "AOD-9604 safety concerns are compound-specific. The main listed side effects are Injection site irritation, Headache, and Mild nausea. The main warning signals are Not FDA approved for any indication, Human clinical trials for obesity did not meet primary endpoints, and Quality and purity of research-grade peptides may vary significantly."
    },
    {
      "title": "Humanin Side Effects: Safety Signals and Warnings",
      "slug": "humanin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/humanin-side-effects-safety/",
      "peptide": "Humanin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Humanin?",
      "directAnswer": "Humanin safety concerns are compound-specific. The main listed side effects are Very limited safety data, No significant adverse effects reported in animal studies, and Potential for excessive anti-apoptotic signaling with chronic administration (theoretical concern for tumorigenesis). The main warning signals are Preclinical research only - no human clinical trials completed, Anti-apoptotic properties raise theoretical concerns about promoting tumor cell survival, and No established human dosing or safety data."
    },
    {
      "title": "Klotho-Derived Peptide Side Effects: Safety Signals and Warnings",
      "slug": "klotho-peptide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/klotho-peptide-side-effects-safety/",
      "peptide": "Klotho-Derived Peptide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Klotho-Derived Peptide?",
      "directAnswer": "Klotho-Derived Peptide safety concerns are compound-specific. The main listed side effects are Unknown in humans, Potential disruption of mineral metabolism (phosphate, vitamin D), and Theoretical risk of altered insulin sensitivity. The main warning signals are No human trials have been conducted with Klotho peptides, The relationship between specific peptide fragments and full-length Klotho activity is not fully mapped, and Disruption of FGF23-Klotho axis could cause mineral metabolism disorders."
    },
    {
      "title": "FGL Peptide Side Effects: Safety Signals and Warnings",
      "slug": "fgl-peptide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/fgl-peptide-side-effects-safety/",
      "peptide": "FGL Peptide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of FGL Peptide?",
      "directAnswer": "FGL Peptide safety concerns are compound-specific. The main listed side effects are No significant adverse effects reported in animal studies, Potential for FGFR-mediated proliferative effects at high doses, and Unknown human safety profile. The main warning signals are No human studies have been conducted, FGFR1 activation could theoretically promote cell proliferation in susceptible tissues, and Long-term effects of chronic FGFR1 stimulation in the brain are unknown."
    },
    {
      "title": "Ac-SDKP Side Effects: Safety Signals and Warnings",
      "slug": "ac-sdkp-side-effects-safety",
      "url": "https://examinepeptides.com/answers/ac-sdkp-side-effects-safety/",
      "peptide": "Ac-SDKP",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Ac-SDKP?",
      "directAnswer": "Ac-SDKP safety concerns are compound-specific. The main listed side effects are No significant adverse effects reported in preclinical studies, Theoretical hypotensive effect at high doses, and Very limited human safety data. The main warning signals are Not approved for clinical use, Extremely short half-life limits practical application, and Endogenous levels are regulated by ACE; exogenous supplementation effects are not fully characterized."
    },
    {
      "title": "P21 (CNTF-Derived Peptide) Side Effects: Safety Signals and Warnings",
      "slug": "p21-peptide-side-effects-safety",
      "url": "https://examinepeptides.com/answers/p21-peptide-side-effects-safety/",
      "peptide": "P21 (CNTF-Derived Peptide)",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of P21 (CNTF-Derived Peptide)?",
      "directAnswer": "P21 (CNTF-Derived Peptide) safety concerns are compound-specific. The main listed side effects are No significant adverse effects reported in animal studies and Potential unknown risks in humans. The main warning signals are No human trials have been conducted, Long-term effects of chronic neurogenesis stimulation are unknown, and Theoretical risk of promoting uncontrolled cell proliferation."
    },
    {
      "title": "Colivelin Side Effects: Safety Signals and Warnings",
      "slug": "colivelin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/colivelin-side-effects-safety/",
      "peptide": "Colivelin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Colivelin?",
      "directAnswer": "Colivelin safety concerns are compound-specific. The main listed side effects are No adverse effects reported in published animal studies, Unknown human safety profile, and Potential for unexpected effects from dual-pathway activation. The main warning signals are All data is preclinical - no human studies exist, Brain delivery remains a major challenge for systemic administration, and Dual-pathway activation (MAPK + STAT3) could have complex effects in chronic administration."
    },
    {
      "title": "5-Amino-1MQ Side Effects: Safety Signals and Warnings",
      "slug": "5-amino-1mq-side-effects-safety",
      "url": "https://examinepeptides.com/answers/5-amino-1mq-side-effects-safety/",
      "peptide": "5-Amino-1MQ",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of 5-Amino-1MQ?",
      "directAnswer": "5-Amino-1MQ safety concerns are compound-specific. The main listed side effects are Limited safety data, No significant adverse effects reported in preclinical studies, and Potential for off-target methyltransferase inhibition at high doses (theoretical). The main warning signals are No human clinical trials completed, Technically a small molecule, not a peptide - regulatory classification differs, and Long-term safety profile unknown."
    },
    {
      "title": "FOXO4-DRI Side Effects: Safety Signals and Warnings",
      "slug": "foxo4-dri-side-effects-safety",
      "url": "https://examinepeptides.com/answers/foxo4-dri-side-effects-safety/",
      "peptide": "FOXO4-DRI",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of FOXO4-DRI?",
      "directAnswer": "FOXO4-DRI safety concerns are compound-specific. The main listed side effects are Transient mild diarrhea (observed in mice), Potential off-target apoptosis at very high doses, and Unknown long-term effects. The main warning signals are No human trials have been conducted, Self-administration is strongly discouraged due to lack of safety data, and Potential risk of excessive cell death if dosing is not carefully controlled."
    },
    {
      "title": "KPV Side Effects: Safety Signals and Warnings",
      "slug": "kpv-side-effects-safety",
      "url": "https://examinepeptides.com/answers/kpv-side-effects-safety/",
      "peptide": "KPV",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of KPV?",
      "directAnswer": "KPV safety concerns are compound-specific. The main listed side effects are Very limited safety data in humans, No significant adverse effects reported in animal studies, and Possible mild GI discomfort with oral dosing. The main warning signals are Not FDA-approved for any indication, All evidence is preclinical, and No established human safety profile."
    },
    {
      "title": "Thymulin Side Effects: Safety Signals and Warnings",
      "slug": "thymulin-side-effects-safety",
      "url": "https://examinepeptides.com/answers/thymulin-side-effects-safety/",
      "peptide": "Thymulin",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Thymulin?",
      "directAnswer": "Thymulin safety concerns are compound-specific. The main listed side effects are Limited human safety data, No significant toxicity reported in animal studies, and Dependent on adequate zinc status for activity. The main warning signals are Not approved for clinical use, Biological activity depends on zinc availability, and May alter immune balance in autoimmune conditions."
    },
    {
      "title": "TB4-Frag Side Effects: Safety Signals and Warnings",
      "slug": "tb4-frag-side-effects-safety",
      "url": "https://examinepeptides.com/answers/tb4-frag-side-effects-safety/",
      "peptide": "TB4-Frag",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of TB4-Frag?",
      "directAnswer": "TB4-Frag safety concerns are compound-specific. The main listed side effects are No significant adverse effects in animal studies, Theoretical risk of hypotension, and Potential interaction with blood pressure regulation. The main warning signals are Not approved for any clinical use, Extremely short half-life limits practical application without continuous infusion or ACE inhibitor co-therapy, and Identical active molecule to Ac-SDKP; sourcing and nomenclature may overlap."
    },
    {
      "title": "GHR Peptide-6 Side Effects: Safety Signals and Warnings",
      "slug": "ghr-peptide-6-side-effects-safety",
      "url": "https://examinepeptides.com/answers/ghr-peptide-6-side-effects-safety/",
      "peptide": "GHR Peptide-6",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of GHR Peptide-6?",
      "directAnswer": "GHR Peptide-6 safety concerns are compound-specific. The main listed side effects are Limited safety data available, Possible local irritation at application site, and Potential appetite stimulation (shared with GHRP-6). The main warning signals are Not approved for clinical use in any country, Evidence base is limited and primarily from a single research group, and Relationship to GHRP-6 may carry similar endocrine side effects at systemic doses."
    },
    {
      "title": "AHK-Cu Side Effects: Safety Signals and Warnings",
      "slug": "copper-ahk-side-effects-safety",
      "url": "https://examinepeptides.com/answers/copper-ahk-side-effects-safety/",
      "peptide": "AHK-Cu",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of AHK-Cu?",
      "directAnswer": "AHK-Cu safety concerns are compound-specific. The main listed side effects are Scalp irritation possible, Contact dermatitis in copper-sensitive individuals, and Skin discoloration at high concentrations. The main warning signals are Extremely limited human clinical data, Not approved for hair loss treatment, and Copper sensitivity should be assessed before use."
    },
    {
      "title": "Palmitoyl Tripeptide-5 Side Effects: Safety Signals and Warnings",
      "slug": "palmitoyl-tripeptide-5-side-effects-safety",
      "url": "https://examinepeptides.com/answers/palmitoyl-tripeptide-5-side-effects-safety/",
      "peptide": "Palmitoyl Tripeptide-5",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Palmitoyl Tripeptide-5?",
      "directAnswer": "Palmitoyl Tripeptide-5 safety concerns are compound-specific. The main listed side effects are Well tolerated in cosmetic use, Rare skin irritation, and Allergic reactions uncommon. The main warning signals are Limited independent clinical validation, Cosmeceutical - not held to pharmaceutical efficacy standards, and TGF-beta activation is a double-edged sword - excessive signaling can promote fibrosis in theory, though topical application is unlikely to cause systemic effects."
    },
    {
      "title": "Leuphasyl Side Effects: Safety Signals and Warnings",
      "slug": "leuphasyl-side-effects-safety",
      "url": "https://examinepeptides.com/answers/leuphasyl-side-effects-safety/",
      "peptide": "Leuphasyl",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Leuphasyl?",
      "directAnswer": "Leuphasyl safety concerns are compound-specific. The main listed side effects are Generally well tolerated topically, Rare skin irritation, and No systemic opioid effects expected from topical application. The main warning signals are Limited independent clinical evidence, Primarily supported by manufacturer data, and Efficacy depends on formulation and skin penetration."
    },
    {
      "title": "SYN-AKE Side Effects: Safety Signals and Warnings",
      "slug": "syn-ake-side-effects-safety",
      "url": "https://examinepeptides.com/answers/syn-ake-side-effects-safety/",
      "peptide": "SYN-AKE",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of SYN-AKE?",
      "directAnswer": "SYN-AKE safety concerns are compound-specific. The main listed side effects are Generally well tolerated, Mild temporary numbness at application site in some users, and Rare skin irritation. The main warning signals are Primarily manufacturer-supported data; limited independent peer review, Should not be considered equivalent to botulinum toxin in efficacy, and Not suitable for individuals with neuromuscular disorders (e.g., myasthenia gravis) as a precaution."
    },
    {
      "title": "Acetyl Tetrapeptide-5 Side Effects: Safety Signals and Warnings",
      "slug": "acetyl-tetrapeptide-5-side-effects-safety",
      "url": "https://examinepeptides.com/answers/acetyl-tetrapeptide-5-side-effects-safety/",
      "peptide": "Acetyl Tetrapeptide-5",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Acetyl Tetrapeptide-5?",
      "directAnswer": "Acetyl Tetrapeptide-5 safety concerns are compound-specific. The main listed side effects are Generally well tolerated around the eyes, Rare mild stinging in sensitive individuals, and Allergic contact reactions uncommon. The main warning signals are Limited independent peer-reviewed evidence, Avoid direct contact with eyes, and Results are modest and may vary by individual."
    },
    {
      "title": "Dihexa Side Effects: Safety Signals and Warnings",
      "slug": "dihexa-side-effects-safety",
      "url": "https://examinepeptides.com/answers/dihexa-side-effects-safety/",
      "peptide": "Dihexa",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Dihexa?",
      "directAnswer": "Dihexa safety concerns are compound-specific. The main listed side effects are No human safety data available, Theoretical risk of excessive cell growth (HGF pathway), and Unknown long-term effects. The main warning signals are EXTREMELY EARLY STAGE - animal data only, No human clinical trials conducted, and HGF/c-Met pathway involved in cancer cell growth and metastasis."
    },
    {
      "title": "NA-Semax-Amidate Side Effects: Safety Signals and Warnings",
      "slug": "na-semax-amidate-side-effects-safety",
      "url": "https://examinepeptides.com/answers/na-semax-amidate-side-effects-safety/",
      "peptide": "NA-Semax-Amidate",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of NA-Semax-Amidate?",
      "directAnswer": "NA-Semax-Amidate safety concerns are compound-specific. The main listed side effects are Headache (extrapolated from Semax), Mild nasal irritation (intranasal), and Dizziness (rare). The main warning signals are No direct human clinical trials exist for NA-Semax-Amidate, Safety and efficacy data extrapolated from Semax research, and Dual modification may create unpredictable pharmacological differences."
    },
    {
      "title": "Melanocortin Receptor Peptides Side Effects: Safety Signals and Warnings",
      "slug": "melanocortin-peptides-side-effects-safety",
      "url": "https://examinepeptides.com/answers/melanocortin-peptides-side-effects-safety/",
      "peptide": "Melanocortin Receptor Peptides",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Melanocortin Receptor Peptides?",
      "directAnswer": "Melanocortin Receptor Peptides safety concerns are compound-specific. The main listed side effects are Nausea (most common, 40% of patients), Flushing, and Injection site reactions. The main warning signals are Bremelanotide is contraindicated in uncontrolled hypertension, Transient blood pressure elevations of 6-12 mmHg reported, and Nausea is the primary tolerability concern - tends to improve with repeat use."
    },
    {
      "title": "Pinealon Side Effects: Safety Signals and Warnings",
      "slug": "pinealon-side-effects-safety",
      "url": "https://examinepeptides.com/answers/pinealon-side-effects-safety/",
      "peptide": "Pinealon",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Pinealon?",
      "directAnswer": "Pinealon safety concerns are compound-specific. The main listed side effects are Mild drowsiness, Headache (rare), and Vivid dreams. The main warning signals are Research is almost exclusively from Russian institutions with limited independent replication, No human clinical trials have been conducted, and Long-term safety profile is unknown."
    },
    {
      "title": "Vilon Side Effects: Safety Signals and Warnings",
      "slug": "vilon-side-effects-safety",
      "url": "https://examinepeptides.com/answers/vilon-side-effects-safety/",
      "peptide": "Vilon",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Vilon?",
      "directAnswer": "Vilon safety concerns are compound-specific. The main listed side effects are Generally well-tolerated in available studies, Mild gastrointestinal discomfort (rare), and Possible immune stimulation effects. The main warning signals are Research is limited to Russian institutions with minimal independent replication, No controlled human clinical trials have been published, and Theoretical risk of immune overactivation in autoimmune conditions."
    },
    {
      "title": "N-Acetyl Selank Side Effects: Safety Signals and Warnings",
      "slug": "n-acetyl-selank-side-effects-safety",
      "url": "https://examinepeptides.com/answers/n-acetyl-selank-side-effects-safety/",
      "peptide": "N-Acetyl Selank",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of N-Acetyl Selank?",
      "directAnswer": "N-Acetyl Selank safety concerns are compound-specific. The main listed side effects are Fatigue (extrapolated from Selank), Nasal irritation (intranasal), and Mild sedation. The main warning signals are No direct human clinical trials exist for N-Acetyl Selank, Efficacy and safety data are extrapolated from Selank research, and The modification may alter pharmacological properties in unpredictable ways."
    },
    {
      "title": "SIRT1-Activating Peptide Side Effects: Safety Signals and Warnings",
      "slug": "sirt1-activator-side-effects-safety",
      "url": "https://examinepeptides.com/answers/sirt1-activator-side-effects-safety/",
      "peptide": "SIRT1-Activating Peptide",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of SIRT1-Activating Peptide?",
      "directAnswer": "SIRT1-Activating Peptide safety concerns are compound-specific. The main listed side effects are Unknown (insufficient clinical data), Theoretical risk of excessive deacetylation, and Potential metabolic disruption at supratherapeutic doses. The main warning signals are Extremely early-stage research with no human data, Peptide delivery to intracellular targets (nucleus) is a major pharmacological challenge, and SIRT1 overactivation may have paradoxical effects in certain cancer contexts."
    },
    {
      "title": "Defensin HD5 Side Effects: Safety Signals and Warnings",
      "slug": "defensin-hd5-side-effects-safety",
      "url": "https://examinepeptides.com/answers/defensin-hd5-side-effects-safety/",
      "peptide": "Defensin HD5",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Defensin HD5?",
      "directAnswer": "Defensin HD5 safety concerns are compound-specific. The main listed side effects are No clinical safety data available, Potential cytotoxicity to host cells at high concentrations in vitro, and May disrupt commensal bacteria alongside pathogens. The main warning signals are Not available for clinical use, Purely a research tool at present, and Recombinant production is challenging due to complex disulfide bonding."
    },
    {
      "title": "Cecropin A Side Effects: Safety Signals and Warnings",
      "slug": "cecropin-a-side-effects-safety",
      "url": "https://examinepeptides.com/answers/cecropin-a-side-effects-safety/",
      "peptide": "Cecropin A",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of Cecropin A?",
      "directAnswer": "Cecropin A safety concerns are compound-specific. The main listed side effects are No human clinical data available, Low mammalian cell toxicity in vitro at bactericidal concentrations, and Potential hemolytic activity at very high concentrations. The main warning signals are Not available for clinical or therapeutic use, Rapidly degraded by mammalian proteases, limiting in vivo utility, and Synthetic analogs are being developed to improve stability."
    },
    {
      "title": "AOD-14 Side Effects: Safety Signals and Warnings",
      "slug": "aod-14-side-effects-safety",
      "url": "https://examinepeptides.com/answers/aod-14-side-effects-safety/",
      "peptide": "AOD-14",
      "intent": "side effects and safety",
      "directQuestion": "What are the side effects of AOD-14?",
      "directAnswer": "AOD-14 safety concerns are compound-specific. The main listed side effects are No clinical safety data available, In vitro studies have not identified significant cytotoxicity, and Theoretical risk of excessive tissue growth at high concentrations. The main warning signals are Extremely early stage of research, No clinical trials have been conducted, and Safety profile is entirely unknown in humans."
    },
    {
      "title": "Semaglutide Benefits: Evidence, Verdict, and Limits",
      "slug": "semaglutide-benefits-evidence",
      "url": "https://examinepeptides.com/answers/semaglutide-benefits-evidence/",
      "peptide": "Semaglutide",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Semaglutide?",
      "directAnswer": "Semaglutide has its strongest evidence for Weight Loss, GI Side Effects, and Blood Sugar Control. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Semaglutide remains the best-validated GLP-1-only agent: FDA-approved for diabetes, obesity, cardiovascular risk reduction, and now higher-dose Wegovy HD 7.2mg. Tirzepatide beats it on weight loss in direct obesity trials, but semaglutide still has the deepest cardiovascular outcomes record and the broadest GLP-1 evidence base."
    },
    {
      "title": "Is Semaglutide Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-semaglutide-legit",
      "url": "https://examinepeptides.com/answers/is-semaglutide-legit/",
      "peptide": "Semaglutide",
      "intent": "evidence verdict",
      "directQuestion": "Is Semaglutide legit?",
      "directAnswer": "Semaglutide is rated Level A. The short verdict: Semaglutide remains the best-validated GLP-1-only agent: FDA-approved for diabetes, obesity, cardiovascular risk reduction, and now higher-dose Wegovy HD 7.2mg. Tirzepatide beats it on weight loss in direct obesity trials, but semaglutide still has the deepest cardiovascular outcomes record and the broadest GLP-1 evidence base."
    },
    {
      "title": "Semaglutide Research Dosage: Published Protocol Reference",
      "slug": "semaglutide-research-dosage",
      "url": "https://examinepeptides.com/answers/semaglutide-research-dosage/",
      "peptide": "Semaglutide",
      "intent": "research dosage",
      "directQuestion": "What dosage of Semaglutide is used in research?",
      "directAnswer": "Semaglutide dosage references vary by route and study context. The database lists Subcutaneous injection (diabetes): 0.25-1.0 mg, Once weekly, Subcutaneous injection (weight): 0.25-2.4 mg, Once weekly, and Subcutaneous injection (higher-dose weight): 7.2 mg maintenance, Once weekly. These are research-context references, not a universal protocol."
    },
    {
      "title": "Semaglutide Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "semaglutide-legal-status",
      "url": "https://examinepeptides.com/answers/semaglutide-legal-status/",
      "peptide": "Semaglutide",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Semaglutide?",
      "directAnswer": "FDA-approved for type 2 diabetes (Ozempic, 2017), chronic weight management (Wegovy, 2021), cardiovascular risk reduction in adults with established CVD and obesity/overweight, and higher-dose Wegovy HD 7.2mg for weight loss and long-term weight maintenance (March 19, 2026). Prescription required."
    },
    {
      "title": "Tirzepatide Benefits: Evidence, Verdict, and Limits",
      "slug": "tirzepatide-benefits-evidence",
      "url": "https://examinepeptides.com/answers/tirzepatide-benefits-evidence/",
      "peptide": "Tirzepatide",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Tirzepatide?",
      "directAnswer": "Tirzepatide has its strongest evidence for Weight Loss, GI Side Effects, and Blood Sugar Control. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Tirzepatide is now the default evidence-backed winner for weight loss among approved incretin drugs: SURMOUNT-5 showed greater weight reduction than semaglutide, and Zepbound also has an FDA indication for moderate-to-severe OSA in adults with obesity. Semaglutide still leads on mature cardiovascular outcomes evidence, but tirzepatide leads on weight-loss magnitude."
    },
    {
      "title": "Is Tirzepatide Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-tirzepatide-legit",
      "url": "https://examinepeptides.com/answers/is-tirzepatide-legit/",
      "peptide": "Tirzepatide",
      "intent": "evidence verdict",
      "directQuestion": "Is Tirzepatide legit?",
      "directAnswer": "Tirzepatide is rated Level A. The short verdict: Tirzepatide is now the default evidence-backed winner for weight loss among approved incretin drugs: SURMOUNT-5 showed greater weight reduction than semaglutide, and Zepbound also has an FDA indication for moderate-to-severe OSA in adults with obesity. Semaglutide still leads on mature cardiovascular outcomes evidence, but tirzepatide leads on weight-loss magnitude."
    },
    {
      "title": "Tirzepatide Research Dosage: Published Protocol Reference",
      "slug": "tirzepatide-research-dosage",
      "url": "https://examinepeptides.com/answers/tirzepatide-research-dosage/",
      "peptide": "Tirzepatide",
      "intent": "research dosage",
      "directQuestion": "What dosage of Tirzepatide is used in research?",
      "directAnswer": "Tirzepatide dosage references vary by route and study context. The database lists Subcutaneous injection (diabetes): 2.5-15 mg, Once weekly and Subcutaneous injection (weight): 2.5-15 mg, Once weekly. These are research-context references, not a universal protocol."
    },
    {
      "title": "Tirzepatide Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "tirzepatide-legal-status",
      "url": "https://examinepeptides.com/answers/tirzepatide-legal-status/",
      "peptide": "Tirzepatide",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Tirzepatide?",
      "directAnswer": "FDA-approved for type 2 diabetes (Mounjaro, 2022), chronic weight management (Zepbound, 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound, December 20, 2024). Prescription required. Availability may be limited due to high demand."
    },
    {
      "title": "Tesamorelin Benefits: Evidence, Verdict, and Limits",
      "slug": "tesamorelin-benefits-evidence",
      "url": "https://examinepeptides.com/answers/tesamorelin-benefits-evidence/",
      "peptide": "Tesamorelin",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Tesamorelin?",
      "directAnswer": "Tesamorelin has its strongest evidence for Visceral Adipose Tissue Reduction, IGF-1 Increase, and Cognitive Function. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Tesamorelin is FDA-approved for HIV-related lipodystrophy and has the strongest human evidence of any GHRH analog in this library - multiple Phase 3 RCTs demonstrating significant visceral fat reduction. Outside its approved indication, human data is limited. For research into GHRH-pathway GH stimulation, tesamorelin provides the reference standard with actual regulatory approval behind it."
    },
    {
      "title": "Is Tesamorelin Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-tesamorelin-legit",
      "url": "https://examinepeptides.com/answers/is-tesamorelin-legit/",
      "peptide": "Tesamorelin",
      "intent": "evidence verdict",
      "directQuestion": "Is Tesamorelin legit?",
      "directAnswer": "Tesamorelin is rated Level A. The short verdict: Tesamorelin is FDA-approved for HIV-related lipodystrophy and has the strongest human evidence of any GHRH analog in this library - multiple Phase 3 RCTs demonstrating significant visceral fat reduction. Outside its approved indication, human data is limited. For research into GHRH-pathway GH stimulation, tesamorelin provides the reference standard with actual regulatory approval behind it."
    },
    {
      "title": "Tesamorelin Research Dosage: Published Protocol Reference",
      "slug": "tesamorelin-research-dosage",
      "url": "https://examinepeptides.com/answers/tesamorelin-research-dosage/",
      "peptide": "Tesamorelin",
      "intent": "research dosage",
      "directQuestion": "What dosage of Tesamorelin is used in research?",
      "directAnswer": "Tesamorelin dosage references vary by route and study context. The database lists Subcutaneous injection: 2 mg, Once daily. These are research-context references, not a universal protocol."
    },
    {
      "title": "Tesamorelin Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "tesamorelin-legal-status",
      "url": "https://examinepeptides.com/answers/tesamorelin-legal-status/",
      "peptide": "Tesamorelin",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Tesamorelin?",
      "directAnswer": "FDA approved (Egrifta). Prescription required. Schedule: Not a controlled substance."
    },
    {
      "title": "PT-141 Benefits: Evidence, Verdict, and Limits",
      "slug": "pt-141-benefits-evidence",
      "url": "https://examinepeptides.com/answers/pt-141-benefits-evidence/",
      "peptide": "PT-141",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of PT-141?",
      "directAnswer": "PT-141 has its strongest evidence for Female Sexual Desire, Nausea, and Male Erectile Function. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women (Vyleesi), providing a regulatory anchor for sexual health research. Phase 3 data in women is solid; male sexual dysfunction data is earlier-stage. For melanocortin-pathway sexual health research, this is the best-evidenced starting point."
    },
    {
      "title": "Is PT-141 Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-pt-141-legit",
      "url": "https://examinepeptides.com/answers/is-pt-141-legit/",
      "peptide": "PT-141",
      "intent": "evidence verdict",
      "directQuestion": "Is PT-141 legit?",
      "directAnswer": "PT-141 is rated Level A. The short verdict: PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women (Vyleesi), providing a regulatory anchor for sexual health research. Phase 3 data in women is solid; male sexual dysfunction data is earlier-stage. For melanocortin-pathway sexual health research, this is the best-evidenced starting point."
    },
    {
      "title": "PT-141 Research Dosage: Published Protocol Reference",
      "slug": "pt-141-research-dosage",
      "url": "https://examinepeptides.com/answers/pt-141-research-dosage/",
      "peptide": "PT-141",
      "intent": "research dosage",
      "directQuestion": "What dosage of PT-141 is used in research?",
      "directAnswer": "PT-141 dosage references vary by route and study context. The database lists Subcutaneous injection (FDA-approved): 1.75 mg, As needed, at least 45 min before activity and Subcutaneous (research): 0.5-2 mg, As needed. These are research-context references, not a universal protocol."
    },
    {
      "title": "PT-141 Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "pt-141-legal-status",
      "url": "https://examinepeptides.com/answers/pt-141-legal-status/",
      "peptide": "PT-141",
      "intent": "legal status",
      "directQuestion": "What is the legal status of PT-141?",
      "directAnswer": "FDA-approved as Vyleesi for HSDD in premenopausal women (2019). Prescription required. Available by auto-injector. Not approved for male sexual dysfunction. Also available as a research peptide."
    },
    {
      "title": "Pramlintide Benefits: Evidence, Verdict, and Limits",
      "slug": "pramlintide-benefits-evidence",
      "url": "https://examinepeptides.com/answers/pramlintide-benefits-evidence/",
      "peptide": "Pramlintide",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Pramlintide?",
      "directAnswer": "Pramlintide has its strongest evidence for Postprandial Glucose Control, Body Weight, and Glucagon Suppression. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Pramlintide (Symlin) is FDA-approved as an adjunct to insulin in both type 1 and type 2 diabetes, with multiple Phase 3 RCTs supporting meaningful HbA1c and postprandial glucose reduction. Its amylin-mimetic mechanism is distinct from GLP-1 agonism. In combination with GLP-1 agents, amylin agonism shows additive weight-loss effects. A well-validated compound with a real regulatory record."
    },
    {
      "title": "Is Pramlintide Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-pramlintide-legit",
      "url": "https://examinepeptides.com/answers/is-pramlintide-legit/",
      "peptide": "Pramlintide",
      "intent": "evidence verdict",
      "directQuestion": "Is Pramlintide legit?",
      "directAnswer": "Pramlintide is rated Level A. The short verdict: Pramlintide (Symlin) is FDA-approved as an adjunct to insulin in both type 1 and type 2 diabetes, with multiple Phase 3 RCTs supporting meaningful HbA1c and postprandial glucose reduction. Its amylin-mimetic mechanism is distinct from GLP-1 agonism. In combination with GLP-1 agents, amylin agonism shows additive weight-loss effects. A well-validated compound with a real regulatory record."
    },
    {
      "title": "Pramlintide Research Dosage: Published Protocol Reference",
      "slug": "pramlintide-research-dosage",
      "url": "https://examinepeptides.com/answers/pramlintide-research-dosage/",
      "peptide": "Pramlintide",
      "intent": "research dosage",
      "directQuestion": "What dosage of Pramlintide is used in research?",
      "directAnswer": "Pramlintide dosage references vary by route and study context. The database lists Subcutaneous injection: 60 mcg (Type 2) or 15-60 mcg (Type 1), Before each major meal. These are research-context references, not a universal protocol."
    },
    {
      "title": "Pramlintide Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "pramlintide-legal-status",
      "url": "https://examinepeptides.com/answers/pramlintide-legal-status/",
      "peptide": "Pramlintide",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Pramlintide?",
      "directAnswer": "FDA approved (2005, Symlin). Prescription required. Not a controlled substance."
    },
    {
      "title": "Leuprolide Benefits: Evidence, Verdict, and Limits",
      "slug": "leuprolide-benefits-evidence",
      "url": "https://examinepeptides.com/answers/leuprolide-benefits-evidence/",
      "peptide": "Leuprolide",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Leuprolide?",
      "directAnswer": "Leuprolide has its strongest evidence for Advanced Prostate Cancer, Endometriosis Management, and Central Precocious Puberty. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Leuprolide (Lupron) is FDA-approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty - one of the broadest indication profiles of any peptide drug in this library. With 40+ years of clinical use and extensive Phase 3 data across multiple indications, it is the reference GnRH agonist. A highly validated compound by any standard."
    },
    {
      "title": "Is Leuprolide Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-leuprolide-legit",
      "url": "https://examinepeptides.com/answers/is-leuprolide-legit/",
      "peptide": "Leuprolide",
      "intent": "evidence verdict",
      "directQuestion": "Is Leuprolide legit?",
      "directAnswer": "Leuprolide is rated Level A. The short verdict: Leuprolide (Lupron) is FDA-approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty - one of the broadest indication profiles of any peptide drug in this library. With 40+ years of clinical use and extensive Phase 3 data across multiple indications, it is the reference GnRH agonist. A highly validated compound by any standard."
    },
    {
      "title": "Leuprolide Research Dosage: Published Protocol Reference",
      "slug": "leuprolide-research-dosage",
      "url": "https://examinepeptides.com/answers/leuprolide-research-dosage/",
      "peptide": "Leuprolide",
      "intent": "research dosage",
      "directQuestion": "What dosage of Leuprolide is used in research?",
      "directAnswer": "Leuprolide dosage references vary by route and study context. The database lists Intramuscular or subcutaneous depot: 7.5 mg (monthly), 22.5 mg (3-month), 30 mg (4-month), 45 mg (6-month), Per depot interval, Subcutaneous (daily): 1 mg/day, Daily, and Subcutaneous implant: 65 mg, Every 12 months. These are research-context references, not a universal protocol."
    },
    {
      "title": "Leuprolide Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "leuprolide-legal-status",
      "url": "https://examinepeptides.com/answers/leuprolide-legal-status/",
      "peptide": "Leuprolide",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Leuprolide?",
      "directAnswer": "FDA-approved prescription medication. Multiple formulations and brand names (Lupron, Eligard, Fensolvi). Not a controlled substance."
    },
    {
      "title": "Exenatide Benefits: Evidence, Verdict, and Limits",
      "slug": "exenatide-benefits-evidence",
      "url": "https://examinepeptides.com/answers/exenatide-benefits-evidence/",
      "peptide": "Exenatide",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Exenatide?",
      "directAnswer": "Exenatide has its strongest evidence for Glycemic Control (HbA1c Reduction), Body Weight Reduction, and Cardiovascular Outcomes. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Exenatide (Byetta/Bydureon) is FDA-approved for type 2 diabetes with extensive clinical data across hundreds of RCTs and real-world use. As the first GLP-1 receptor agonist approved for clinical use, it established the entire drug class. Compared to newer once-weekly GLP-1 agents like semaglutide, it has less weight-loss efficacy and inferior convenience, but its safety record spans two decades. For GLP-1 receptor agonist research, it is a reliable reference compound."
    },
    {
      "title": "Is Exenatide Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-exenatide-legit",
      "url": "https://examinepeptides.com/answers/is-exenatide-legit/",
      "peptide": "Exenatide",
      "intent": "evidence verdict",
      "directQuestion": "Is Exenatide legit?",
      "directAnswer": "Exenatide is rated Level A. The short verdict: Exenatide (Byetta/Bydureon) is FDA-approved for type 2 diabetes with extensive clinical data across hundreds of RCTs and real-world use. As the first GLP-1 receptor agonist approved for clinical use, it established the entire drug class. Compared to newer once-weekly GLP-1 agents like semaglutide, it has less weight-loss efficacy and inferior convenience, but its safety record spans two decades. For GLP-1 receptor agonist research, it is a reliable reference compound."
    },
    {
      "title": "Exenatide Research Dosage: Published Protocol Reference",
      "slug": "exenatide-research-dosage",
      "url": "https://examinepeptides.com/answers/exenatide-research-dosage/",
      "peptide": "Exenatide",
      "intent": "research dosage",
      "directQuestion": "What dosage of Exenatide is used in research?",
      "directAnswer": "Exenatide dosage references vary by route and study context. The database lists Subcutaneous injection: 5-10 mcg, Twice daily (Byetta) and Subcutaneous injection: 2 mg, Once weekly (Bydureon). These are research-context references, not a universal protocol."
    },
    {
      "title": "Exenatide Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "exenatide-legal-status",
      "url": "https://examinepeptides.com/answers/exenatide-legal-status/",
      "peptide": "Exenatide",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Exenatide?",
      "directAnswer": "FDA approved (2005 Byetta, 2012 Bydureon). Prescription required. Not a controlled substance."
    },
    {
      "title": "Daptomycin Benefits: Evidence, Verdict, and Limits",
      "slug": "daptomycin-benefits-evidence",
      "url": "https://examinepeptides.com/answers/daptomycin-benefits-evidence/",
      "peptide": "Daptomycin",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Daptomycin?",
      "directAnswer": "Daptomycin has its strongest evidence for MRSA Bacteremia Treatment, Complicated Skin Infections, and CPK Elevation (Adverse). ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Daptomycin (Cubicin) is FDA-approved for serious gram-positive infections including MRSA bacteremia, endocarditis, and complicated skin infections. It is a first-line IV antibiotic with extensive Phase 3 data and a 20+ year clinical track record. For researchers studying gram-positive infection treatment, daptomycin is a validated standard-of-care option with high-quality evidence."
    },
    {
      "title": "Is Daptomycin Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-daptomycin-legit",
      "url": "https://examinepeptides.com/answers/is-daptomycin-legit/",
      "peptide": "Daptomycin",
      "intent": "evidence verdict",
      "directQuestion": "Is Daptomycin legit?",
      "directAnswer": "Daptomycin is rated Level A. The short verdict: Daptomycin (Cubicin) is FDA-approved for serious gram-positive infections including MRSA bacteremia, endocarditis, and complicated skin infections. It is a first-line IV antibiotic with extensive Phase 3 data and a 20+ year clinical track record. For researchers studying gram-positive infection treatment, daptomycin is a validated standard-of-care option with high-quality evidence."
    },
    {
      "title": "Daptomycin Research Dosage: Published Protocol Reference",
      "slug": "daptomycin-research-dosage",
      "url": "https://examinepeptides.com/answers/daptomycin-research-dosage/",
      "peptide": "Daptomycin",
      "intent": "research dosage",
      "directQuestion": "What dosage of Daptomycin is used in research?",
      "directAnswer": "Daptomycin dosage references vary by route and study context. The database lists Intravenous: 4 mg/kg, Once daily, Intravenous: 6 mg/kg, Once daily, and Intravenous: 8-12 mg/kg, Once daily. These are research-context references, not a universal protocol."
    },
    {
      "title": "Daptomycin Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "daptomycin-legal-status",
      "url": "https://examinepeptides.com/answers/daptomycin-legal-status/",
      "peptide": "Daptomycin",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Daptomycin?",
      "directAnswer": "FDA-approved since 2003 (Cubicin). Prescription required. Available generically. Approved worldwide for complicated skin infections and S. aureus bacteremia. On the WHO Essential Medicines List."
    },
    {
      "title": "Vancomycin Benefits: Evidence, Verdict, and Limits",
      "slug": "vancomycin-benefits-evidence",
      "url": "https://examinepeptides.com/answers/vancomycin-benefits-evidence/",
      "peptide": "Vancomycin",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Vancomycin?",
      "directAnswer": "Vancomycin has its strongest evidence for MRSA Infection Treatment, Nephrotoxicity (Adverse), and C. difficile Infection (Oral). ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Vancomycin is FDA-approved and remains the gold standard for MRSA treatment and serious gram-positive infections where beta-lactams are contraindicated. With decades of clinical data, well-established PK/PD targets, and consistent Phase 3 evidence, it is one of the most validated antibiotics in medicine. For gram-positive infection research, vancomycin is the reference compound."
    },
    {
      "title": "Is Vancomycin Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-vancomycin-legit",
      "url": "https://examinepeptides.com/answers/is-vancomycin-legit/",
      "peptide": "Vancomycin",
      "intent": "evidence verdict",
      "directQuestion": "Is Vancomycin legit?",
      "directAnswer": "Vancomycin is rated Level A. The short verdict: Vancomycin is FDA-approved and remains the gold standard for MRSA treatment and serious gram-positive infections where beta-lactams are contraindicated. With decades of clinical data, well-established PK/PD targets, and consistent Phase 3 evidence, it is one of the most validated antibiotics in medicine. For gram-positive infection research, vancomycin is the reference compound."
    },
    {
      "title": "Vancomycin Research Dosage: Published Protocol Reference",
      "slug": "vancomycin-research-dosage",
      "url": "https://examinepeptides.com/answers/vancomycin-research-dosage/",
      "peptide": "Vancomycin",
      "intent": "research dosage",
      "directQuestion": "What dosage of Vancomycin is used in research?",
      "directAnswer": "Vancomycin dosage references vary by route and study context. The database lists Intravenous: 15-20 mg/kg, Every 8-12 hours, Oral: 125-500 mg, Four times daily for 10-14 days, and Intravenous (loading dose): 25-30 mg/kg, Once (then standard dosing). These are research-context references, not a universal protocol."
    },
    {
      "title": "Vancomycin Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "vancomycin-legal-status",
      "url": "https://examinepeptides.com/answers/vancomycin-legal-status/",
      "peptide": "Vancomycin",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Vancomycin?",
      "directAnswer": "FDA-approved since 1958. Prescription required. Available generically. Listed on the WHO Essential Medicines List. Available worldwide. Both IV and oral formulations are approved."
    },
    {
      "title": "Linaclotide Benefits: Evidence, Verdict, and Limits",
      "slug": "linaclotide-benefits-evidence",
      "url": "https://examinepeptides.com/answers/linaclotide-benefits-evidence/",
      "peptide": "Linaclotide",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Linaclotide?",
      "directAnswer": "Linaclotide has its strongest evidence for IBS-C Symptom Relief, Diarrhea (Adverse), and Chronic Idiopathic Constipation Relief. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Linaclotide (Linzess) is FDA-approved for IBS-C and chronic idiopathic constipation, with robust Phase 3 data across multiple trials. It is one of the most prescribed GI peptide drugs in the US, with real-world data supporting its Phase 3 results. For guanylate cyclase-C agonism and IBS-C research, linaclotide is the established reference compound."
    },
    {
      "title": "Is Linaclotide Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-linaclotide-legit",
      "url": "https://examinepeptides.com/answers/is-linaclotide-legit/",
      "peptide": "Linaclotide",
      "intent": "evidence verdict",
      "directQuestion": "Is Linaclotide legit?",
      "directAnswer": "Linaclotide is rated Level A. The short verdict: Linaclotide (Linzess) is FDA-approved for IBS-C and chronic idiopathic constipation, with robust Phase 3 data across multiple trials. It is one of the most prescribed GI peptide drugs in the US, with real-world data supporting its Phase 3 results. For guanylate cyclase-C agonism and IBS-C research, linaclotide is the established reference compound."
    },
    {
      "title": "Linaclotide Research Dosage: Published Protocol Reference",
      "slug": "linaclotide-research-dosage",
      "url": "https://examinepeptides.com/answers/linaclotide-research-dosage/",
      "peptide": "Linaclotide",
      "intent": "research dosage",
      "directQuestion": "What dosage of Linaclotide is used in research?",
      "directAnswer": "Linaclotide dosage references vary by route and study context. The database lists Oral: 290 mcg, Once daily, Oral: 145 mcg, Once daily, and Oral: 72 mcg, Once daily. These are research-context references, not a universal protocol."
    },
    {
      "title": "Linaclotide Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "linaclotide-legal-status",
      "url": "https://examinepeptides.com/answers/linaclotide-legal-status/",
      "peptide": "Linaclotide",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Linaclotide?",
      "directAnswer": "FDA-approved (Linzess) since August 2012 for IBS-C and CIC. Marketed as Constella in Europe (EMA-approved 2012). Prescription required. Available worldwide in multiple markets."
    },
    {
      "title": "Afamelanotide Benefits: Evidence, Verdict, and Limits",
      "slug": "melanotan-i-benefits-evidence",
      "url": "https://examinepeptides.com/answers/melanotan-i-benefits-evidence/",
      "peptide": "Afamelanotide",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Afamelanotide?",
      "directAnswer": "Afamelanotide has its strongest evidence for Skin Pigmentation, EPP Phototoxicity Reduction, and Photoprotection. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Afamelanotide (Scenesse) is FDA-approved for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP) - a rare, severely debilitating condition. The Phase 3 evidence in EPP is solid and the approval is well-founded. Outside EPP, evidence for vitiligo is emerging in Phase 2. This is a legitimate, approved therapeutic for its specific indication."
    },
    {
      "title": "Is Afamelanotide Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-melanotan-i-legit",
      "url": "https://examinepeptides.com/answers/is-melanotan-i-legit/",
      "peptide": "Afamelanotide",
      "intent": "evidence verdict",
      "directQuestion": "Is Afamelanotide legit?",
      "directAnswer": "Afamelanotide is rated Level A. The short verdict: Afamelanotide (Scenesse) is FDA-approved for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP) - a rare, severely debilitating condition. The Phase 3 evidence in EPP is solid and the approval is well-founded. Outside EPP, evidence for vitiligo is emerging in Phase 2. This is a legitimate, approved therapeutic for its specific indication."
    },
    {
      "title": "Afamelanotide Research Dosage: Published Protocol Reference",
      "slug": "melanotan-i-research-dosage",
      "url": "https://examinepeptides.com/answers/melanotan-i-research-dosage/",
      "peptide": "Afamelanotide",
      "intent": "research dosage",
      "directQuestion": "What dosage of Afamelanotide is used in research?",
      "directAnswer": "Afamelanotide dosage references vary by route and study context. The database lists Subcutaneous implant: 16 mg, Every 2 months (up to 3 implants per year for EPP). These are research-context references, not a universal protocol."
    },
    {
      "title": "Afamelanotide Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "melanotan-i-legal-status",
      "url": "https://examinepeptides.com/answers/melanotan-i-legal-status/",
      "peptide": "Afamelanotide",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Afamelanotide?",
      "directAnswer": "FDA-approved (Scenesse) for erythropoietic protoporphyria (EPP) in adults. Also approved by EMA. Available only through restricted distribution programs (REMS). Prescription only."
    },
    {
      "title": "Oxytocin Benefits: Evidence, Verdict, and Limits",
      "slug": "oxytocin-benefits-evidence",
      "url": "https://examinepeptides.com/answers/oxytocin-benefits-evidence/",
      "peptide": "Oxytocin",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Oxytocin?",
      "directAnswer": "Oxytocin has its strongest evidence for Labor Induction & Augmentation, Postpartum Hemorrhage Prevention, and Lactation Support. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Oxytocin (Pitocin/Syntocinon) is FDA-approved for obstetric indications with an extensive clinical record spanning decades. The evidence for its approved uses - labor induction and postpartum hemorrhage - is robust. Research into its prosocial, anxiolytic, and sexual health effects is active but Phase 2 level. For sexual health research involving trust, bonding, and social cognition, oxytocin is the most studied peptide candidate."
    },
    {
      "title": "Is Oxytocin Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-oxytocin-legit",
      "url": "https://examinepeptides.com/answers/is-oxytocin-legit/",
      "peptide": "Oxytocin",
      "intent": "evidence verdict",
      "directQuestion": "Is Oxytocin legit?",
      "directAnswer": "Oxytocin is rated Level A. The short verdict: Oxytocin (Pitocin/Syntocinon) is FDA-approved for obstetric indications with an extensive clinical record spanning decades. The evidence for its approved uses - labor induction and postpartum hemorrhage - is robust. Research into its prosocial, anxiolytic, and sexual health effects is active but Phase 2 level. For sexual health research involving trust, bonding, and social cognition, oxytocin is the most studied peptide candidate."
    },
    {
      "title": "Oxytocin Research Dosage: Published Protocol Reference",
      "slug": "oxytocin-research-dosage",
      "url": "https://examinepeptides.com/answers/oxytocin-research-dosage/",
      "peptide": "Oxytocin",
      "intent": "research dosage",
      "directQuestion": "What dosage of Oxytocin is used in research?",
      "directAnswer": "Oxytocin dosage references vary by route and study context. The database lists Intravenous infusion: 0.5-6 mU/min (labor induction), Continuous titration during labor, Intramuscular: 10 IU, Single dose post-delivery, and Intranasal: 20-40 IU, Single dose or as directed. These are research-context references, not a universal protocol."
    },
    {
      "title": "Oxytocin Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "oxytocin-legal-status",
      "url": "https://examinepeptides.com/answers/oxytocin-legal-status/",
      "peptide": "Oxytocin",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Oxytocin?",
      "directAnswer": "FDA-approved prescription medication (Pitocin). Available by prescription only. Not a controlled substance. On the WHO List of Essential Medicines."
    },
    {
      "title": "Setmelanotide Benefits: Evidence, Verdict, and Limits",
      "slug": "setmelanotide-benefits-evidence",
      "url": "https://examinepeptides.com/answers/setmelanotide-benefits-evidence/",
      "peptide": "Setmelanotide",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Setmelanotide?",
      "directAnswer": "Setmelanotide has its strongest evidence for Weight Loss in Genetic Obesity, Skin Hyperpigmentation, and Hunger Reduction. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Setmelanotide (Imcivree) is FDA-approved for chronic weight management in patients with specific genetic obesity syndromes (POMC, PCSK1, or LEPR deficiency). In its approved population, it produces dramatic and clinically meaningful weight loss. Outside this narrow genetic indication, there is no evidence base. It is not a general obesity treatment - but for research into melanocortin pathway obesity, it is the only approved compound in its class."
    },
    {
      "title": "Is Setmelanotide Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-setmelanotide-legit",
      "url": "https://examinepeptides.com/answers/is-setmelanotide-legit/",
      "peptide": "Setmelanotide",
      "intent": "evidence verdict",
      "directQuestion": "Is Setmelanotide legit?",
      "directAnswer": "Setmelanotide is rated Level A. The short verdict: Setmelanotide (Imcivree) is FDA-approved for chronic weight management in patients with specific genetic obesity syndromes (POMC, PCSK1, or LEPR deficiency). In its approved population, it produces dramatic and clinically meaningful weight loss. Outside this narrow genetic indication, there is no evidence base. It is not a general obesity treatment - but for research into melanocortin pathway obesity, it is the only approved compound in its class."
    },
    {
      "title": "Setmelanotide Research Dosage: Published Protocol Reference",
      "slug": "setmelanotide-research-dosage",
      "url": "https://examinepeptides.com/answers/setmelanotide-research-dosage/",
      "peptide": "Setmelanotide",
      "intent": "research dosage",
      "directQuestion": "What dosage of Setmelanotide is used in research?",
      "directAnswer": "Setmelanotide dosage references vary by route and study context. The database lists Subcutaneous injection: 2-3 mg (adults), Once daily and Subcutaneous injection: 1-2 mg (pediatric, 6-11 years), Once daily. These are research-context references, not a universal protocol."
    },
    {
      "title": "Setmelanotide Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "setmelanotide-legal-status",
      "url": "https://examinepeptides.com/answers/setmelanotide-legal-status/",
      "peptide": "Setmelanotide",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Setmelanotide?",
      "directAnswer": "FDA approved (2020, Imcivree). Prescription required. Available through specialty pharmacy only. REMS program required."
    },
    {
      "title": "Triptorelin Benefits: Evidence, Verdict, and Limits",
      "slug": "triptorelin-benefits-evidence",
      "url": "https://examinepeptides.com/answers/triptorelin-benefits-evidence/",
      "peptide": "Triptorelin",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Triptorelin?",
      "directAnswer": "Triptorelin has its strongest evidence for Prostate Cancer Control, Endometriosis Symptom Relief, and Central Precocious Puberty Arrest. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Triptorelin (Trelstar) is FDA-approved for prostate cancer androgen deprivation and gender-affirming hormone therapy, with multiple Phase 3 RCTs supporting both indications. As a GnRH agonist, it produces reliable castrate-level testosterone suppression with a well-characterized adverse effect profile. For research into GnRH agonist pharmacology or testosterone suppression, it is a validated reference compound."
    },
    {
      "title": "Is Triptorelin Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-triptorelin-legit",
      "url": "https://examinepeptides.com/answers/is-triptorelin-legit/",
      "peptide": "Triptorelin",
      "intent": "evidence verdict",
      "directQuestion": "Is Triptorelin legit?",
      "directAnswer": "Triptorelin is rated Level A. The short verdict: Triptorelin (Trelstar) is FDA-approved for prostate cancer androgen deprivation and gender-affirming hormone therapy, with multiple Phase 3 RCTs supporting both indications. As a GnRH agonist, it produces reliable castrate-level testosterone suppression with a well-characterized adverse effect profile. For research into GnRH agonist pharmacology or testosterone suppression, it is a validated reference compound."
    },
    {
      "title": "Triptorelin Research Dosage: Published Protocol Reference",
      "slug": "triptorelin-research-dosage",
      "url": "https://examinepeptides.com/answers/triptorelin-research-dosage/",
      "peptide": "Triptorelin",
      "intent": "research dosage",
      "directQuestion": "What dosage of Triptorelin is used in research?",
      "directAnswer": "Triptorelin dosage references vary by route and study context. The database lists Intramuscular depot: 3.75 mg (monthly) or 11.25 mg (3-month) or 22.5 mg (6-month), Monthly, quarterly, or semi-annually and Subcutaneous: 0.1 mg/day, Daily (short protocol for IVF). These are research-context references, not a universal protocol."
    },
    {
      "title": "Triptorelin Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "triptorelin-legal-status",
      "url": "https://examinepeptides.com/answers/triptorelin-legal-status/",
      "peptide": "Triptorelin",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Triptorelin?",
      "directAnswer": "FDA-approved prescription medication (Trelstar). Available by prescription only. Not a controlled substance."
    },
    {
      "title": "Dulaglutide Benefits: Evidence, Verdict, and Limits",
      "slug": "dulaglutide-benefits-evidence",
      "url": "https://examinepeptides.com/answers/dulaglutide-benefits-evidence/",
      "peptide": "Dulaglutide",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Dulaglutide?",
      "directAnswer": "Dulaglutide has its strongest evidence for Glycemic Control, Body Weight Reduction, and Cardiovascular Risk Reduction. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Dulaglutide (Trulicity) is FDA-approved for type 2 diabetes and cardiovascular risk reduction, with the REWIND trial demonstrating significant CV event reduction in a broad diabetic population. As a once-weekly GLP-1 agonist, it offers meaningful convenience. Its weight-loss efficacy is modest compared to semaglutide, but its CV outcome data is robust. A well-validated option for GLP-1 pathway research with strong regulatory backing."
    },
    {
      "title": "Is Dulaglutide Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-dulaglutide-legit",
      "url": "https://examinepeptides.com/answers/is-dulaglutide-legit/",
      "peptide": "Dulaglutide",
      "intent": "evidence verdict",
      "directQuestion": "Is Dulaglutide legit?",
      "directAnswer": "Dulaglutide is rated Level A. The short verdict: Dulaglutide (Trulicity) is FDA-approved for type 2 diabetes and cardiovascular risk reduction, with the REWIND trial demonstrating significant CV event reduction in a broad diabetic population. As a once-weekly GLP-1 agonist, it offers meaningful convenience. Its weight-loss efficacy is modest compared to semaglutide, but its CV outcome data is robust. A well-validated option for GLP-1 pathway research with strong regulatory backing."
    },
    {
      "title": "Dulaglutide Research Dosage: Published Protocol Reference",
      "slug": "dulaglutide-research-dosage",
      "url": "https://examinepeptides.com/answers/dulaglutide-research-dosage/",
      "peptide": "Dulaglutide",
      "intent": "research dosage",
      "directQuestion": "What dosage of Dulaglutide is used in research?",
      "directAnswer": "Dulaglutide dosage references vary by route and study context. The database lists Subcutaneous injection: 0.75 mg, Once weekly and Subcutaneous injection: 1.5 mg or 3.0 mg or 4.5 mg, Once weekly. These are research-context references, not a universal protocol."
    },
    {
      "title": "Dulaglutide Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "dulaglutide-legal-status",
      "url": "https://examinepeptides.com/answers/dulaglutide-legal-status/",
      "peptide": "Dulaglutide",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Dulaglutide?",
      "directAnswer": "FDA approved (2014). Prescription required. Not a controlled substance."
    },
    {
      "title": "Nafarelin Benefits: Evidence, Verdict, and Limits",
      "slug": "nafarelin-benefits-evidence",
      "url": "https://examinepeptides.com/answers/nafarelin-benefits-evidence/",
      "peptide": "Nafarelin",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Nafarelin?",
      "directAnswer": "Nafarelin has its strongest evidence for Endometriosis Pain Relief, Central Precocious Puberty Treatment, and Uterine Fibroid Reduction. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Nafarelin (Synarel) is FDA-approved for endometriosis and central precocious puberty via intranasal delivery - an unusual route for a peptide drug that demonstrates its unique pharmaceutical development. Phase 3 evidence for both indications is solid. For GnRH agonist research requiring intranasal administration, nafarelin is the validated option."
    },
    {
      "title": "Is Nafarelin Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-nafarelin-legit",
      "url": "https://examinepeptides.com/answers/is-nafarelin-legit/",
      "peptide": "Nafarelin",
      "intent": "evidence verdict",
      "directQuestion": "Is Nafarelin legit?",
      "directAnswer": "Nafarelin is rated Level A. The short verdict: Nafarelin (Synarel) is FDA-approved for endometriosis and central precocious puberty via intranasal delivery - an unusual route for a peptide drug that demonstrates its unique pharmaceutical development. Phase 3 evidence for both indications is solid. For GnRH agonist research requiring intranasal administration, nafarelin is the validated option."
    },
    {
      "title": "Nafarelin Research Dosage: Published Protocol Reference",
      "slug": "nafarelin-research-dosage",
      "url": "https://examinepeptides.com/answers/nafarelin-research-dosage/",
      "peptide": "Nafarelin",
      "intent": "research dosage",
      "directQuestion": "What dosage of Nafarelin is used in research?",
      "directAnswer": "Nafarelin dosage references vary by route and study context. The database lists Intranasal spray: 200 mcg per spray, Endometriosis: 1 spray in one nostril AM, 1 spray in other nostril PM (400 mcg/day) and Intranasal spray: 200 mcg per spray, CPP: 2 sprays each nostril AM and PM (1600 mcg/day). These are research-context references, not a universal protocol."
    },
    {
      "title": "Nafarelin Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "nafarelin-legal-status",
      "url": "https://examinepeptides.com/answers/nafarelin-legal-status/",
      "peptide": "Nafarelin",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Nafarelin?",
      "directAnswer": "FDA-approved prescription medication (Synarel). Prescription only. Not a controlled substance."
    },
    {
      "title": "Plecanatide Benefits: Evidence, Verdict, and Limits",
      "slug": "plecanatide-benefits-evidence",
      "url": "https://examinepeptides.com/answers/plecanatide-benefits-evidence/",
      "peptide": "Plecanatide",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Plecanatide?",
      "directAnswer": "Plecanatide has its strongest evidence for Chronic Idiopathic Constipation Relief, Diarrhea (Adverse), and IBS-C Symptom Improvement. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Plecanatide (Trulance) is FDA-approved for chronic idiopathic constipation and IBS with constipation, with Phase 3 RCTs demonstrating consistent efficacy on validated endpoints. As a uroguanylin analog that works locally in the GI tract with minimal systemic absorption, it has an excellent safety profile. For guanylate cyclase-C agonist research and IBS-C/CIC treatment, it is a validated option alongside linaclotide."
    },
    {
      "title": "Is Plecanatide Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-plecanatide-legit",
      "url": "https://examinepeptides.com/answers/is-plecanatide-legit/",
      "peptide": "Plecanatide",
      "intent": "evidence verdict",
      "directQuestion": "Is Plecanatide legit?",
      "directAnswer": "Plecanatide is rated Level A. The short verdict: Plecanatide (Trulance) is FDA-approved for chronic idiopathic constipation and IBS with constipation, with Phase 3 RCTs demonstrating consistent efficacy on validated endpoints. As a uroguanylin analog that works locally in the GI tract with minimal systemic absorption, it has an excellent safety profile. For guanylate cyclase-C agonist research and IBS-C/CIC treatment, it is a validated option alongside linaclotide."
    },
    {
      "title": "Plecanatide Research Dosage: Published Protocol Reference",
      "slug": "plecanatide-research-dosage",
      "url": "https://examinepeptides.com/answers/plecanatide-research-dosage/",
      "peptide": "Plecanatide",
      "intent": "research dosage",
      "directQuestion": "What dosage of Plecanatide is used in research?",
      "directAnswer": "Plecanatide dosage references vary by route and study context. The database lists Oral: 3 mg, Once daily. These are research-context references, not a universal protocol."
    },
    {
      "title": "Plecanatide Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "plecanatide-legal-status",
      "url": "https://examinepeptides.com/answers/plecanatide-legal-status/",
      "peptide": "Plecanatide",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Plecanatide?",
      "directAnswer": "FDA-approved (Trulance) since January 2017 for CIC, and March 2018 for IBS-C. Prescription required. Available in the United States. Patent-protected."
    },
    {
      "title": "Degarelix Benefits: Evidence, Verdict, and Limits",
      "slug": "degarelix-benefits-evidence",
      "url": "https://examinepeptides.com/answers/degarelix-benefits-evidence/",
      "peptide": "Degarelix",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Degarelix?",
      "directAnswer": "Degarelix has its strongest evidence for Testosterone Suppression, Prostate Cancer Control, and Cardiovascular Events. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Degarelix (Firmagon) is FDA-approved for advanced prostate cancer with Phase 3 data demonstrating faster testosterone suppression to castrate levels than LHRH agonists (within 3 days vs. 3-4 weeks), without the initial testosterone flare. Multiple comparative trials establish it as a first-line option in patients requiring rapid androgen deprivation. A highly validated prostate cancer treatment with clear pharmacological advantages over GnRH agonists in specific clinical scenarios."
    },
    {
      "title": "Is Degarelix Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-degarelix-legit",
      "url": "https://examinepeptides.com/answers/is-degarelix-legit/",
      "peptide": "Degarelix",
      "intent": "evidence verdict",
      "directQuestion": "Is Degarelix legit?",
      "directAnswer": "Degarelix is rated Level A. The short verdict: Degarelix (Firmagon) is FDA-approved for advanced prostate cancer with Phase 3 data demonstrating faster testosterone suppression to castrate levels than LHRH agonists (within 3 days vs. 3-4 weeks), without the initial testosterone flare. Multiple comparative trials establish it as a first-line option in patients requiring rapid androgen deprivation. A highly validated prostate cancer treatment with clear pharmacological advantages over GnRH agonists in specific clinical scenarios."
    },
    {
      "title": "Degarelix Research Dosage: Published Protocol Reference",
      "slug": "degarelix-research-dosage",
      "url": "https://examinepeptides.com/answers/degarelix-research-dosage/",
      "peptide": "Degarelix",
      "intent": "research dosage",
      "directQuestion": "What dosage of Degarelix is used in research?",
      "directAnswer": "Degarelix dosage references vary by route and study context. The database lists Subcutaneous injection: 240 mg (loading dose), Once (first dose) and Subcutaneous injection: 80 mg, Every 28 days (maintenance). These are research-context references, not a universal protocol."
    },
    {
      "title": "Degarelix Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "degarelix-legal-status",
      "url": "https://examinepeptides.com/answers/degarelix-legal-status/",
      "peptide": "Degarelix",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Degarelix?",
      "directAnswer": "FDA-approved for the treatment of advanced prostate cancer. Available by prescription only. Marketed as Firmagon by Ferring Pharmaceuticals."
    },
    {
      "title": "Bivalirudin Benefits: Evidence, Verdict, and Limits",
      "slug": "bivalirudin-benefits-evidence",
      "url": "https://examinepeptides.com/answers/bivalirudin-benefits-evidence/",
      "peptide": "Bivalirudin",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Bivalirudin?",
      "directAnswer": "Bivalirudin has its strongest evidence for PCI Anticoagulation, Reduced Major Bleeding, and Acute Stent Thrombosis. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Bivalirudin (Angiomax) is FDA-approved as an anticoagulant for PCI with Phase 3 data from the HORIZONS-AMI and ACUITY trials showing comparable efficacy to heparin plus GP IIb/IIIa inhibitors with significantly reduced bleeding risk. Its direct thrombin inhibition with predictable pharmacokinetics makes it a preferred anticoagulant in specific interventional cardiology settings."
    },
    {
      "title": "Is Bivalirudin Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-bivalirudin-legit",
      "url": "https://examinepeptides.com/answers/is-bivalirudin-legit/",
      "peptide": "Bivalirudin",
      "intent": "evidence verdict",
      "directQuestion": "Is Bivalirudin legit?",
      "directAnswer": "Bivalirudin is rated Level A. The short verdict: Bivalirudin (Angiomax) is FDA-approved as an anticoagulant for PCI with Phase 3 data from the HORIZONS-AMI and ACUITY trials showing comparable efficacy to heparin plus GP IIb/IIIa inhibitors with significantly reduced bleeding risk. Its direct thrombin inhibition with predictable pharmacokinetics makes it a preferred anticoagulant in specific interventional cardiology settings."
    },
    {
      "title": "Bivalirudin Research Dosage: Published Protocol Reference",
      "slug": "bivalirudin-research-dosage",
      "url": "https://examinepeptides.com/answers/bivalirudin-research-dosage/",
      "peptide": "Bivalirudin",
      "intent": "research dosage",
      "directQuestion": "What dosage of Bivalirudin is used in research?",
      "directAnswer": "Bivalirudin dosage references vary by route and study context. The database lists Intravenous bolus + infusion: 0.75 mg/kg bolus, then 1.75 mg/kg/h, During PCI, continued for up to 4 hours post-procedure and Intravenous infusion: 0.15-0.2 mg/kg/h, Continuous (for HIT patients). These are research-context references, not a universal protocol."
    },
    {
      "title": "Bivalirudin Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "bivalirudin-legal-status",
      "url": "https://examinepeptides.com/answers/bivalirudin-legal-status/",
      "peptide": "Bivalirudin",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Bivalirudin?",
      "directAnswer": "FDA-approved for use as an anticoagulant in patients undergoing PCI and for patients with or at risk of HIT undergoing PCI. Available by prescription for hospital use. Marketed as Angiomax by The Medicines Company. Generic versions available."
    },
    {
      "title": "Nesiritide Benefits: Evidence, Verdict, and Limits",
      "slug": "nesiritide-benefits-evidence",
      "url": "https://examinepeptides.com/answers/nesiritide-benefits-evidence/",
      "peptide": "Nesiritide",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Nesiritide?",
      "directAnswer": "Nesiritide has its strongest evidence for Hemodynamic Improvement, Dyspnea Relief in Acute HF, and Renal Function Concerns. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Nesiritide (Natrecor) is FDA-approved for acute decompensated heart failure with initial enthusiasm tempered by subsequent analysis showing limited mortality benefit and possible renal harm at higher doses. Current guidelines reserve it for symptom relief when other therapies are inadequate. It is a validated BNP analog with a well-characterized pharmacology, but its role in HF management has narrowed with evolving evidence."
    },
    {
      "title": "Is Nesiritide Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-nesiritide-legit",
      "url": "https://examinepeptides.com/answers/is-nesiritide-legit/",
      "peptide": "Nesiritide",
      "intent": "evidence verdict",
      "directQuestion": "Is Nesiritide legit?",
      "directAnswer": "Nesiritide is rated Level A. The short verdict: Nesiritide (Natrecor) is FDA-approved for acute decompensated heart failure with initial enthusiasm tempered by subsequent analysis showing limited mortality benefit and possible renal harm at higher doses. Current guidelines reserve it for symptom relief when other therapies are inadequate. It is a validated BNP analog with a well-characterized pharmacology, but its role in HF management has narrowed with evolving evidence."
    },
    {
      "title": "Nesiritide Research Dosage: Published Protocol Reference",
      "slug": "nesiritide-research-dosage",
      "url": "https://examinepeptides.com/answers/nesiritide-research-dosage/",
      "peptide": "Nesiritide",
      "intent": "research dosage",
      "directQuestion": "What dosage of Nesiritide is used in research?",
      "directAnswer": "Nesiritide dosage references vary by route and study context. The database lists Intravenous bolus + infusion: 2 mcg/kg bolus, then 0.01 mcg/kg/min, Continuous infusion for up to 48 hours. These are research-context references, not a universal protocol."
    },
    {
      "title": "Nesiritide Legal Status: Approval, Research Use, and Regulatory Notes",
      "slug": "nesiritide-legal-status",
      "url": "https://examinepeptides.com/answers/nesiritide-legal-status/",
      "peptide": "Nesiritide",
      "intent": "legal status",
      "directQuestion": "What is the legal status of Nesiritide?",
      "directAnswer": "FDA-approved (2001) for treatment of acutely decompensated heart failure. Available by prescription for hospital/clinic use only. Marketed as Natrecor by Janssen."
    },
    {
      "title": "Vasopressin Benefits: Evidence, Verdict, and Limits",
      "slug": "vasopressin-benefits-evidence",
      "url": "https://examinepeptides.com/answers/vasopressin-benefits-evidence/",
      "peptide": "Vasopressin",
      "intent": "benefits and evidence",
      "directQuestion": "What are the benefits of Vasopressin?",
      "directAnswer": "Vasopressin has its strongest evidence for Diabetes Insipidus Management, Vasodilatory Shock Treatment, and Cardiac Arrest Adjunct. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Vasopressin (Vasostrict) is FDA-approved for vasodilatory shock (septic shock, post-cardiotomy vasodilatory shock) with Phase 3 evidence from the VASST trial showing non-inferiority to norepinephrine and steroid-sparing potential in septic shock. As an endogenous hormone with a distinct vasoconstrictive mechanism, it is a standard vasopressor in critical care medicine."
    },
    {
      "title": "Is Vasopressin Legit? Evidence Grade and Plain-English Verdict",
      "slug": "is-vasopressin-legit",
      "url": "https://examinepeptides.com/answers/is-vasopressin-legit/",
      "peptide": "Vasopressin",
      "intent": "evidence verdict",
      "directQuestion": "Is Vasopressin legit?",
      "directAnswer": "Vasopressin is rated Level A. The short verdict: Vasopressin (Vasostrict) is FDA-approved for vasodilatory shock (septic shock, post-cardiotomy vasodilatory shock) with Phase 3 evidence from the VASST trial showing non-inferiority to norepinephrine and steroid-sparing potential in septic shock. As an endogenous hormone with a distinct vasoconstrictive mechanism, it is a standard vasopressor in critical care medicine."
    },
    {
      "title": "Vasopressin Research Dosage: Published Protocol Reference",
      "slug": "vasopressin-research-dosage",
      "url": "https://examinepeptides.com/answers/vasopressin-research-dosage/",
      "peptide": "Vasopressin",
      "intent": "research dosage",
      "directQuestion": "What dosage of Vasopressin is used in research?",
      "directAnswer": "Vasopressin dosage references vary by route and study context. The database lists Intravenous infusion: 0.01-0.04 units/min, Continuous (for vasodilatory shock), Intramuscular/Subcutaneous: 5-10 units, Every 4-6 hours as needed, and Intravenous bolus: 40 units, Single dose (in cardiac arrest). These are research-context references, not a universal protocol."
    }
  ],
  "peptides": [
    {
      "name": "Semaglutide",
      "slug": "semaglutide",
      "url": "https://examinepeptides.com/library/semaglutide",
      "aliases": [
        "Ozempic",
        "Wegovy",
        "Rybelsus"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Obesity, type 2 diabetes, cardiovascular risk reduction in overweight patients",
      "verdict": "Semaglutide remains the best-validated GLP-1-only agent: FDA-approved for diabetes, obesity, cardiovascular risk reduction, and now higher-dose Wegovy HD 7.2mg. Tirzepatide beats it on weight loss in direct obesity trials, but semaglutide still has the deepest cardiovascular outcomes record and the broadest GLP-1 evidence base.",
      "lastReviewed": "2026-06-01",
      "primarySources": [
        {
          "title": "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)",
          "journal": "N Engl J Med",
          "year": 2021,
          "url": "https://pubmed.ncbi.nlm.nih.gov/33567185/"
        },
        {
          "title": "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)",
          "journal": "N Engl J Med",
          "year": 2016,
          "url": "https://pubmed.ncbi.nlm.nih.gov/27633186/"
        },
        {
          "title": "Semaglutide and Cardiovascular Outcomes in Obesity (SELECT)",
          "journal": "N Engl J Med",
          "year": 2023,
          "url": "https://pubmed.ncbi.nlm.nih.gov/37952131/"
        },
        {
          "title": "Two-Year Effects of Semaglutide on Weight (STEP 5)",
          "journal": "Nat Med",
          "year": 2022,
          "url": "https://pubmed.ncbi.nlm.nih.gov/35132148/"
        }
      ]
    },
    {
      "name": "Tirzepatide",
      "slug": "tirzepatide",
      "url": "https://examinepeptides.com/library/tirzepatide",
      "aliases": [
        "Mounjaro",
        "Zepbound"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Obesity, type 2 diabetes, obstructive sleep apnea with obesity, metabolic syndrome research",
      "verdict": "Tirzepatide is now the default evidence-backed winner for weight loss among approved incretin drugs: SURMOUNT-5 showed greater weight reduction than semaglutide, and Zepbound also has an FDA indication for moderate-to-severe OSA in adults with obesity. Semaglutide still leads on mature cardiovascular outcomes evidence, but tirzepatide leads on weight-loss magnitude.",
      "lastReviewed": "2026-06-01",
      "primarySources": [
        {
          "title": "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)",
          "journal": "N Engl J Med",
          "year": 2022,
          "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/"
        },
        {
          "title": "Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2)",
          "journal": "N Engl J Med",
          "year": 2021,
          "url": "https://pubmed.ncbi.nlm.nih.gov/34170647/"
        },
        {
          "title": "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)",
          "journal": "N Engl J Med",
          "year": 2025,
          "url": "https://pubmed.ncbi.nlm.nih.gov/40353578/"
        },
        {
          "title": "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)",
          "journal": "N Engl J Med",
          "year": 2024,
          "url": "https://pubmed.ncbi.nlm.nih.gov/39413392/"
        }
      ]
    },
    {
      "name": "Tesamorelin",
      "slug": "tesamorelin",
      "url": "https://examinepeptides.com/library/tesamorelin",
      "aliases": [
        "Egrifta",
        "TH9507",
        "Tesamorelin acetate"
      ],
      "category": "Growth Hormone",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "HIV-associated lipodystrophy, visceral fat reduction, GHRH-mediated GH research",
      "verdict": "Tesamorelin is FDA-approved for HIV-related lipodystrophy and has the strongest human evidence of any GHRH analog in this library - multiple Phase 3 RCTs demonstrating significant visceral fat reduction. Outside its approved indication, human data is limited. For research into GHRH-pathway GH stimulation, tesamorelin provides the reference standard with actual regulatory approval behind it.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation",
          "journal": "Journal of the American Medical Association",
          "year": 2007,
          "url": "https://doi.org/10.1001/jama.298.4.409"
        },
        {
          "title": "Tesamorelin in HIV-associated lipodystrophy: a Phase 3 randomized controlled trial",
          "journal": "Annals of Internal Medicine",
          "year": 2010,
          "url": "https://doi.org/10.7326/0003-4819-153-7-201010050-00005"
        },
        {
          "title": "Tesamorelin effects on cognition in HIV patients with normal cognition, mild cognitive impairment, and dementia",
          "journal": "Neurology",
          "year": 2020,
          "url": "https://doi.org/10.1212/WNL.0000000000009014"
        }
      ]
    },
    {
      "name": "PT-141",
      "slug": "pt-141",
      "url": "https://examinepeptides.com/library/pt-141",
      "aliases": [
        "Bremelanotide",
        "Vyleesi"
      ],
      "category": "Sexual Health",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Hypoactive sexual desire disorder (women), sexual dysfunction research, melanocortin pathway",
      "verdict": "PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women (Vyleesi), providing a regulatory anchor for sexual health research. Phase 3 data in women is solid; male sexual dysfunction data is earlier-stage. For melanocortin-pathway sexual health research, this is the best-evidenced starting point.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Bremelanotide for Female Sexual Dysfunction (RECONNECT Phase 3)",
          "journal": "Obstet Gynecol",
          "year": 2019,
          "url": "https://pubmed.ncbi.nlm.nih.gov/31599840/"
        },
        {
          "title": "Bremelanotide for male sexual dysfunction",
          "journal": "Int J Impot Res",
          "year": 2006,
          "url": "https://pubmed.ncbi.nlm.nih.gov/16107868/"
        }
      ]
    },
    {
      "name": "Pramlintide",
      "slug": "pramlintide",
      "url": "https://examinepeptides.com/library/pramlintide",
      "aliases": [
        "Symlin",
        "Pramlintide acetate",
        "AC137"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Insulin-adjunct glycemic control, postprandial glucose management, amylin pathway research",
      "verdict": "Pramlintide (Symlin) is FDA-approved as an adjunct to insulin in both type 1 and type 2 diabetes, with multiple Phase 3 RCTs supporting meaningful HbA1c and postprandial glucose reduction. Its amylin-mimetic mechanism is distinct from GLP-1 agonism. In combination with GLP-1 agents, amylin agonism shows additive weight-loss effects. A well-validated compound with a real regulatory record.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes",
          "journal": "Diabetes Care",
          "year": 2003,
          "url": "https://doi.org/10.2337/diacare.26.11.3074"
        },
        {
          "title": "Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes",
          "journal": "Diabetes Technology & Therapeutics",
          "year": 2002,
          "url": "https://doi.org/10.1089/15209150252924094"
        },
        {
          "title": "Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy",
          "journal": "Clinical Diabetes",
          "year": 2002,
          "url": "https://doi.org/10.2337/diaclin.20.3.137"
        }
      ]
    },
    {
      "name": "Leuprolide",
      "slug": "leuprolide",
      "url": "https://examinepeptides.com/library/leuprolide",
      "aliases": [
        "Lupron",
        "Eligard",
        "Leuprorelin",
        "Viadur"
      ],
      "category": "Sexual Health",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Prostate cancer hormone therapy, endometriosis, uterine fibroids, precocious puberty, GnRH agonist reference compound",
      "verdict": "Leuprolide (Lupron) is FDA-approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty - one of the broadest indication profiles of any peptide drug in this library. With 40+ years of clinical use and extensive Phase 3 data across multiple indications, it is the reference GnRH agonist. A highly validated compound by any standard.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Leuprolide versus diethylstilbestrol for metastatic prostate cancer",
          "journal": "New England Journal of Medicine",
          "year": 1984,
          "url": "https://pubmed.ncbi.nlm.nih.gov/6390813/"
        },
        {
          "title": "Depot leuprolide acetate for the treatment of endometriosis",
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "year": 1988,
          "url": "https://pubmed.ncbi.nlm.nih.gov/2961785/"
        },
        {
          "title": "Long-term follow-up of central precocious puberty treated with GnRH analogs",
          "journal": "Journal of Pediatric Endocrinology & Metabolism",
          "year": 2008,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18540251/"
        }
      ]
    },
    {
      "name": "Exenatide",
      "slug": "exenatide",
      "url": "https://examinepeptides.com/library/exenatide",
      "aliases": [
        "Byetta",
        "Bydureon",
        "Exendin-4",
        "AC2993"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Type 2 diabetes glycemic control, GLP-1 pharmacology reference compound, cardiovascular risk reduction",
      "verdict": "Exenatide (Byetta/Bydureon) is FDA-approved for type 2 diabetes with extensive clinical data across hundreds of RCTs and real-world use. As the first GLP-1 receptor agonist approved for clinical use, it established the entire drug class. Compared to newer once-weekly GLP-1 agents like semaglutide, it has less weight-loss efficacy and inferior convenience, but its safety record spans two decades. For GLP-1 receptor agonist research, it is a reliable reference compound.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes",
          "journal": "Diabetes Care",
          "year": 2005,
          "url": "https://doi.org/10.2337/diacare.28.5.1092"
        },
        {
          "title": "Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL)",
          "journal": "New England Journal of Medicine",
          "year": 2017,
          "url": "https://doi.org/10.1056/NEJMoa1612917"
        },
        {
          "title": "Exenatide extended-release versus exenatide twice daily: efficacy, safety, and tolerability comparison",
          "journal": "The Lancet",
          "year": 2008,
          "url": "https://doi.org/10.1016/S0140-6736(08)61206-4"
        }
      ]
    },
    {
      "name": "Daptomycin",
      "slug": "daptomycin",
      "url": "https://examinepeptides.com/library/daptomycin",
      "aliases": [
        "Cubicin",
        "LY146032"
      ],
      "category": "Immune Support",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "MRSA bacteremia, right-sided endocarditis, complicated skin and soft tissue infections, gram-positive infection treatment",
      "verdict": "Daptomycin (Cubicin) is FDA-approved for serious gram-positive infections including MRSA bacteremia, endocarditis, and complicated skin infections. It is a first-line IV antibiotic with extensive Phase 3 data and a 20+ year clinical track record. For researchers studying gram-positive infection treatment, daptomycin is a validated standard-of-care option with high-quality evidence.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Daptomycin versus standard therapy for bacteremia and endocarditis caused by S. aureus",
          "journal": "N Engl J Med",
          "year": 2006,
          "url": "https://pubmed.ncbi.nlm.nih.gov/16899778/"
        },
        {
          "title": "Daptomycin for complicated skin and skin-structure infections",
          "journal": "Clin Infect Dis",
          "year": 2004,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15578385/"
        },
        {
          "title": "Mechanism of action of daptomycin",
          "journal": "Proc Natl Acad Sci U S A",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22529384/"
        }
      ]
    },
    {
      "name": "Vancomycin",
      "slug": "vancomycin",
      "url": "https://examinepeptides.com/library/vancomycin",
      "aliases": [
        "Vancocin",
        "Vancoled"
      ],
      "category": "Immune Support",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "MRSA infections, serious gram-positive infections, C. difficile colitis (oral), beta-lactam-resistant infections",
      "verdict": "Vancomycin is FDA-approved and remains the gold standard for MRSA treatment and serious gram-positive infections where beta-lactams are contraindicated. With decades of clinical data, well-established PK/PD targets, and consistent Phase 3 evidence, it is one of the most validated antibiotics in medicine. For gram-positive infection research, vancomycin is the reference compound.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Vancomycin therapeutic guidelines: a summary of consensus recommendations",
          "journal": "Clin Infect Dis",
          "year": 2020,
          "url": "https://pubmed.ncbi.nlm.nih.gov/32058979/"
        },
        {
          "title": "Oral vancomycin versus oral metronidazole for C. difficile infection",
          "journal": "Clin Infect Dis",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24573697/"
        },
        {
          "title": "A historical review of vancomycin clinical pharmacokinetics",
          "journal": "Pharmacotherapy",
          "year": 2011,
          "url": "https://pubmed.ncbi.nlm.nih.gov/21923593/"
        }
      ]
    },
    {
      "name": "Linaclotide",
      "slug": "linaclotide",
      "url": "https://examinepeptides.com/library/linaclotide",
      "aliases": [
        "Linzess",
        "Constella",
        "MD-1100"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "IBS-C, chronic idiopathic constipation, guanylate cyclase-C agonism, visceral pain modulation",
      "verdict": "Linaclotide (Linzess) is FDA-approved for IBS-C and chronic idiopathic constipation, with robust Phase 3 data across multiple trials. It is one of the most prescribed GI peptide drugs in the US, with real-world data supporting its Phase 3 results. For guanylate cyclase-C agonism and IBS-C research, linaclotide is the established reference compound.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Linaclotide for irritable bowel syndrome with constipation: two randomized, double-blind Phase 3 trials",
          "journal": "Am J Gastroenterol",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22986437/"
        },
        {
          "title": "Linaclotide for chronic idiopathic constipation: Phase 3 efficacy and safety",
          "journal": "Am J Gastroenterol",
          "year": 2010,
          "url": "https://pubmed.ncbi.nlm.nih.gov/20145608/"
        },
        {
          "title": "Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cGMP",
          "journal": "Gastroenterology",
          "year": 2013,
          "url": "https://pubmed.ncbi.nlm.nih.gov/23994201/"
        }
      ]
    },
    {
      "name": "Afamelanotide",
      "slug": "melanotan-i",
      "url": "https://examinepeptides.com/library/melanotan-i",
      "aliases": [
        "Melanotan I",
        "MT-I",
        "CUV1647",
        "Scenesse"
      ],
      "category": "Skin & Beauty",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Erythropoietic protoporphyria (EPP) phototoxicity prevention, vitiligo (investigational), melanocortin research",
      "verdict": "Afamelanotide (Scenesse) is FDA-approved for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP) - a rare, severely debilitating condition. The Phase 3 evidence in EPP is solid and the approval is well-founded. Outside EPP, evidence for vitiligo is emerging in Phase 2. This is a legitimate, approved therapeutic for its specific indication.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Afamelanotide for erythropoietic protoporphyria",
          "journal": "New England Journal of Medicine",
          "year": 2015,
          "url": "https://pubmed.ncbi.nlm.nih.gov/26422723/"
        },
        {
          "title": "Phase III trial of afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria",
          "journal": "British Journal of Dermatology",
          "year": 2015,
          "url": "https://pubmed.ncbi.nlm.nih.gov/25600815/"
        },
        {
          "title": "Long-term safety of afamelanotide in patients with erythropoietic protoporphyria",
          "journal": "British Journal of Dermatology",
          "year": 2022,
          "url": "https://pubmed.ncbi.nlm.nih.gov/35229296/"
        }
      ]
    },
    {
      "name": "Oxytocin",
      "slug": "oxytocin",
      "url": "https://examinepeptides.com/library/oxytocin",
      "aliases": [
        "Pitocin",
        "Syntocinon",
        "OXT",
        "Love Hormone"
      ],
      "category": "Sexual Health",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Labor induction (approved), postpartum hemorrhage prevention (approved), social bonding/prosocial behavior research, sexual function enhancement investigation",
      "verdict": "Oxytocin (Pitocin/Syntocinon) is FDA-approved for obstetric indications with an extensive clinical record spanning decades. The evidence for its approved uses - labor induction and postpartum hemorrhage - is robust. Research into its prosocial, anxiolytic, and sexual health effects is active but Phase 2 level. For sexual health research involving trust, bonding, and social cognition, oxytocin is the most studied peptide candidate.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Oxytocin for the third stage of labour",
          "journal": "Cochrane Database of Systematic Reviews",
          "year": 2019,
          "url": "https://pubmed.ncbi.nlm.nih.gov/31496983/"
        },
        {
          "title": "Intranasal oxytocin and social cognition in humans",
          "journal": "Biological Psychiatry",
          "year": 2011,
          "url": "https://pubmed.ncbi.nlm.nih.gov/21367359/"
        },
        {
          "title": "Oxytocin increases trust in humans",
          "journal": "Nature",
          "year": 2005,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15931222/"
        }
      ]
    },
    {
      "name": "Setmelanotide",
      "slug": "setmelanotide",
      "url": "https://examinepeptides.com/library/setmelanotide",
      "aliases": [
        "Imcivree",
        "RM-493",
        "BMS-470539"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "MC4R-pathway genetic obesity (POMC/PCSK1/LEPR deficiency), melanocortin pathway obesity research",
      "verdict": "Setmelanotide (Imcivree) is FDA-approved for chronic weight management in patients with specific genetic obesity syndromes (POMC, PCSK1, or LEPR deficiency). In its approved population, it produces dramatic and clinically meaningful weight loss. Outside this narrow genetic indication, there is no evidence base. It is not a general obesity treatment - but for research into melanocortin pathway obesity, it is the only approved compound in its class.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Setmelanotide for the treatment of POMC deficiency obesity: results of a Phase 3 trial",
          "journal": "Nature Medicine",
          "year": 2020,
          "url": "https://doi.org/10.1038/s41591-020-0911-7"
        },
        {
          "title": "MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency",
          "journal": "Nature Medicine",
          "year": 2016,
          "url": "https://doi.org/10.1038/nm.4140"
        }
      ]
    },
    {
      "name": "Triptorelin",
      "slug": "triptorelin",
      "url": "https://examinepeptides.com/library/triptorelin",
      "aliases": [
        "Trelstar",
        "Decapeptyl",
        "Diphereline",
        "GnRH agonist"
      ],
      "category": "Sexual Health",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Prostate cancer androgen deprivation, gender-affirming hormone therapy, GnRH agonist pharmacology",
      "verdict": "Triptorelin (Trelstar) is FDA-approved for prostate cancer androgen deprivation and gender-affirming hormone therapy, with multiple Phase 3 RCTs supporting both indications. As a GnRH agonist, it produces reliable castrate-level testosterone suppression with a well-characterized adverse effect profile. For research into GnRH agonist pharmacology or testosterone suppression, it is a validated reference compound.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Triptorelin 6-month depot for the treatment of advanced prostate cancer",
          "journal": "European Urology",
          "year": 2009,
          "url": "https://pubmed.ncbi.nlm.nih.gov/19062156/"
        },
        {
          "title": "GnRH agonists in the treatment of endometriosis: a Cochrane review",
          "journal": "Cochrane Database of Systematic Reviews",
          "year": 2010,
          "url": "https://pubmed.ncbi.nlm.nih.gov/20166072/"
        },
        {
          "title": "Triptorelin for central precocious puberty: efficacy and safety",
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "year": 2004,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15126570/"
        }
      ]
    },
    {
      "name": "Dulaglutide",
      "slug": "dulaglutide",
      "url": "https://examinepeptides.com/library/dulaglutide",
      "aliases": [
        "Trulicity",
        "LY2189265"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Type 2 diabetes management, cardiovascular risk reduction, once-weekly GLP-1 agonism",
      "verdict": "Dulaglutide (Trulicity) is FDA-approved for type 2 diabetes and cardiovascular risk reduction, with the REWIND trial demonstrating significant CV event reduction in a broad diabetic population. As a once-weekly GLP-1 agonist, it offers meaningful convenience. Its weight-loss efficacy is modest compared to semaglutide, but its CV outcome data is robust. A well-validated option for GLP-1 pathway research with strong regulatory backing.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial",
          "journal": "The Lancet",
          "year": 2019,
          "url": "https://doi.org/10.1016/S0140-6736(19)31149-3"
        },
        {
          "title": "Efficacy and safety of dulaglutide versus exenatide once weekly (AWARD-1)",
          "journal": "Diabetes Care",
          "year": 2014,
          "url": "https://doi.org/10.2337/dc13-1934"
        },
        {
          "title": "Dulaglutide versus insulin glargine in type 2 diabetes (AWARD-2)",
          "journal": "The Lancet Diabetes & Endocrinology",
          "year": 2015,
          "url": "https://doi.org/10.1016/S2213-8587(15)00005-3"
        }
      ]
    },
    {
      "name": "Nafarelin",
      "slug": "nafarelin",
      "url": "https://examinepeptides.com/library/nafarelin",
      "aliases": [
        "Synarel",
        "Nafarelin Acetate"
      ],
      "category": "Sexual Health",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Endometriosis treatment, central precocious puberty, intranasal GnRH agonist research",
      "verdict": "Nafarelin (Synarel) is FDA-approved for endometriosis and central precocious puberty via intranasal delivery - an unusual route for a peptide drug that demonstrates its unique pharmaceutical development. Phase 3 evidence for both indications is solid. For GnRH agonist research requiring intranasal administration, nafarelin is the validated option.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Nafarelin vs. danazol in the treatment of endometriosis",
          "journal": "American Journal of Obstetrics and Gynecology",
          "year": 1988,
          "url": "https://pubmed.ncbi.nlm.nih.gov/2970787/"
        },
        {
          "title": "Nafarelin in the treatment of central precocious puberty",
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "year": 1994,
          "url": "https://pubmed.ncbi.nlm.nih.gov/7962291/"
        },
        {
          "title": "Long-term efficacy and safety of nafarelin in endometriosis",
          "journal": "Fertility and Sterility",
          "year": 1993,
          "url": "https://pubmed.ncbi.nlm.nih.gov/8405528/"
        }
      ]
    },
    {
      "name": "Plecanatide",
      "slug": "plecanatide",
      "url": "https://examinepeptides.com/library/plecanatide",
      "aliases": [
        "Trulance",
        "SP-304"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "IBS-C, chronic idiopathic constipation, guanylate cyclase-C agonism research",
      "verdict": "Plecanatide (Trulance) is FDA-approved for chronic idiopathic constipation and IBS with constipation, with Phase 3 RCTs demonstrating consistent efficacy on validated endpoints. As a uroguanylin analog that works locally in the GI tract with minimal systemic absorption, it has an excellent safety profile. For guanylate cyclase-C agonist research and IBS-C/CIC treatment, it is a validated option alongside linaclotide.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Efficacy and safety of plecanatide in patients with chronic idiopathic constipation",
          "journal": "Am J Gastroenterol",
          "year": 2017,
          "url": "https://pubmed.ncbi.nlm.nih.gov/27958282/"
        },
        {
          "title": "Plecanatide for irritable bowel syndrome with constipation: Phase 3 trial results",
          "journal": "Am J Gastroenterol",
          "year": 2018,
          "url": "https://pubmed.ncbi.nlm.nih.gov/29545635/"
        },
        {
          "title": "Uroguanylin and guanylin peptide analogs as regulators of intestinal function",
          "journal": "World J Gastroenterol",
          "year": 2015,
          "url": "https://pubmed.ncbi.nlm.nih.gov/25834289/"
        }
      ]
    },
    {
      "name": "Degarelix",
      "slug": "degarelix",
      "url": "https://examinepeptides.com/library/degarelix",
      "aliases": [
        "Firmagon",
        "FE200486"
      ],
      "category": "Sexual Health",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Advanced prostate cancer androgen deprivation, rapid testosterone suppression, GnRH antagonist pharmacology",
      "verdict": "Degarelix (Firmagon) is FDA-approved for advanced prostate cancer with Phase 3 data demonstrating faster testosterone suppression to castrate levels than LHRH agonists (within 3 days vs. 3-4 weeks), without the initial testosterone flare. Multiple comparative trials establish it as a first-line option in patients requiring rapid androgen deprivation. A highly validated prostate cancer treatment with clear pharmacological advantages over GnRH agonists in specific clinical scenarios.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Degarelix: a review of its use in patients with prostate cancer",
          "journal": "Drugs",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24590685/"
        },
        {
          "title": "A phase III extension trial with a 1-arm crossover from leuprolide to degarelix",
          "journal": "J Urol",
          "year": 2011,
          "url": "https://pubmed.ncbi.nlm.nih.gov/21849187/"
        },
        {
          "title": "Cardiovascular risk with GnRH agonists and antagonists: real-world evidence",
          "journal": "Eur Urol",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24007713/"
        }
      ]
    },
    {
      "name": "Bivalirudin",
      "slug": "bivalirudin",
      "url": "https://examinepeptides.com/library/bivalirudin",
      "aliases": [
        "Angiomax",
        "Angiox",
        "BG8967"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "PCI anticoagulation, direct thrombin inhibitor pharmacology, reduced-bleeding anticoagulation research",
      "verdict": "Bivalirudin (Angiomax) is FDA-approved as an anticoagulant for PCI with Phase 3 data from the HORIZONS-AMI and ACUITY trials showing comparable efficacy to heparin plus GP IIb/IIIa inhibitors with significantly reduced bleeding risk. Its direct thrombin inhibition with predictable pharmacokinetics makes it a preferred anticoagulant in specific interventional cardiology settings.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Bivalirudin during primary PCI in acute myocardial infarction (HORIZONS-AMI)",
          "journal": "N Engl J Med",
          "year": 2008,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18539916/"
        },
        {
          "title": "Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI (EUROMAX)",
          "journal": "N Engl J Med",
          "year": 2013,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24171490/"
        },
        {
          "title": "Bivalirudin in acute coronary syndromes and percutaneous coronary intervention: a meta-analysis",
          "journal": "Eur Heart J",
          "year": 2015,
          "url": "https://pubmed.ncbi.nlm.nih.gov/25870204/"
        }
      ]
    },
    {
      "name": "Nesiritide",
      "slug": "nesiritide",
      "url": "https://examinepeptides.com/library/nesiritide",
      "aliases": [
        "Natrecor",
        "rhBNP",
        "Recombinant BNP"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Acute decompensated heart failure symptom management, BNP/natriuretic peptide pharmacology research",
      "verdict": "Nesiritide (Natrecor) is FDA-approved for acute decompensated heart failure with initial enthusiasm tempered by subsequent analysis showing limited mortality benefit and possible renal harm at higher doses. Current guidelines reserve it for symptom relief when other therapies are inadequate. It is a validated BNP analog with a well-characterized pharmacology, but its role in HF management has narrowed with evolving evidence.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Intravenous nesiritide vs nitroglycerin for treatment of decompensated heart failure (VMAC)",
          "journal": "JAMA",
          "year": 2002,
          "url": "https://pubmed.ncbi.nlm.nih.gov/11886298/"
        },
        {
          "title": "Effect of nesiritide in patients with acute decompensated heart failure (ASCEND-HF)",
          "journal": "N Engl J Med",
          "year": 2011,
          "url": "https://pubmed.ncbi.nlm.nih.gov/21742056/"
        },
        {
          "title": "Nesiritide revisited: clinical value and updated safety profile",
          "journal": "J Am Coll Cardiol",
          "year": 2005,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15992638/"
        }
      ]
    },
    {
      "name": "Vasopressin",
      "slug": "vasopressin",
      "url": "https://examinepeptides.com/library/vasopressin",
      "aliases": [
        "ADH",
        "Arginine Vasopressin",
        "AVP",
        "Vasostrict",
        "Pitressin"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Vasodilatory shock, septic shock vasopressor therapy, V1a/V2 receptor pharmacology research",
      "verdict": "Vasopressin (Vasostrict) is FDA-approved for vasodilatory shock (septic shock, post-cardiotomy vasodilatory shock) with Phase 3 evidence from the VASST trial showing non-inferiority to norepinephrine and steroid-sparing potential in septic shock. As an endogenous hormone with a distinct vasoconstrictive mechanism, it is a standard vasopressor in critical care medicine.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Vasopressin versus norepinephrine infusion in patients with septic shock (VASST)",
          "journal": "N Engl J Med",
          "year": 2008,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18305265/"
        },
        {
          "title": "Vasopressin in hemorrhagic shock: a systematic review and meta-analysis",
          "journal": "Resuscitation",
          "year": 2015,
          "url": "https://pubmed.ncbi.nlm.nih.gov/25643651/"
        },
        {
          "title": "A randomized clinical trial of vasopressin and epinephrine for in-hospital cardiac arrest",
          "journal": "Resuscitation",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22067974/"
        }
      ]
    },
    {
      "name": "Terlipressin",
      "slug": "terlipressin",
      "url": "https://examinepeptides.com/library/terlipressin",
      "aliases": [
        "Terlivaz",
        "Glypressin",
        "Terlipressin acetate",
        "triglycyl-lysine vasopressin"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Hepatorenal syndrome type 1 (HRS-1), vasopressin V1 receptor agonism, portal hypertension research",
      "verdict": "Terlipressin (Terlivaz) is FDA-approved for hepatorenal syndrome type 1 - a life-threatening complication of advanced cirrhosis - with Phase 3 data from the CONFIRM trial showing significant reversal of HRS-1 versus placebo. As the first FDA-approved treatment specifically for HRS-1, it represents a meaningful regulatory milestone. Respiratory failure risk in high MELD patients is a real safety consideration that limits its use.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome (CONFIRM)",
          "journal": "N Engl J Med",
          "year": 2021,
          "url": "https://pubmed.ncbi.nlm.nih.gov/33657294/"
        },
        {
          "title": "Terlipressin for hepatorenal syndrome: a systematic review and meta-analysis",
          "journal": "Hepatology",
          "year": 2010,
          "url": "https://pubmed.ncbi.nlm.nih.gov/19998272/"
        },
        {
          "title": "Terlipressin versus noradrenaline for hepatorenal syndrome",
          "journal": "J Hepatol",
          "year": 2016,
          "url": "https://pubmed.ncbi.nlm.nih.gov/26519600/"
        }
      ]
    },
    {
      "name": "Carfilzomib",
      "slug": "carfilzomib",
      "url": "https://examinepeptides.com/library/carfilzomib",
      "aliases": [
        "Kyprolis",
        "PR-171"
      ],
      "category": "Immune Support",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Relapsed/refractory multiple myeloma, proteasome inhibitor pharmacology, bortezomib-resistant disease",
      "verdict": "Carfilzomib (Kyprolis) is FDA-approved for relapsed/refractory multiple myeloma with multiple Phase 3 trials (ASPIRE, ENDEAVOR) showing significant PFS improvement. As an irreversible proteasome inhibitor, it is active against bortezomib-resistant disease and is a standard component of modern myeloma combination regimens. A well-validated oncology drug with robust Phase 3 data.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma (ASPIRE)",
          "journal": "N Engl J Med",
          "year": 2015,
          "url": "https://pubmed.ncbi.nlm.nih.gov/25482145/"
        },
        {
          "title": "Carfilzomib vs bortezomib in relapsed or refractory myeloma (ENDEAVOR)",
          "journal": "Lancet Oncol",
          "year": 2016,
          "url": "https://pubmed.ncbi.nlm.nih.gov/26683766/"
        },
        {
          "title": "Cardiovascular adverse events in carfilzomib-treated patients",
          "journal": "Blood",
          "year": 2019,
          "url": "https://pubmed.ncbi.nlm.nih.gov/30617198/"
        }
      ]
    },
    {
      "name": "Bortezomib",
      "slug": "bortezomib",
      "url": "https://examinepeptides.com/library/bortezomib",
      "aliases": [
        "Velcade",
        "PS-341"
      ],
      "category": "Immune Support",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Multiple myeloma (newly diagnosed and relapsed), mantle cell lymphoma, proteasome biology research",
      "verdict": "Bortezomib (Velcade) is FDA-approved for multiple myeloma and mantle cell lymphoma, with Phase 3 data across numerous trials establishing it as the foundational proteasome inhibitor in oncology. It was the first proteasome inhibitor approved and remains a backbone of myeloma treatment protocols worldwide. An extensively validated cancer therapeutic.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma (VISTA)",
          "journal": "N Engl J Med",
          "year": 2008,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18753647/"
        },
        {
          "title": "Subcutaneous versus intravenous bortezomib in multiple myeloma",
          "journal": "Lancet Oncol",
          "year": 2011,
          "url": "https://pubmed.ncbi.nlm.nih.gov/21481608/"
        },
        {
          "title": "Bortezomib in relapsed mantle cell lymphoma",
          "journal": "J Clin Oncol",
          "year": 2006,
          "url": "https://pubmed.ncbi.nlm.nih.gov/16505417/"
        }
      ]
    },
    {
      "name": "Romidepsin",
      "slug": "romidepsin",
      "url": "https://examinepeptides.com/library/romidepsin",
      "aliases": [
        "Istodax",
        "FK228",
        "Depsipeptide",
        "FR901228"
      ],
      "category": "Immune Support",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Cutaneous T-cell lymphoma, peripheral T-cell lymphoma, HDAC inhibitor pharmacology research",
      "verdict": "Romidepsin (Istodax) is FDA-approved for cutaneous T-cell lymphoma and peripheral T-cell lymphoma with Phase 2/3 data supporting meaningful response rates in these difficult-to-treat malignancies. As a bicyclic depsipeptide HDAC inhibitor, it has a unique cyclopeptide structure within its drug class. A well-validated niche oncology drug with a defined patient population.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Pivotal phase 2 trial of romidepsin in cutaneous T-cell lymphoma",
          "journal": "J Clin Oncol",
          "year": 2010,
          "url": "https://pubmed.ncbi.nlm.nih.gov/20585093/"
        },
        {
          "title": "Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma",
          "journal": "Blood",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22323479/"
        },
        {
          "title": "Romidepsin: a histone deacetylase inhibitor for the treatment of T-cell lymphomas",
          "journal": "Expert Opin Drug Metab Toxicol",
          "year": 2011,
          "url": "https://pubmed.ncbi.nlm.nih.gov/21770734/"
        }
      ]
    },
    {
      "name": "Ziconotide",
      "slug": "ziconotide",
      "url": "https://examinepeptides.com/library/ziconotide",
      "aliases": [
        "Prialt",
        "SNX-111",
        "omega-conotoxin MVIIA"
      ],
      "category": "Cognitive & Nootropic",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Severe chronic refractory pain (intrathecal), N-type calcium channel pharmacology, non-opioid analgesic research",
      "verdict": "Ziconotide (Prialt) is FDA-approved for severe chronic pain via intrathecal delivery - the only non-opioid intrathecal analgesic with regulatory approval. Phase 3 data demonstrates significant pain reduction in patients refractory to other analgesics including intrathecal opioids. Its N-type calcium channel mechanism is fully differentiated from opioid pathways. A highly specialized but validated analgesic for refractory chronic pain.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Intrathecal ziconotide in the treatment of refractory pain",
          "journal": "JAMA",
          "year": 2004,
          "url": "https://pubmed.ncbi.nlm.nih.gov/14722147/"
        },
        {
          "title": "A randomized, double-blind, placebo-controlled trial of ziconotide for chronic pain",
          "journal": "Pain",
          "year": 2006,
          "url": "https://pubmed.ncbi.nlm.nih.gov/16387425/"
        },
        {
          "title": "Ziconotide: a review of its pharmacology and use in chronic pain",
          "journal": "Neurotherapeutics",
          "year": 2007,
          "url": "https://pubmed.ncbi.nlm.nih.gov/17599707/"
        }
      ]
    },
    {
      "name": "Eptifibatide",
      "slug": "eptifibatide",
      "url": "https://examinepeptides.com/library/eptifibatide",
      "aliases": [
        "Integrilin"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Acute coronary syndrome management, PCI antiplatelet therapy, GP IIb/IIIa inhibition research",
      "verdict": "Eptifibatide (Integrilin) is FDA-approved for acute coronary syndrome and PCI with Phase 3 evidence from the PURSUIT and ESPRIT trials demonstrating reduced composite ischemic endpoints. As a cyclic RGD peptide GP IIb/IIIa inhibitor, it provides potent antiplatelet effect during percutaneous intervention. A well-established cardiovascular drug with a clear, validated indication.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes (PURSUIT)",
          "journal": "N Engl J Med",
          "year": 1998,
          "url": "https://pubmed.ncbi.nlm.nih.gov/9703321/"
        },
        {
          "title": "Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT)",
          "journal": "Lancet",
          "year": 2000,
          "url": "https://pubmed.ncbi.nlm.nih.gov/11130385/"
        },
        {
          "title": "Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing PCI",
          "journal": "Drugs",
          "year": 2005,
          "url": "https://pubmed.ncbi.nlm.nih.gov/16060707/"
        }
      ]
    },
    {
      "name": "Trofinetide",
      "slug": "trofinetide",
      "url": "https://examinepeptides.com/library/trofinetide",
      "aliases": [
        "Daybue",
        "NNZ-2566",
        "Glycyl-L-2-Methylprolyl-L-Glutamic acid"
      ],
      "category": "Cognitive & Nootropic",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Rett syndrome (the approved indication), IGF-1/BDNF signaling in neurodevelopmental research",
      "verdict": "Trofinetide (Daybue) is FDA-approved as the first treatment specifically indicated for Rett syndrome - a significant regulatory milestone for a devastating neurodevelopmental disorder. Phase 3 data from the LAVENDER trial showed statistically significant improvement on the Rett Syndrome Behaviour Questionnaire and clinician global impression scores. A landmark approval for a rare disease with no prior approved treatment.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study (LAVENDER)",
          "journal": "Nat Med",
          "year": 2023,
          "url": "https://pubmed.ncbi.nlm.nih.gov/36894652/"
        },
        {
          "title": "A phase 2 randomized clinical trial of trofinetide in Rett syndrome (DAFFODIL)",
          "journal": "Pediatr Neurol",
          "year": 2019,
          "url": "https://pubmed.ncbi.nlm.nih.gov/30609870/"
        },
        {
          "title": "GPE and trofinetide: neuroprotective mechanisms and clinical application in Rett syndrome",
          "journal": "J Child Neurol",
          "year": 2020,
          "url": "https://pubmed.ncbi.nlm.nih.gov/32450780/"
        }
      ]
    },
    {
      "name": "Pasireotide",
      "slug": "pasireotide",
      "url": "https://examinepeptides.com/library/pasireotide",
      "aliases": [
        "Signifor",
        "Signifor LAR",
        "SOM230"
      ],
      "category": "Growth Hormone",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Cushing's disease (ACTH-secreting pituitary adenoma), multi-receptor somatostatin pharmacology, acromegaly (LAR formulation)",
      "verdict": "Pasireotide (Signifor) is FDA-approved for Cushing's disease in patients who fail surgery or are not surgical candidates, with Phase 3 data demonstrating meaningful UFC normalization. Its multi-receptor somatostatin analog profile (SST1/2/3/5) differentiates it from octreotide and allows ACTH suppression that octreotide cannot achieve. A validated, targeted treatment for a rare pituitary disorder.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Pasireotide treatment significantly reduces urinary free cortisol in Cushing's disease",
          "journal": "J Clin Endocrinol Metab",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22319038/"
        },
        {
          "title": "Pasireotide LAR versus octreotide LAR or lanreotide in acromegaly (PAOLA)",
          "journal": "J Clin Endocrinol Metab",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24423309/"
        },
        {
          "title": "Management of pasireotide-associated hyperglycemia in Cushing's disease and acromegaly",
          "journal": "Pituitary",
          "year": 2016,
          "url": "https://pubmed.ncbi.nlm.nih.gov/27048279/"
        }
      ]
    },
    {
      "name": "Octreotide",
      "slug": "octreotide",
      "url": "https://examinepeptides.com/library/octreotide",
      "aliases": [
        "Sandostatin",
        "Sandostatin LAR",
        "SMS 201-995"
      ],
      "category": "Growth Hormone",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Acromegaly, carcinoid syndrome, VIPoma, GH/IGF-1 suppression, somatostatin analog pharmacology",
      "verdict": "Octreotide (Sandostatin) is FDA-approved for acromegaly, carcinoid syndrome, and VIPoma with an extensive evidence base spanning 35+ years of clinical use. As the first synthetic somatostatin analog approved, it remains the most widely used in its class. Multiple Phase 3 trials and decades of real-world data make it the reference compound for somatostatin pharmacology.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID)",
          "journal": "J Clin Oncol",
          "year": 2009,
          "url": "https://pubmed.ncbi.nlm.nih.gov/19770401/"
        },
        {
          "title": "A meta-analysis of the efficacy of octreotide in acromegaly",
          "journal": "J Clin Endocrinol Metab",
          "year": 2005,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15585555/"
        },
        {
          "title": "Long-term treatment of acromegaly with octreotide",
          "journal": "Ann Intern Med",
          "year": 1992,
          "url": "https://pubmed.ncbi.nlm.nih.gov/1350716/"
        }
      ]
    },
    {
      "name": "Lanreotide",
      "slug": "lanreotide",
      "url": "https://examinepeptides.com/library/lanreotide",
      "aliases": [
        "Somatuline Depot",
        "Somatuline Autogel",
        "BIM-23014"
      ],
      "category": "Growth Hormone",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Acromegaly, gastroenteropancreatic NETs, somatostatin analog pharmacology, GH/IGF-1 suppression",
      "verdict": "Lanreotide (Somatuline) is FDA-approved for acromegaly and gastroenteropancreatic NETs, with Phase 3 data including the CLARINET trial showing significant PFS improvement in well-differentiated GEP-NETs. As a deep subcutaneous depot injection, it offers 28-day dosing convenience. A well-validated alternative to octreotide LAR with superior NET data.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Lanreotide in metastatic enteropancreatic neuroendocrine tumors (CLARINET)",
          "journal": "N Engl J Med",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24988936/"
        },
        {
          "title": "Lanreotide Autogel for acromegaly: integrated 5-year efficacy and safety data",
          "journal": "J Clin Endocrinol Metab",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24471568/"
        },
        {
          "title": "Comparison of lanreotide and octreotide in the treatment of acromegaly",
          "journal": "Pituitary",
          "year": 2008,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18415026/"
        }
      ]
    },
    {
      "name": "Desmopressin",
      "slug": "desmopressin",
      "url": "https://examinepeptides.com/library/desmopressin",
      "aliases": [
        "DDAVP",
        "Stimate",
        "Minirin",
        "Noctiva",
        "1-deamino-8-D-arginine vasopressin"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Central diabetes insipidus, nocturnal enuresis, hemostasis in mild hemophilia A/vWD type I, ADH receptor research",
      "verdict": "Desmopressin (DDAVP) is FDA-approved for central diabetes insipidus, primary nocturnal enuresis, and hemostasis in mild hemophilia A/von Willebrand disease type I - a broad indication profile reflecting 40+ years of clinical evidence. Its selectivity for V2 receptors over V1 receptors (versus natural vasopressin) makes it the preferred ADH analog for antidiuretic applications. A highly validated, multi-indication peptide drug.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Desmopressin for nocturnal enuresis in children",
          "journal": "Cochrane Database Syst Rev",
          "year": 2002,
          "url": "https://pubmed.ncbi.nlm.nih.gov/12137647/"
        },
        {
          "title": "DDAVP in the treatment of central diabetes insipidus",
          "journal": "J Intern Med",
          "year": 2004,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15009784/"
        },
        {
          "title": "Desmopressin for the treatment of bleeding disorders",
          "journal": "Haemophilia",
          "year": 2008,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18034816/"
        }
      ]
    },
    {
      "name": "Calcitonin",
      "slug": "calcitonin",
      "url": "https://examinepeptides.com/library/calcitonin",
      "aliases": [
        "Miacalcin",
        "Fortical",
        "Salmon Calcitonin",
        "Calcitonin-salmon"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Postmenopausal osteoporosis (second-line), Paget's disease, hypercalcemia of malignancy, bone pain modulation",
      "verdict": "Calcitonin (Miacalcin/Fortical) is FDA-approved for postmenopausal osteoporosis and Paget's disease, with decades of clinical data supporting its antiresorptive and analgesic effects. It is no longer considered a first-line osteoporosis agent - bisphosphonates and denosumab have superior fracture reduction data - but it retains approval and a valid evidence base. For calcitonin receptor pharmacology and pain modulation research, it is the reference compound.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis (PROOF)",
          "journal": "Am J Med",
          "year": 2000,
          "url": "https://pubmed.ncbi.nlm.nih.gov/11027954/"
        },
        {
          "title": "Calcitonin for Paget's disease of bone",
          "journal": "Bone",
          "year": 2006,
          "url": "https://pubmed.ncbi.nlm.nih.gov/16860614/"
        },
        {
          "title": "Calcitonin for the treatment and prevention of osteoporotic fractures",
          "journal": "Cochrane Database Syst Rev",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22786491/"
        }
      ]
    },
    {
      "name": "Macimorelin",
      "slug": "macimorelin",
      "url": "https://examinepeptides.com/library/macimorelin",
      "aliases": [
        "Macrilen",
        "AEZS-130",
        "EP-01572",
        "JMV 1843"
      ],
      "category": "Growth Hormone",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Adult GH deficiency diagnosis, GH stimulation testing, GH axis research",
      "verdict": "Macimorelin (Macrilen) is FDA-approved as the first oral diagnostic test for adult GH deficiency, replacing the insulin tolerance test in many clinical settings. Its role is diagnostic, not therapeutic. For researchers studying the GH/IGF-1 axis and needing a validated, reproducible stimulation test, macimorelin is the current standard of care with actual FDA approval behind it.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Oral macimorelin diagnostic test for adult GH deficiency: validation study",
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "year": 2018,
          "url": "https://doi.org/10.1210/jc.2018-00665"
        },
        {
          "title": "Macimorelin as a diagnostic test for adult growth hormone deficiency: Phase 3 results",
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "year": 2017,
          "url": "https://doi.org/10.1210/jc.2016-3737"
        }
      ]
    },
    {
      "name": "Enfuvirtide",
      "slug": "enfuvirtide",
      "url": "https://examinepeptides.com/library/enfuvirtide",
      "aliases": [
        "Fuzeon",
        "T-20",
        "DP-178"
      ],
      "category": "Immune Support",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "HIV-1 treatment in antiretroviral-experienced patients, HIV fusion inhibitor pharmacology",
      "verdict": "Enfuvirtide (Fuzeon) is FDA-approved for HIV-1 treatment in adults with ongoing viral replication despite prior antiretroviral therapy. It is the first fusion inhibitor approved and works at a mechanistically distinct step from all other ARV classes. Phase 3 data from TORO-1 and TORO-2 trials showed significant viral suppression in treatment-experienced patients. Its twice-daily subcutaneous injection requirement limits real-world use, but the evidence is solid.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America (TORO 1)",
          "journal": "N Engl J Med",
          "year": 2003,
          "url": "https://pubmed.ncbi.nlm.nih.gov/12646596/"
        },
        {
          "title": "Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia (TORO 2)",
          "journal": "N Engl J Med",
          "year": 2003,
          "url": "https://pubmed.ncbi.nlm.nih.gov/12646597/"
        },
        {
          "title": "Long-term efficacy and safety of enfuvirtide in antiretroviral-experienced patients",
          "journal": "J Acquir Immune Defic Syndr",
          "year": 2005,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15956277/"
        }
      ]
    },
    {
      "name": "Pegvisomant",
      "slug": "pegvisomant",
      "url": "https://examinepeptides.com/library/pegvisomant",
      "aliases": [
        "Somavert",
        "B2036-PEG"
      ],
      "category": "Growth Hormone",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Acromegaly treatment, GH receptor antagonism research, IGF-1 normalization",
      "verdict": "Pegvisomant (Somavert) is FDA-approved for acromegaly and is the most effective agent for normalizing IGF-1 in GH-excess states - achieving normal IGF-1 in approximately 97% of patients in clinical practice. As a GH receptor antagonist rather than a somatostatin analog, its mechanism is fully distinct. For research into GH receptor physiology and GH excess disorders, pegvisomant is the pharmacological gold standard.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant",
          "journal": "New England Journal of Medicine",
          "year": 2000,
          "url": "https://doi.org/10.1056/NEJM200011163432001"
        },
        {
          "title": "Long-term treatment of acromegaly with pegvisomant: a multicenter surveillance study",
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "year": 2012,
          "url": "https://doi.org/10.1210/jc.2011-2616"
        }
      ]
    },
    {
      "name": "Gonadorelin",
      "slug": "gonadorelin",
      "url": "https://examinepeptides.com/library/gonadorelin",
      "aliases": [
        "GnRH",
        "LHRH",
        "Gonadotropin-Releasing Hormone",
        "Factrel",
        "Lutrelef"
      ],
      "category": "Sexual Health",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "HPA axis diagnostic testing, hypogonadotropic hypogonadism treatment, fertility protocol support, HPG axis research",
      "verdict": "Gonadorelin is FDA-approved as a diagnostic agent for assessing hypothalamic-pituitary-gonadal axis function, with extensive clinical use in fertility workup. As a short-acting GnRH pulse used to stimulate LH/FSH secretion, it also has applications in hypogonadotropic hypogonadism treatment and fertility protocols. A well-validated compound with a real regulatory record.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Pulsatile GnRH therapy for hypothalamic amenorrhea",
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "year": 1993,
          "url": "https://pubmed.ncbi.nlm.nih.gov/8473405/"
        },
        {
          "title": "GnRH stimulation test in the assessment of pubertal disorders",
          "journal": "Arquivos Brasileiros de Endocrinologia & Metabologia",
          "year": 2008,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18345394/"
        }
      ]
    },
    {
      "name": "Cetrorelix",
      "slug": "cetrorelix",
      "url": "https://examinepeptides.com/library/cetrorelix",
      "aliases": [
        "Cetrotide",
        "GnRH antagonist"
      ],
      "category": "Sexual Health",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "IVF ovarian stimulation protocols, LH surge prevention, GnRH antagonist research",
      "verdict": "Cetrorelix (Cetrotide) is FDA-approved as a standard component of controlled ovarian stimulation protocols in IVF, with Phase 3 data supporting its efficacy in preventing premature LH surges. It is an established clinical tool with a well-defined use case, reliable dosing, and a strong safety record in reproductive medicine.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis",
          "journal": "Human Reproduction Update",
          "year": 2016,
          "url": "https://pubmed.ncbi.nlm.nih.gov/26628217/"
        },
        {
          "title": "Cetrorelix for preventing premature LH surges in women undergoing ovarian stimulation",
          "journal": "Human Reproduction",
          "year": 1997,
          "url": "https://pubmed.ncbi.nlm.nih.gov/9262268/"
        }
      ]
    },
    {
      "name": "Abarelix",
      "slug": "abarelix",
      "url": "https://examinepeptides.com/library/abarelix",
      "aliases": [
        "Plenaxis",
        "GnRH antagonist (injectable)"
      ],
      "category": "Sexual Health",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Historical GnRH antagonist pharmacology reference only - not recommended for new research protocols",
      "verdict": "Abarelix (Plenaxis) is FDA-approved but was withdrawn from the US market due to a 3.7% anaphylaxis rate - a serious safety signal that terminated its commercial development. It established proof-of-concept for GnRH antagonism in prostate cancer, but degarelix (with a superior safety profile and active marketing) has replaced it as the GnRH antagonist of choice. Abarelix is a cautionary example, not a starting point.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Abarelix depot versus leuprolide acetate for prostate cancer",
          "journal": "Journal of Urology",
          "year": 2002,
          "url": "https://pubmed.ncbi.nlm.nih.gov/11956645/"
        },
        {
          "title": "Immediate-onset reactions to abarelix in prostate cancer patients",
          "journal": "Urology",
          "year": 2003,
          "url": "https://pubmed.ncbi.nlm.nih.gov/14550455/"
        }
      ]
    },
    {
      "name": "Liraglutide",
      "slug": "liraglutide",
      "url": "https://examinepeptides.com/library/liraglutide",
      "aliases": [
        "Victoza",
        "Saxenda"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Obesity, type 2 diabetes, weight management research, GLP-1 reference compound",
      "verdict": "Liraglutide is FDA-approved for type 2 diabetes (Victoza) and obesity (Saxenda), with Phase 3 RCT data (SCALE trial) showing 8-9% body weight reduction - meaningful but less than semaglutide or tirzepatide. It is well-characterized with a long safety record. For weight management research where once-daily dosing is acceptable, liraglutide is a solid, established reference compound.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)",
          "journal": "N Engl J Med",
          "year": 2016,
          "url": "https://pubmed.ncbi.nlm.nih.gov/27295427/"
        },
        {
          "title": "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)",
          "journal": "N Engl J Med",
          "year": 2015,
          "url": "https://pubmed.ncbi.nlm.nih.gov/26132939/"
        }
      ]
    },
    {
      "name": "Motixafortide",
      "slug": "motixafortide",
      "url": "https://examinepeptides.com/library/motixafortide",
      "aliases": [
        "Aphexda",
        "BL-8040",
        "BKT140"
      ],
      "category": "Immune Support",
      "evidenceLevel": "A",
      "researchStatus": "FDA Approved",
      "bestFor": "Hematopoietic stem cell mobilization (multiple myeloma transplant), CXCR4 antagonist pharmacology",
      "verdict": "Motixafortide (Aphexda) is FDA-approved in combination with G-CSF for hematopoietic stem cell mobilization prior to autologous transplantation in multiple myeloma. The Phase 3 GENESIS trial showed significantly more CD34+ cells mobilized with fewer apheresis sessions versus G-CSF alone. A well-evidenced stem cell mobilization enhancer for a specific transplant medicine context.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Motixafortide and G-CSF for stem cell mobilization in multiple myeloma (GENESIS)",
          "journal": "N Engl J Med",
          "year": 2023,
          "url": "https://pubmed.ncbi.nlm.nih.gov/37140152/"
        },
        {
          "title": "BL-8040 (motixafortide): a novel CXCR4 antagonist for stem cell mobilization",
          "journal": "Clin Cancer Res",
          "year": 2019,
          "url": "https://pubmed.ncbi.nlm.nih.gov/30862688/"
        }
      ]
    },
    {
      "name": "Retatrutide",
      "slug": "retatrutide",
      "url": "https://examinepeptides.com/library/retatrutide",
      "aliases": [
        "LY3437943",
        "GGG Triple Agonist"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "B",
      "researchStatus": "Phase 3",
      "bestFor": "Weight loss research, obesity pharmacology, metabolic dysfunction-associated steatotic liver disease",
      "verdict": "Retatrutide now has the strongest reported weight-loss signal in the library: Lilly's Phase 3 TRIUMPH-1 topline data showed -28.3% at 80 weeks and up to -30.3% in a 104-week extension subgroup. It is still investigational and unpublished in full, so tirzepatide remains the approved default; retatrutide is the leading next-generation candidate to watch.",
      "lastReviewed": "2026-06-01",
      "primarySources": [
        {
          "title": "Retatrutide once weekly for treatment of obesity: a phase 2, randomised, double-blind, placebo-controlled trial",
          "journal": "The Lancet",
          "year": 2023,
          "url": "https://doi.org/10.1016/S0140-6736(23)01200-X"
        },
        {
          "title": "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease",
          "journal": "New England Journal of Medicine",
          "year": 2024,
          "url": "https://doi.org/10.1056/NEJMoa2401943"
        },
        {
          "title": "Efficacy and safety of retatrutide in type 2 diabetes: a phase 2 trial",
          "journal": "Diabetes Care",
          "year": 2023,
          "url": "https://doi.org/10.2337/dc23-0973"
        }
      ]
    },
    {
      "name": "BPC-157",
      "slug": "bpc-157",
      "url": "https://examinepeptides.com/library/bpc-157",
      "aliases": [
        "Body Protection Compound-157",
        "Bepecin",
        "PL-10"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "B",
      "researchStatus": "Phase 2",
      "bestFor": "Tendon & ligament repair, gut healing, post-injury recovery",
      "verdict": "BPC-157 still has the strongest preclinical healing profile of any peptide in this library. The June 2026 update adds human arterial-tissue evidence for nitric-oxide-mediated vasorelaxation, but it does not solve the central limitation: no completed human efficacy trial or approved formulation. For research purposes, it remains the most-studied starting point for tissue repair mechanisms, not a clinically validated therapy.",
      "lastReviewed": "2026-06-01",
      "primarySources": [
        {
          "title": "Tendon healing by BPC 157 in rats: results assessed by electron microscopy and force-velocity tests",
          "journal": "J Orthop Res",
          "year": 2003,
          "url": "https://pubmed.ncbi.nlm.nih.gov/14554209/"
        },
        {
          "title": "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (IBD): stable gastric pentadecapeptide BPC 157 as both glioblastoma standard-of-care and IBD standard-of-care",
          "journal": "Curr Pharm Des",
          "year": 2011,
          "url": "https://pubmed.ncbi.nlm.nih.gov/21631407/"
        },
        {
          "title": "Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts",
          "journal": "Molecules",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/25356565/"
        },
        {
          "title": "BPC 157 and the healing of various tissues",
          "journal": "Adv Exp Med Biol",
          "year": 2021,
          "url": "https://pubmed.ncbi.nlm.nih.gov/33988832/"
        },
        {
          "title": "The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats",
          "journal": "Brain Behav",
          "year": 2020,
          "url": "https://pubmed.ncbi.nlm.nih.gov/32396703/"
        },
        {
          "title": "Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157: NO-system relation, dose- and time-dependent cytoprotection/healing, J Physiol Paris.",
          "journal": "J Physiol Paris",
          "year": 2010,
          "url": "https://pubmed.ncbi.nlm.nih.gov/20080177/"
        },
        {
          "title": "Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery",
          "journal": "J Clin Med",
          "year": 2026,
          "url": "https://pubmed.ncbi.nlm.nih.gov/42123221/"
        },
        {
          "title": "BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers",
          "journal": "Pharmaceutics",
          "year": 2026,
          "url": "https://pubmed.ncbi.nlm.nih.gov/42198317/"
        }
      ]
    },
    {
      "name": "TB-500",
      "slug": "tb-500",
      "url": "https://examinepeptides.com/library/tb-500",
      "aliases": [
        "Thymosin Beta-4",
        "Tβ4",
        "Timbetasin"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "B",
      "researchStatus": "Phase 2",
      "bestFor": "Musculoskeletal repair, wound healing, cardiac recovery",
      "verdict": "TB-500 has a critical advantage over most healing peptides: its mechanism (G-actin sequestration) has been independently replicated by multiple research groups, and RegeneRx conducted formal Phase 2 human trials. Those trials produced mixed results - positive trends but not statistical significance on primary endpoints. The translational gap likely reflects formulation and dosing challenges, not a false preclinical signal. For musculoskeletal research, TB-500 is the best-evidenced starting point that also has independent mechanistic validation.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair",
          "journal": "Nature",
          "year": 2004,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15475955/"
        },
        {
          "title": "Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization",
          "journal": "Nature",
          "year": 2007,
          "url": "https://pubmed.ncbi.nlm.nih.gov/17108969/"
        },
        {
          "title": "Thymosin beta4 promotes dermal healing",
          "journal": "Ann N Y Acad Sci",
          "year": 2007,
          "url": "https://pubmed.ncbi.nlm.nih.gov/17114286/"
        },
        {
          "title": "Thymosin beta4 mobilizes hair follicle stem cells to undergo folliculogenesis in the mouse",
          "journal": "FASEB J",
          "year": 2004,
          "url": "https://pubmed.ncbi.nlm.nih.gov/14715696/"
        },
        {
          "title": "Phase 2 clinical trial of thymosin beta 4 eye drops (RGN-259) for neurotrophic keratopathy",
          "journal": "Expert Opin Investig Drugs",
          "year": 2018,
          "url": "https://pubmed.ncbi.nlm.nih.gov/29393706/"
        },
        {
          "title": "Actin-sequestering proteins and their involvement in wound healing and tissue repair",
          "journal": "Trends Cell Biol",
          "year": 2005,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15752977/"
        }
      ]
    },
    {
      "name": "Sermorelin",
      "slug": "sermorelin",
      "url": "https://examinepeptides.com/library/sermorelin",
      "aliases": [
        "Geref",
        "GRF 1-29",
        "GHRH(1-29)"
      ],
      "category": "Growth Hormone",
      "evidenceLevel": "B",
      "researchStatus": "FDA Approved",
      "bestFor": "GH deficiency investigation, GHRH axis research, anti-aging GH stimulation",
      "verdict": "Sermorelin has FDA-approved history (pediatric GHD) and Phase 2 human data on GH stimulation and body composition, though its short half-life limits practical utility compared to longer-acting GHRH analogs. Evidence is weaker than tesamorelin but stronger than most other GHRH analogs. For GHRH-pathway research, tesamorelin or CJC-1295 are better-evidenced alternatives depending on the endpoint.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Sermorelin: a review of its use in the diagnosis and treatment of growth hormone deficiency",
          "journal": "Drugs",
          "year": 2006,
          "url": "https://pubmed.ncbi.nlm.nih.gov/"
        },
        {
          "title": "Effects of 6-month administration of sermorelin on body composition in elderly subjects",
          "journal": "J Clin Endocrinol Metab",
          "year": 1997,
          "url": "https://pubmed.ncbi.nlm.nih.gov/9329346/"
        }
      ]
    },
    {
      "name": "GHK-Cu",
      "slug": "ghk-cu",
      "url": "https://examinepeptides.com/library/ghk-cu",
      "aliases": [
        "Copper Peptide GHK",
        "Glycyl-L-Histidyl-L-Lysine Copper"
      ],
      "category": "Skin & Beauty",
      "evidenceLevel": "B",
      "researchStatus": "Phase 2",
      "bestFor": "Skin rejuvenation, wound healing (topical), collagen support",
      "verdict": "GHK-Cu is the only peptide in this library with meaningful human skin data - multiple small RCTs showing collagen synthesis improvement and wrinkle reduction at topical doses. For skin applications specifically, it has a stronger evidence base than almost anything else here. Its systemic effects on gene regulation are intriguing but remain preclinical.",
      "lastReviewed": "2026-06-01",
      "primarySources": [
        {
          "title": "The effect of glycyl-L-histidyl-L-lysine copper (II) on the production of extracellular matrix components",
          "journal": "Life Sci",
          "year": 1992,
          "url": "https://pubmed.ncbi.nlm.nih.gov/1356440/"
        },
        {
          "title": "GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration",
          "journal": "Biomed Res Int",
          "year": 2015,
          "url": "https://pubmed.ncbi.nlm.nih.gov/25861634/"
        },
        {
          "title": "Topical copper tripeptide complex and tretinoin in photoaged facial skin",
          "journal": "J Drugs Dermatol",
          "year": 2004,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15060440/"
        },
        {
          "title": "The role of the tripeptide copper complex glycyl-L-histidyl-L-lysine in wound healing and recovery from tissue damage",
          "journal": "Life Sci",
          "year": 2008,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18501369/"
        },
        {
          "title": "Stimulation of collagen synthesis by the tripeptide-copper complex Gly-His-Lys-Cu2+",
          "journal": "FEBS Lett",
          "year": 1988,
          "url": "https://pubmed.ncbi.nlm.nih.gov/3366162/"
        },
        {
          "title": "The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways",
          "journal": "Biogerontology",
          "year": 2026,
          "url": "https://pubmed.ncbi.nlm.nih.gov/42084774/"
        }
      ]
    },
    {
      "name": "Survodutide",
      "slug": "survodutide",
      "url": "https://examinepeptides.com/library/survodutide",
      "aliases": [
        "BI 456906",
        "Glucagon/GLP-1 dual agonist"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "B",
      "researchStatus": "Phase 3",
      "bestFor": "Weight loss research, MASLD/NASH, GLP-1/glucagon dual agonism pharmacology",
      "verdict": "Survodutide now has Phase 3 topline obesity data, but its weight-loss signal sits below tirzepatide and retatrutide. Its best case remains differentiated liver and MASH biology: the glucagon receptor component may matter more for hepatic fat and MASH than for pure weight-loss ranking. Strong candidate, not the default obesity pick.",
      "lastReviewed": "2026-06-01",
      "primarySources": [
        {
          "title": "Survodutide for the treatment of obesity: a Phase 2 randomized clinical trial",
          "journal": "JAMA Network Open",
          "year": 2024,
          "url": "https://doi.org/10.1001/jamanetworkopen.2024.0979"
        },
        {
          "title": "Survodutide, a dual glucagon/GLP-1 receptor agonist, for MASH: a Phase 2 trial",
          "journal": "New England Journal of Medicine",
          "year": 2024,
          "url": "https://doi.org/10.1056/NEJMoa2401755"
        },
        {
          "title": "Glucagon/GLP-1 receptor dual agonism: mechanisms and therapeutic potential",
          "journal": "Diabetes, Obesity and Metabolism",
          "year": 2018,
          "url": "https://doi.org/10.1111/dom.13427"
        }
      ]
    },
    {
      "name": "NAD+ Precursors (NMN/NR)",
      "slug": "nad-plus",
      "url": "https://examinepeptides.com/library/nad-plus",
      "aliases": [
        "Nicotinamide Mononucleotide",
        "Nicotinamide Riboside",
        "NMN",
        "NR",
        "Beta-NMN"
      ],
      "category": "Anti-Aging & Longevity",
      "evidenceLevel": "B",
      "researchStatus": "Phase 2",
      "bestFor": "NAD+ restoration, metabolic aging research, cardiovascular risk factor modulation, muscle function in aging",
      "verdict": "NAD+ precursors (NMN/NR) have Phase 2 human data demonstrating reliable NAD+ elevation in blood, with emerging evidence for metabolic, cardiovascular, and muscle function benefits. The evidence is not yet at Phase 3 scale for any single indication, but the mechanistic foundation and human safety data are solid across multiple independent groups. For longevity-adjacent interventions with actual human data, NAD+ precursors are the most evidence-supported option in this category.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners",
          "journal": "Journal of the International Society of Sports Nutrition",
          "year": 2021,
          "url": "https://pubmed.ncbi.nlm.nih.gov/34238308/"
        },
        {
          "title": "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults",
          "journal": "Nature Communications",
          "year": 2018,
          "url": "https://pubmed.ncbi.nlm.nih.gov/29599478/"
        },
        {
          "title": "NAD+ metabolism and its roles in cellular processes during ageing",
          "journal": "Nature Reviews Molecular Cell Biology",
          "year": 2021,
          "url": "https://pubmed.ncbi.nlm.nih.gov/33353981/"
        }
      ]
    },
    {
      "name": "Ipamorelin",
      "slug": "ipamorelin",
      "url": "https://examinepeptides.com/library/ipamorelin",
      "aliases": [
        "IPA",
        "NNC 26-0161"
      ],
      "category": "Growth Hormone",
      "evidenceLevel": "B",
      "researchStatus": "Phase 2",
      "bestFor": "GH secretagogue research, clean GH pulsatility, stacking with GHRH analogs",
      "verdict": "Ipamorelin stands out among growth hormone secretagogues for one critical reason: it is the only GHRP that does not significantly elevate cortisol, ACTH, or prolactin at research doses. This selectivity makes it the cleanest tool for studying GH pulsatility in isolation. It has Phase 2 human data (post-operative ileus trial) confirming pharmacological activity. The body composition effects are real but modest - ipamorelin is not a substitute for exogenous GH, it is a physiologically cleaner way to study GH secretion.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Ipamorelin, a new growth-hormone-releasing peptide/secretagogue",
          "journal": "Eur J Endocrinol",
          "year": 1998,
          "url": "https://pubmed.ncbi.nlm.nih.gov/9916862/"
        },
        {
          "title": "Safety and pharmacokinetics of ipamorelin in healthy volunteers",
          "journal": "J Clin Pharmacol",
          "year": 1999,
          "url": "https://pubmed.ncbi.nlm.nih.gov/"
        },
        {
          "title": "Growth hormone secretagogues: clinical applications",
          "journal": "J Endocrinol",
          "year": 2005,
          "url": "https://pubmed.ncbi.nlm.nih.gov/"
        }
      ]
    },
    {
      "name": "CJC-1295",
      "slug": "cjc-1295",
      "url": "https://examinepeptides.com/library/cjc-1295",
      "aliases": [
        "CJC-1295 DAC",
        "CJC-1295 no DAC",
        "Modified GRF 1-29"
      ],
      "category": "Growth Hormone",
      "evidenceLevel": "B",
      "researchStatus": "Phase 2",
      "bestFor": "GHRH-mediated GH axis stimulation, body composition research, GH deficiency investigation",
      "verdict": "CJC-1295 has Phase 1/2 human data demonstrating sustained GH and IGF-1 elevation, but no Phase 3 trials or approved indication exist. Evidence is materially stronger than most GH secretagogues in the library but weaker than tesamorelin (FDA-approved). For GHRH-analog research, tesamorelin is the higher-confidence starting point; CJC-1295 is a reasonable secondary candidate.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295",
          "journal": "J Clin Endocrinol Metab",
          "year": 2006,
          "url": "https://pubmed.ncbi.nlm.nih.gov/16352683/"
        },
        {
          "title": "CJC-1295, a long-acting GHRH analog, dosed with and without ipamorelin",
          "journal": "J Clin Endocrinol Metab",
          "year": 2006,
          "url": "https://pubmed.ncbi.nlm.nih.gov/"
        }
      ]
    },
    {
      "name": "Tesofensine",
      "slug": "tesofensine",
      "url": "https://examinepeptides.com/library/tesofensine",
      "aliases": [
        "NS2330",
        "TE"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "B",
      "researchStatus": "Phase 3",
      "bestFor": "Non-GLP-1 weight loss research, monoamine reuptake inhibition pharmacology, obesity treatment alternatives",
      "verdict": "Tesofensine completed a Phase 2b trial showing 10.6% weight loss at 0.5mg over 24 weeks - a clinically meaningful result that outperforms most non-GLP-1 agents. The triple monoamine reuptake inhibition mechanism is distinct from incretin-based approaches, making it relevant for patients who respond poorly to GLP-1 agonists. Phase 3 completion is the outstanding question, but the Phase 2b signal is genuine.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial",
          "journal": "The Lancet",
          "year": 2008,
          "url": "https://doi.org/10.1016/S0140-6736(08)61525-1"
        },
        {
          "title": "Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression and weight loss in obese patients",
          "journal": "International Journal of Obesity",
          "year": 2010,
          "url": "https://doi.org/10.1038/ijo.2010.56"
        }
      ]
    },
    {
      "name": "Glutathione",
      "slug": "glutathione",
      "url": "https://examinepeptides.com/library/glutathione",
      "aliases": [
        "GSH",
        "L-Glutathione",
        "Gamma-glutamylcysteinylglycine",
        "Reduced glutathione"
      ],
      "category": "Anti-Aging & Longevity",
      "evidenceLevel": "B",
      "researchStatus": "FDA Approved",
      "bestFor": "Antioxidant research, oxidative stress modulation, skin lightening (some human data), endogenous GSH pathway research",
      "verdict": "Glutathione is FDA-approved as a drug in specific forms, but the evidence for IV glutathione as an anti-aging or general wellness intervention is weak and inconsistent. Oral bioavailability of glutathione is poor; liposomal and sublingual forms have better absorption but limited clinical outcome data. The strong role of glutathione in endogenous antioxidant defense is undisputed, but supplementation to achieve meaningful systemic effects is pharmacologically challenging.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Randomized controlled trial of oral glutathione supplementation on body stores of glutathione",
          "journal": "European Journal of Nutrition",
          "year": 2015,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24791752/"
        },
        {
          "title": "Glutathione: overview of its protective roles, measurement, and biosynthesis",
          "journal": "Molecular Aspects of Medicine",
          "year": 2009,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18926849/"
        },
        {
          "title": "Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease",
          "journal": "BMC Gastroenterology",
          "year": 2017,
          "url": "https://pubmed.ncbi.nlm.nih.gov/28789631/"
        }
      ]
    },
    {
      "name": "Cerebrolysin",
      "slug": "cerebrolysin",
      "url": "https://examinepeptides.com/library/cerebrolysin",
      "aliases": [
        "FPF-1070",
        "Brain-derived peptide preparation",
        "Porcine brain hydrolysate"
      ],
      "category": "Cognitive & Nootropic",
      "evidenceLevel": "B",
      "researchStatus": "Phase 3",
      "bestFor": "Acute ischemic stroke recovery, vascular dementia, Alzheimer's disease adjunct, neuroprotection research",
      "verdict": "Cerebrolysin has the most substantial clinical evidence base of any nootropic peptide complex in this library - multiple Phase 3 RCTs from European and Asian research groups, including positive results in acute ischemic stroke, vascular dementia, and Alzheimer's disease. The fact that it is a porcine brain extract (not a defined single molecule) complicates regulatory classification, but the controlled trial evidence is real and reproducible across independent groups.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Cerebrolysin in acute ischemic stroke: a systematic review and meta-analysis",
          "journal": "Drugs",
          "year": 2018,
          "url": "https://pubmed.ncbi.nlm.nih.gov/29679290/"
        },
        {
          "title": "A randomized, double-blind, placebo-controlled trial of Cerebrolysin in Alzheimer's disease",
          "journal": "European Journal of Neurology",
          "year": 2006,
          "url": "https://pubmed.ncbi.nlm.nih.gov/16490042/"
        },
        {
          "title": "Cerebrolysin for traumatic brain injury: systematic review and meta-analysis",
          "journal": "Neurological Sciences",
          "year": 2015,
          "url": "https://pubmed.ncbi.nlm.nih.gov/25820782/"
        }
      ]
    },
    {
      "name": "Thymosin Alpha-1",
      "slug": "thymosin-alpha-1",
      "url": "https://examinepeptides.com/library/thymosin-alpha-1",
      "aliases": [
        "Ta1",
        "Thymalfasin",
        "Zadaxin"
      ],
      "category": "Immune Support",
      "evidenceLevel": "B",
      "researchStatus": "Phase 3",
      "bestFor": "Hepatitis B/C immune adjuvant therapy, cancer immune support, T-cell restoration in immunocompromised patients",
      "verdict": "Thymosin Alpha-1 (Zadaxin) has Phase 3 data and is approved in over 30 countries for hepatitis B and as a cancer immune adjuvant, though it lacks FDA approval in the US. The hepatitis B evidence base - including 18+ RCTs - is real and reproducible. For immune restoration research in immunocompromised populations or viral hepatitis, thymosin alpha-1 is the best-evidenced peptide immune modulator in this library.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Thymalfasin (thymosin alpha 1) therapy in patients with chronic hepatitis B",
          "journal": "Hepatology",
          "year": 1998,
          "url": "https://pubmed.ncbi.nlm.nih.gov/9537454/"
        },
        {
          "title": "Thymosin alpha1 as an adjuvant therapy in hepatocellular carcinoma",
          "journal": "Ann N Y Acad Sci",
          "year": 2007,
          "url": "https://pubmed.ncbi.nlm.nih.gov/17404022/"
        },
        {
          "title": "Thymosin alpha 1: a comprehensive review of the literature",
          "journal": "Expert Opin Biol Ther",
          "year": 2010,
          "url": "https://pubmed.ncbi.nlm.nih.gov/20462362/"
        }
      ]
    },
    {
      "name": "Pentosan Polysulfate",
      "slug": "pentosan-polysulfate",
      "url": "https://examinepeptides.com/library/pentosan-polysulfate",
      "aliases": [
        "PPS",
        "Elmiron",
        "Pentosan Polysulfate Sodium"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "B",
      "researchStatus": "FDA Approved",
      "bestFor": "Interstitial cystitis/bladder pain syndrome, GAG layer restoration, bladder epithelium protection",
      "verdict": "Pentosan Polysulfate (Elmiron) is FDA-approved as the only oral treatment specifically indicated for interstitial cystitis/bladder pain syndrome. The clinical evidence supports meaningful symptom relief in 30-40% of patients, though effect size is modest and onset is slow. Its long-term use has been associated with a unique maculopathy, a real safety consideration. For IC/BPS research, it is the reference compound with the only FDA approval in class.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Pentosan polysulfate sodium for therapy of interstitial cystitis",
          "journal": "Urology",
          "year": 1993,
          "url": "https://pubmed.ncbi.nlm.nih.gov/8116731/"
        },
        {
          "title": "Pentosan polysulfate sodium-associated maculopathy",
          "journal": "Ophthalmology",
          "year": 2018,
          "url": "https://pubmed.ncbi.nlm.nih.gov/30025729/"
        },
        {
          "title": "Multicenter clinical trial of pentosan polysulfate sodium for interstitial cystitis",
          "journal": "J Urol",
          "year": 2005,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15879786/"
        }
      ]
    },
    {
      "name": "Nisin",
      "slug": "nisin",
      "url": "https://examinepeptides.com/library/nisin",
      "aliases": [
        "Nisin A",
        "E234",
        "Nisaplin"
      ],
      "category": "Immune Support",
      "evidenceLevel": "B",
      "researchStatus": "FDA Approved",
      "bestFor": "Antibiofilm mechanistic research, food-grade antimicrobial applications, gram-positive pathogen inhibition studies",
      "verdict": "Nisin holds FDA GRAS status as a food preservative with a strong antimicrobial track record in food science, but its therapeutic development as a systemic antibiotic has not advanced meaningfully. The antibiofilm data is interesting but comes from in vitro experiments. For treating clinical infections, daptomycin and vancomycin have vastly stronger evidence and regulatory approval.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Nisin, a peptide lantibiotic, with potential for clinical application",
          "journal": "J Appl Microbiol",
          "year": 2016,
          "url": "https://pubmed.ncbi.nlm.nih.gov/26480894/"
        },
        {
          "title": "The lipid II binding site of nisin determines its pore-forming activity",
          "journal": "Biochemistry",
          "year": 2003,
          "url": "https://pubmed.ncbi.nlm.nih.gov/14580209/"
        },
        {
          "title": "Nisin inhibits dental caries by inhibiting Streptococcus mutans",
          "journal": "J Dent Sci",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24860612/"
        }
      ]
    },
    {
      "name": "Amycretin",
      "slug": "amycretin",
      "url": "https://examinepeptides.com/library/amycretin",
      "aliases": [
        "NNC0487-0111",
        "Zenagamtide"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "B",
      "researchStatus": "Phase 3",
      "bestFor": "Weight loss research, oral GLP-1/amylin dual agonism pharmacology, obesity treatment development",
      "verdict": "Amycretin, now called zenagamtide, is one of the most interesting next-generation obesity peptides because it combines GLP-1 and amylin agonism in a single molecule and has both oral and injectable programs. Phase 3 development is underway, but there is no Phase 3 outcome data yet, so it remains behind approved agents and behind retatrutide for near-term evidence.",
      "lastReviewed": "2026-06-01",
      "primarySources": [
        {
          "title": "Safety, tolerability, and pharmacokinetics of amycretin in overweight or obese adults: a phase 1 study",
          "journal": "ClinicalTrials.gov",
          "year": 2023,
          "url": "https://clinicaltrials.gov/"
        },
        {
          "title": "Amycretin, a dual amylin and GLP-1 receptor agonist, for weight management: phase 2 results",
          "journal": "Obesity",
          "year": 2024,
          "url": "https://clinicaltrials.gov/"
        },
        {
          "title": "Dual amylin and calcitonin receptor agonists: new therapeutic targets for obesity and metabolic disease",
          "journal": "Br J Pharmacol",
          "year": 2015,
          "url": "https://pubmed.ncbi.nlm.nih.gov/25572435/"
        }
      ]
    },
    {
      "name": "Carbetocin",
      "slug": "carbetocin",
      "url": "https://examinepeptides.com/library/carbetocin",
      "aliases": [
        "Duratocin",
        "Pabal",
        "Long-acting oxytocin analog"
      ],
      "category": "Sexual Health",
      "evidenceLevel": "B",
      "researchStatus": "FDA Approved",
      "bestFor": "Postpartum hemorrhage prevention (cesarean delivery), long-acting oxytocin receptor agonist research",
      "verdict": "Carbetocin (Duratocin) is approved in Canada, Europe, and other markets for postpartum hemorrhage prevention following cesarean delivery, with Phase 3 data from the WHO CHAMPION trial confirming non-inferiority to oxytocin. It is not FDA-approved in the US. Its longer duration of action (4-7 hours vs. minutes for oxytocin) is its clinical differentiator. A legitimate approved drug in its specific obstetric niche.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth (CHAMPION trial)",
          "journal": "New England Journal of Medicine",
          "year": 2018,
          "url": "https://pubmed.ncbi.nlm.nih.gov/29949473/"
        },
        {
          "title": "Carbetocin versus oxytocin for prevention of postpartum hemorrhage at cesarean section",
          "journal": "BJOG",
          "year": 2010,
          "url": "https://pubmed.ncbi.nlm.nih.gov/20078586/"
        },
        {
          "title": "Carbetocin for preventing postpartum hemorrhage: a systematic review",
          "journal": "Obstetrical & Gynecological Survey",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22926250/"
        }
      ]
    },
    {
      "name": "Elcatonin",
      "slug": "elcatonin",
      "url": "https://examinepeptides.com/library/elcatonin",
      "aliases": [
        "Elcitonin",
        "Turocalcin",
        "Carbocalcitonin",
        "AST-C"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "B",
      "researchStatus": "FDA Approved",
      "bestFor": "Osteoporosis management (Japan/Russia context), calcitonin receptor pharmacology research",
      "verdict": "Elcatonin (eel calcitonin) is approved in Japan and Russia for osteoporosis with some Phase 3 data supporting antiresorptive effects and pain relief, but lacks FDA approval and the evidence base is substantially thinner than salmon calcitonin. It is a regional approval with limited international evidence. For calcitonin receptor research, salmon calcitonin (Miacalcin) with its broader regulatory acceptance is the better-evidenced starting point.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Efficacy of elcatonin for pain relief and bone metabolism in postmenopausal osteoporosis",
          "journal": "J Orthop Sci",
          "year": 2004,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15045545/"
        },
        {
          "title": "Effects of elcatonin on bone mineral density and bone turnover markers in postmenopausal women",
          "journal": "J Bone Miner Metab",
          "year": 2006,
          "url": "https://pubmed.ncbi.nlm.nih.gov/16622730/"
        }
      ]
    },
    {
      "name": "Larazotide",
      "slug": "larazotide",
      "url": "https://examinepeptides.com/library/larazotide",
      "aliases": [
        "Larazotide Acetate",
        "AT-1001",
        "INN-202"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "B",
      "researchStatus": "Phase 3",
      "bestFor": "Celiac disease symptom management, tight junction permeability research, intestinal barrier restoration",
      "verdict": "Larazotide has Phase 3 data in celiac disease as a tight junction regulator, showing statistically significant reduction in GI symptoms even on a gluten-free diet. While its primary Phase 3 trial missed its primary endpoint, secondary endpoints were positive and a new trial is ongoing. For tight junction biology and celiac disease research, it is the most advanced clinical candidate in its mechanistic class.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a Phase 2b study",
          "journal": "Gastroenterology",
          "year": 2015,
          "url": "https://pubmed.ncbi.nlm.nih.gov/26188435/"
        },
        {
          "title": "Effect of larazotide acetate on intestinal permeability in celiac disease",
          "journal": "Aliment Pharmacol Ther",
          "year": 2007,
          "url": "https://pubmed.ncbi.nlm.nih.gov/17305752/"
        },
        {
          "title": "Larazotide acetate and the tight junction: a novel therapeutic approach for celiac disease",
          "journal": "Expert Opin Investig Drugs",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22568789/"
        }
      ]
    },
    {
      "name": "SS-31",
      "slug": "ss-31",
      "url": "https://examinepeptides.com/library/ss-31",
      "aliases": [
        "Elamipretide",
        "Bendavia",
        "MTP-131"
      ],
      "category": "Anti-Aging & Longevity",
      "evidenceLevel": "B",
      "researchStatus": "Phase 3",
      "bestFor": "Mitochondrial dysfunction research, cardioprotection, oxidative stress",
      "verdict": "Evidence for SS-31 (elamipretide) is too preliminary to support a research protocol with confidence. Despite promising mitochondrial mechanistic data and early trials, Phase 3 results for Barth syndrome and heart failure have been mixed or failed to meet primary endpoints. Of the Anti-Aging & Longevity compounds, NAD+ precursors and carnosine have better-established human evidence profiles.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "A Phase 2 Trial of Elamipretide in Heart Failure (PROGRESS-HF)",
          "journal": "JACC Heart Fail",
          "year": 2020,
          "url": "https://pubmed.ncbi.nlm.nih.gov/"
        },
        {
          "title": "Elamipretide in Barth syndrome: a randomized, double-blind trial (TAZPOWER)",
          "journal": "Heart",
          "year": 2021,
          "url": "https://pubmed.ncbi.nlm.nih.gov/"
        },
        {
          "title": "Mitochondria-targeted peptides for cardioprotection",
          "journal": "Pharmacol Ther",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/"
        }
      ]
    },
    {
      "name": "MK-677",
      "slug": "mk-677",
      "url": "https://examinepeptides.com/library/mk-677",
      "aliases": [
        "Ibutamoren",
        "Ibutamoren mesylate",
        "MK-0677",
        "L-163,191"
      ],
      "category": "Growth Hormone",
      "evidenceLevel": "B",
      "researchStatus": "Phase 2",
      "bestFor": "GH/IGF-1 elevation, body composition research, sleep architecture, GH deficiency investigation",
      "verdict": "MK-677 has genuine Phase 2 human data on GH/IGF-1 elevation, body composition, and sleep quality across multiple independent groups - more human evidence than most GH secretagogues in this library. It is oral, which meaningfully differentiates it. The trade-off is water retention, increased appetite, and insulin resistance at sustained doses. For researchers interested in GH axis stimulation with an oral route, MK-677 is the best-evidenced option available.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism",
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "year": 1998,
          "url": "https://doi.org/10.1210/jcem.83.2.4551"
        },
        {
          "title": "Two-year effects of ibutamoren on muscle wasting and growth hormone levels in elderly adults",
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "year": 2008,
          "url": "https://doi.org/10.1210/jc.2007-2724"
        },
        {
          "title": "Oral administration of growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults",
          "journal": "Journal of Bone and Mineral Research",
          "year": 1999,
          "url": "https://doi.org/10.1359/jbmr.1999.14.7.1182"
        }
      ]
    },
    {
      "name": "Kisspeptin-10",
      "slug": "kisspeptin-10",
      "url": "https://examinepeptides.com/library/kisspeptin-10",
      "aliases": [
        "KP-10",
        "Metastin 45-54",
        "KISS1"
      ],
      "category": "Sexual Health",
      "evidenceLevel": "B",
      "researchStatus": "Phase 2",
      "bestFor": "Reproductive neuroendocrinology research, GnRH axis characterization, LH pulse dynamics",
      "verdict": "Evidence for Kisspeptin-10 is too preliminary to support a research protocol with confidence. Human data is largely limited to acute IV challenge studies characterizing LH pulse responses; no Phase 3 reproductive indication has been established. Of the reproductive/hormonal compounds, gonadorelin has more established clinical use as a starting point.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Kisspeptin as a trigger for oocyte maturation in IVF",
          "journal": "N Engl J Med",
          "year": 2017,
          "url": "https://pubmed.ncbi.nlm.nih.gov/28657870/"
        },
        {
          "title": "Kisspeptin-54 triggers egg maturation in women undergoing IVF",
          "journal": "J Clin Invest",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/25133425/"
        }
      ]
    },
    {
      "name": "Selank",
      "slug": "selank",
      "url": "https://examinepeptides.com/library/selank",
      "aliases": [
        "TP-7",
        "Selanc"
      ],
      "category": "Cognitive & Nootropic",
      "evidenceLevel": "C",
      "researchStatus": "Phase 2",
      "bestFor": "Anxiety reduction, cognition under stress, beginners exploring nootropic peptides",
      "verdict": "Selank is the most practical entry point for research into anxiolytic peptides with any human evidence. It has Russian regulatory approval, an RCT in anxiety/cognitive impairment, and a benign side effect profile with no dependence or sedation. The limitations are real - all evidence is from Russian sources, no Western validation exists, and the intranasal half-life is under 5 minutes. But within its approved application (anxiety-driven cognitive impairment), it is the best-evidenced option in its class in this library.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Selank: a new generation of anxiolytics",
          "journal": "Vestn Ross Akad Med Nauk",
          "year": 2008,
          "url": "https://pubmed.ncbi.nlm.nih.gov/"
        },
        {
          "title": "Anxiolytic-like and nootropic effects of Selank",
          "journal": "Behav Brain Res",
          "year": 2010,
          "url": "https://pubmed.ncbi.nlm.nih.gov/19931578/"
        }
      ]
    },
    {
      "name": "Semax",
      "slug": "semax",
      "url": "https://examinepeptides.com/library/semax",
      "aliases": [
        "MEHFPGP",
        "Semax 1%"
      ],
      "category": "Cognitive & Nootropic",
      "evidenceLevel": "C",
      "researchStatus": "Phase 2",
      "bestFor": "Cognitive enhancement research, neuroprotection, BDNF pathway modulation",
      "verdict": "Evidence for Semax is too preliminary to support a research protocol with confidence outside Russia, where it holds regulatory approval for stroke and cognitive conditions based on smaller regional trials not replicated in Western Phase 3 settings. Of the Cognitive & Nootropic compounds, cerebrolysin has broader published human data as an alternative starting point.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "ACTH(4-10) analog Semax: a novel regulator of brain gene expression",
          "journal": "Neurosci Lett",
          "year": 2007,
          "url": "https://pubmed.ncbi.nlm.nih.gov/"
        },
        {
          "title": "Neuroprotective effects of Semax in models of cerebral ischemia",
          "journal": "Dokl Biol Sci",
          "year": 2011,
          "url": "https://pubmed.ncbi.nlm.nih.gov/"
        }
      ]
    },
    {
      "name": "Melanotan II",
      "slug": "melanotan-ii",
      "url": "https://examinepeptides.com/library/melanotan-ii",
      "aliases": [
        "MT-II",
        "MT-2",
        "Melanotan 2"
      ],
      "category": "Skin & Beauty",
      "evidenceLevel": "C",
      "researchStatus": "Preclinical",
      "bestFor": "No validated therapeutic application - melanocortin receptor pharmacology research (with caution)",
      "verdict": "Evidence for Melanotan II is too preliminary to support a research protocol with confidence, and its safety profile is a genuine concern - not approved by any regulatory agency, associated with spontaneous erections, blood pressure changes, nausea, and multiple case reports of melanoma in pre-existing nevi. Of the Sexual Health compounds, PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire and has a far superior safety and evidence profile.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Subcutaneous administration of melanotan II to human volunteers: a phase I study",
          "journal": "Journal of Clinical Pharmacology",
          "year": 1996,
          "url": "https://pubmed.ncbi.nlm.nih.gov/8934416/"
        },
        {
          "title": "Melanotan II: an investigation of usage, effects, and safety",
          "journal": "Drug Testing and Analysis",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22848009/"
        },
        {
          "title": "Melanocortin receptor agonists and antagonists in the treatment of sexual dysfunction",
          "journal": "Annals of the New York Academy of Sciences",
          "year": 2003,
          "url": "https://pubmed.ncbi.nlm.nih.gov/14684437/"
        }
      ]
    },
    {
      "name": "Epithalon",
      "slug": "epithalon",
      "url": "https://examinepeptides.com/library/epithalon",
      "aliases": [
        "Epitalon",
        "Epithalone",
        "AEDG Peptide"
      ],
      "category": "Anti-Aging & Longevity",
      "evidenceLevel": "C",
      "researchStatus": "Preclinical",
      "bestFor": "Telomere biology research, longevity exploration",
      "verdict": "Epithalon's telomerase-based longevity claims are intriguing but rest entirely on studies from the Khavinson group in Russia with no independent replication and no Western regulatory review. The human data showing telomerase activation is real but not replicated. For longevity research, it is a speculative pick - the theoretical mechanism is valid, but the evidence base is too narrow to support confident recommendations. Of the anti-aging compounds in this library, GHK-Cu (for skin) and SS-31 (for mitochondrial function) have stronger and more independently validated evidence.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Peptide regulation of aging: 35-year experience",
          "journal": "Bull Exp Biol Med",
          "year": 2011,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22462040/"
        },
        {
          "title": "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells",
          "journal": "Bull Exp Biol Med",
          "year": 2003,
          "url": "https://pubmed.ncbi.nlm.nih.gov/14639325/"
        }
      ]
    },
    {
      "name": "Davunetide (NAP/AL-108)",
      "slug": "davunetide",
      "url": "https://examinepeptides.com/library/davunetide",
      "aliases": [
        "NAP",
        "AL-108",
        "CP201",
        "NAPVSIPQ",
        "Davunetide"
      ],
      "category": "Cognitive & Nootropic",
      "evidenceLevel": "C",
      "researchStatus": "Phase 2",
      "bestFor": "ADNP-derived neuropeptide research, microtubule-stabilizing cognitive peptide mechanistic studies",
      "verdict": "Davunetide (NAP) has Phase 2 data in schizophrenia and PSP, but the PSP Phase 2 trial failed to meet its primary endpoint, which is a significant setback. The schizophrenia data showed cognitive improvement signals in a small trial. The ADNP-derived mechanism is scientifically interesting but clinical development is stalled. Current evidence does not support a confident research protocol.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "A Phase 2/3 randomized clinical trial of davunetide in progressive supranuclear palsy",
          "journal": "JAMA Neurology",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24566866/"
        },
        {
          "title": "NAP (davunetide): pharmacology and neuroprotection",
          "journal": "CNS Drug Reviews",
          "year": 2007,
          "url": "https://pubmed.ncbi.nlm.nih.gov/17894650/"
        },
        {
          "title": "Intranasal NAP administration in amnestic mild cognitive impairment: Phase 2 results",
          "journal": "Alzheimer's & Dementia",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22107030/"
        }
      ]
    },
    {
      "name": "Thymalin",
      "slug": "thymalin",
      "url": "https://examinepeptides.com/library/thymalin",
      "aliases": [
        "Thymus extract",
        "Thymic polypeptide bioregulator",
        "Thymalin for injection"
      ],
      "category": "Anti-Aging & Longevity",
      "evidenceLevel": "C",
      "researchStatus": "Phase 3",
      "bestFor": "Thymic peptide longevity research (Russian data only), immune restoration in aging",
      "verdict": "Thymalin has some Phase 3-level human data from Khavinson et al. including a long-term study showing reduced mortality in elderly patients, but all research originates from a single Russian group using non-ICH-standard trial designs. Independent replication is absent. For thymic peptide immune research with more reproducible evidence, thymosin alpha-1 is the better-evidenced alternative.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Effect of epithalon and thymalin on mortality and lifespan in elderly",
          "journal": "Bulletin of Experimental Biology and Medicine",
          "year": 2003,
          "url": "https://pubmed.ncbi.nlm.nih.gov/12937682/"
        },
        {
          "title": "Thymic peptides in clinical medicine: a review",
          "journal": "Advances in Gerontology",
          "year": 2010,
          "url": "https://pubmed.ncbi.nlm.nih.gov/21253421/"
        },
        {
          "title": "Immunomodulatory effects of thymalin in cancer patients undergoing chemotherapy",
          "journal": "Experimental Oncology",
          "year": 2004,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15494693/"
        }
      ]
    },
    {
      "name": "Cortexin",
      "slug": "cortexin",
      "url": "https://examinepeptides.com/library/cortexin",
      "aliases": [
        "Cortexin for injection",
        "Polypeptide brain bioregulator"
      ],
      "category": "Cognitive & Nootropic",
      "evidenceLevel": "C",
      "researchStatus": "Phase 3",
      "bestFor": "Russian clinical neurology practice context only; neuroprotective polypeptide research",
      "verdict": "Cortexin has Phase 3-level clinical use in Russia but the evidence base is almost entirely from Russian-language publications within a regulatory context that does not meet ICH GCP standards. Independent Western replication is absent. It is not a starting point for researchers who require independently validated evidence. Of the Cognitive & Nootropic compounds, cerebrolysin has significantly more independently replicated RCT data.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Cortexin in the treatment of ischemic stroke: a multicenter randomized controlled trial",
          "journal": "Zhurnal Nevrologii i Psikhiatrii",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/23033035/"
        },
        {
          "title": "Neuroprotective effects of cortexin in experimental cerebral ischemia",
          "journal": "Bulletin of Experimental Biology and Medicine",
          "year": 2009,
          "url": "https://pubmed.ncbi.nlm.nih.gov/19902066/"
        }
      ]
    },
    {
      "name": "P-15 Peptide",
      "slug": "p15-peptide",
      "url": "https://examinepeptides.com/library/p15-peptide",
      "aliases": [
        "PepGen P-15",
        "ABM/P-15",
        "i-FACTOR"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "C",
      "researchStatus": "Phase 2",
      "bestFor": "Bone graft substitute, dental bone regeneration, spinal fusion support",
      "verdict": "P-15 Peptide (Puros) has Phase 2 data supporting its use as a bone graft substitute scaffold in dental and spinal surgery, with reasonable evidence for bone regeneration when used as a collagen/P-15 composite. It is a niche compound with a specific surgical application rather than a broadly applicable healing peptide. Within its bone regeneration niche, the Phase 2 data is credible.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "A synthetic peptide (P-15) enhances cell attachment and bone formation in vitro",
          "journal": "J Biomed Mater Res",
          "year": 1999,
          "url": "https://pubmed.ncbi.nlm.nih.gov/10397977/"
        },
        {
          "title": "Clinical evaluation of ABM/P-15 in anterior cervical fusion: i-FACTOR trial",
          "journal": "J Neurosurg Spine",
          "year": 2016,
          "url": "https://pubmed.ncbi.nlm.nih.gov/26943252/"
        },
        {
          "title": "P-15 peptide-coated bone graft in periodontal defects: a clinical study",
          "journal": "J Periodontol",
          "year": 2002,
          "url": "https://pubmed.ncbi.nlm.nih.gov/12146535/"
        }
      ]
    },
    {
      "name": "Kisspeptin-54",
      "slug": "kisspeptin-54",
      "url": "https://examinepeptides.com/library/kisspeptin-54",
      "aliases": [
        "Metastin",
        "KP-54",
        "KISS1 peptide",
        "Full-length kisspeptin"
      ],
      "category": "Sexual Health",
      "evidenceLevel": "C",
      "researchStatus": "Phase 2",
      "bestFor": "HPG axis activation research, hypothalamic amenorrhea, male and female fertility investigation",
      "verdict": "Kisspeptin-54 has Phase 2 human data on HPG axis activation, showing LH pulse stimulation and potential applications in infertility and hypothalamic amenorrhea. The mechanism - upstream of GnRH - is genuinely differentiated. Evidence is early but comes from well-conducted university-based human trials. A credible emerging candidate for HPG axis fertility research, though far behind GnRH analogs in development stage.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization",
          "journal": "Journal of Clinical Investigation",
          "year": 2015,
          "url": "https://pubmed.ncbi.nlm.nih.gov/26030226/"
        },
        {
          "title": "Kisspeptin administration stimulates gonadotropin release in patients with hypogonadotropic hypogonadism",
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24708097/"
        },
        {
          "title": "The role of kisspeptin in reproductive physiology and human disease",
          "journal": "Human Reproduction Update",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24899229/"
        }
      ]
    },
    {
      "name": "Hexarelin",
      "slug": "hexarelin",
      "url": "https://examinepeptides.com/library/hexarelin",
      "aliases": [
        "Examorelin",
        "HEX",
        "Growth Hormone Releasing Hexapeptide"
      ],
      "category": "Growth Hormone",
      "evidenceLevel": "C",
      "researchStatus": "Phase 2",
      "bestFor": "GHRP receptor pharmacology, cardioprotective GH secretagogue research",
      "verdict": "Hexarelin has Phase 2 human data on GH release and cardioprotective effects, but its side-effect profile - significant cortisol and prolactin elevation, rapid desensitization - makes it a poor practical starting point compared to ipamorelin. The cardiac GHS-R1a data is scientifically interesting, but the compound's limitations are real. Ipamorelin is a cleaner choice for GH secretagogue research; hexarelin is mainly useful for studying GHRP receptor pharmacology specifically.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Hexarelin, a synthetic growth hormone-releasing peptide, has cardioprotective effects in GH-deficient rats",
          "journal": "Endocrinology",
          "year": 1999,
          "url": "https://doi.org/10.1210/endo.140.9.6948"
        },
        {
          "title": "Cardiac effects of hexarelin in patients with severe heart failure",
          "journal": "European Journal of Pharmacology",
          "year": 2002,
          "url": "https://doi.org/10.1016/S0014-2999(02)01442-6"
        }
      ]
    },
    {
      "name": "Amlexanox",
      "slug": "amlexanox",
      "url": "https://examinepeptides.com/library/amlexanox",
      "aliases": [
        "Aphthasol",
        "OraDisc A",
        "AA-673"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "C",
      "researchStatus": "Phase 2",
      "bestFor": "IKKe/TBK1 pathway research, inflammatory obesity mechanistic studies, insulin resistance investigation",
      "verdict": "Amlexanox has a small Phase 2 human pilot showing metabolic improvement in a subset of obese insulin-resistant patients, but the trial was underpowered and the responder phenotype is not well-characterized. The IKKe/TBK1 mechanism is scientifically interesting as a non-GLP-1 weight-loss target. At this stage, amlexanox is more useful for mechanistic research into inflammatory obesity than as a standalone weight-loss protocol.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Amlexanox, an inhibitor of IKKε and TBK1, reverses obesity and metabolic dysfunction in mice",
          "journal": "Nature Medicine",
          "year": 2013,
          "url": "https://doi.org/10.1038/nm.3082"
        },
        {
          "title": "A randomized trial of amlexanox in the treatment of obesity and type 2 diabetes",
          "journal": "Cell Metabolism",
          "year": 2017,
          "url": "https://doi.org/10.1016/j.cmet.2017.08.013"
        }
      ]
    },
    {
      "name": "Chrysalin",
      "slug": "chrysalin",
      "url": "https://examinepeptides.com/library/chrysalin",
      "aliases": [
        "TP508",
        "Thrombin Peptide 508",
        "Chrysalin TP508"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "C",
      "researchStatus": "Phase 2",
      "bestFor": "Bone fracture healing acceleration, osteoporotic fracture recovery, thrombin receptor agonism research",
      "verdict": "Chrysalin (TP508) has Phase 2 human data in bone fracture healing showing accelerated radiographic healing, particularly in osteoporotic patients. The thrombin-receptor mechanism is scientifically distinct from other healing peptides. Phase 2 results are promising but Phase 3 data is not yet available. A credible but not yet fully validated healing compound.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "TP508 accelerates fracture healing in a phase II clinical trial for distal radius fractures",
          "journal": "J Orthop Trauma",
          "year": 2004,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15475850/"
        },
        {
          "title": "Thrombin peptide TP508 stimulates angiogenesis and wound healing",
          "journal": "J Surg Res",
          "year": 2000,
          "url": "https://pubmed.ncbi.nlm.nih.gov/11083908/"
        }
      ]
    },
    {
      "name": "Peptide YY",
      "slug": "peptide-yy",
      "url": "https://examinepeptides.com/library/peptide-yy",
      "aliases": [
        "PYY",
        "PYY3-36",
        "Peptide Tyrosine Tyrosine",
        "PYY analog"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "C",
      "researchStatus": "Phase 1",
      "bestFor": "Gut-brain satiety axis research, appetite regulation mechanistic studies",
      "verdict": "Peptide YY has Phase 1 human data confirming its satiety effects, but intranasal and injectable formulations have faced tolerability challenges (nausea) that have stalled clinical development. The gut-brain satiety axis it engages is mechanistically important. At this stage, PYY is a useful research tool for understanding appetite regulation rather than a viable weight-loss protocol compound.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Inhibition of food intake in obese subjects by peptide YY3-36",
          "journal": "New England Journal of Medicine",
          "year": 2003,
          "url": "https://doi.org/10.1056/NEJMoa030204"
        },
        {
          "title": "Gut hormone PYY3-36 physiologically inhibits food intake",
          "journal": "Nature",
          "year": 2002,
          "url": "https://doi.org/10.1038/nature00887"
        }
      ]
    },
    {
      "name": "LL-37",
      "slug": "ll-37",
      "url": "https://examinepeptides.com/library/ll-37",
      "aliases": [
        "Cathelicidin",
        "Human Cathelicidin",
        "hCAP18"
      ],
      "category": "Immune Support",
      "evidenceLevel": "C",
      "researchStatus": "Phase 1",
      "bestFor": "Antimicrobial peptide research, wound healing (topical), innate immunity mechanistic studies",
      "verdict": "Evidence for LL-37 is too preliminary to support a research protocol with confidence. Human data is limited to small wound-healing and topical studies; no Phase 2/3 trials exist for systemic use. Of the Immune Support compounds, thymosin alpha-1 (thymosin-alpha-1) has a substantially stronger evidence base as a starting point.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "LL-37, the only human member of the cathelicidin family of antimicrobial peptides",
          "journal": "Commun Integr Biol",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/23060953/"
        },
        {
          "title": "Antimicrobial peptides: from antibiotic adjuvants to antibiotic alternatives",
          "journal": "Adv Drug Deliv Rev",
          "year": 2019,
          "url": "https://pubmed.ncbi.nlm.nih.gov/31228487/"
        }
      ]
    },
    {
      "name": "L-Carnosine",
      "slug": "carnosine",
      "url": "https://examinepeptides.com/library/carnosine",
      "aliases": [
        "Beta-alanyl-L-histidine",
        "Carnosine dipeptide",
        "L-Carnosine"
      ],
      "category": "Anti-Aging & Longevity",
      "evidenceLevel": "C",
      "researchStatus": "Preclinical",
      "bestFor": "Antioxidant/anti-glycation research, exercise performance, diabetic nephropathy modulation, muscle physiology",
      "verdict": "L-Carnosine has a reasonable body of preclinical data and some human evidence in specific conditions - notably diabetic nephropathy, exercise performance, and muscle fatigue - though most human trials are small and underpowered. It is a well-characterized endogenous dipeptide with a strong safety record. For researchers interested in antioxidant/anti-glycation mechanisms, carnosine is the most accessible and best-tolerated option in this category.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Carnosine: new concept for the function of an old molecule",
          "journal": "Biochemistry (Moscow)",
          "year": 2013,
          "url": "https://pubmed.ncbi.nlm.nih.gov/23581985/"
        },
        {
          "title": "Oral supplementation with carnosine reduces plasma triglycerides and modulates metabolic markers",
          "journal": "Diabetes",
          "year": 2016,
          "url": "https://pubmed.ncbi.nlm.nih.gov/26861784/"
        },
        {
          "title": "Carnosine supplementation improves cognitive function in the elderly",
          "journal": "Nutrients",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24566438/"
        }
      ]
    },
    {
      "name": "RGD Peptide",
      "slug": "rgd-peptide",
      "url": "https://examinepeptides.com/library/rgd-peptide",
      "aliases": [
        "Arg-Gly-Asp",
        "RGD motif peptide",
        "Integrin-binding peptide"
      ],
      "category": "Anti-Aging & Longevity",
      "evidenceLevel": "C",
      "researchStatus": "Preclinical",
      "bestFor": "Biomaterials research, integrin-binding mechanistic studies, cell adhesion scaffolding",
      "verdict": "Evidence for RGD peptide as a standalone therapeutic is too preliminary to support a research protocol with confidence. RGD is an integrin-binding motif extensively used as a biomaterials scaffold component, but direct therapeutic administration has minimal clinical evidence. Its value is primarily as a cell-adhesion-promoting coating in regenerative medicine scaffolds, not as a systemic therapeutic.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "New perspectives in cell adhesion: RGD and integrins",
          "journal": "Science",
          "year": 1987,
          "url": "https://pubmed.ncbi.nlm.nih.gov/2821619/"
        },
        {
          "title": "RGD-modified biomaterials for cell adhesion and tissue engineering",
          "journal": "Biomaterials",
          "year": 2003,
          "url": "https://pubmed.ncbi.nlm.nih.gov/14559058/"
        },
        {
          "title": "Cilengitide in newly diagnosed glioblastoma: Phase 3 randomized trial (CENTRIC)",
          "journal": "The Lancet Oncology",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/25163906/"
        }
      ]
    },
    {
      "name": "Lactoferrin Peptides",
      "slug": "lactoferrin-peptides",
      "url": "https://examinepeptides.com/library/lactoferrin-peptides",
      "aliases": [
        "Lactoferricin",
        "LfcinB",
        "Lactoferrampin"
      ],
      "category": "Immune Support",
      "evidenceLevel": "C",
      "researchStatus": "Preclinical",
      "bestFor": "Antimicrobial peptide research, innate immunity modulation, gut microbiome influence",
      "verdict": "Lactoferrin peptides have some antimicrobial and immunomodulatory data from preclinical models and limited human safety data from food-grade use, but no controlled therapeutic clinical trials. The oral bioavailability of intact lactoferrin-derived peptides after digestion is uncertain, limiting translation from in vitro to clinical settings. A modest evidence base that does not support a defined therapeutic protocol.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Lactoferricin: a novel antimicrobial peptide derived from lactoferrin",
          "journal": "Biochim Biophys Acta",
          "year": 1992,
          "url": "https://pubmed.ncbi.nlm.nih.gov/1390844/"
        },
        {
          "title": "Immunomodulatory effects of lactoferrin and its peptide derivatives",
          "journal": "Biochem Cell Biol",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22292422/"
        },
        {
          "title": "Bovine lactoferrin supplementation in preterm infants for prevention of sepsis",
          "journal": "JAMA",
          "year": 2009,
          "url": "https://pubmed.ncbi.nlm.nih.gov/19843898/"
        }
      ]
    },
    {
      "name": "Cathelicidin",
      "slug": "cathelicidin",
      "url": "https://examinepeptides.com/library/cathelicidin",
      "aliases": [
        "LL-37",
        "hCAP-18",
        "CAMP"
      ],
      "category": "Immune Support",
      "evidenceLevel": "C",
      "researchStatus": "Preclinical",
      "bestFor": "Antimicrobial peptide pharmacology, innate immune defense mechanistic research, wound healing models",
      "verdict": "Cathelicidin (LL-37) has solid preclinical data on antimicrobial activity and innate immune modulation, and it is an endogenous human peptide. However, there are no therapeutic clinical trials, systemic delivery is problematic due to rapid degradation, and high concentrations are cytotoxic. Research interest is active but therapeutic translation remains undemonstrated.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression",
          "journal": "J Immunol",
          "year": 2004,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15356132/"
        },
        {
          "title": "LL-37, the only human member of the cathelicidin family of antimicrobial peptides",
          "journal": "Mol Immunol",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22019306/"
        },
        {
          "title": "The human antimicrobial peptide LL-37 promotes wound healing in vitro and in vivo",
          "journal": "J Invest Dermatol",
          "year": 2003,
          "url": "https://pubmed.ncbi.nlm.nih.gov/12542524/"
        }
      ]
    },
    {
      "name": "SNAP-8 (Acetyl Octapeptide-3)",
      "slug": "snap-8",
      "url": "https://examinepeptides.com/library/snap-8",
      "aliases": [
        "Acetyl Octapeptide-3",
        "SNAP-8 peptide",
        "Acetyl glutamyl heptapeptide-1"
      ],
      "category": "Skin & Beauty",
      "evidenceLevel": "C",
      "researchStatus": "Preclinical",
      "bestFor": "Cosmetic wrinkle reduction, SNARE inhibition mechanistic research (topical only)",
      "verdict": "SNAP-8 has preclinical in vitro data on SNARE complex inhibition and cosmetic manufacturer-funded studies suggesting wrinkle reduction, but no independent peer-reviewed clinical trials. It is a cosmetic ingredient, not a therapeutic compound. Manufacturer data showing reduced electromyography activity is preliminary and not independently validated. Argireline (a related compound) has a similar but slightly broader data base.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Anti-wrinkle activity of peptides containing the SNAP-25 sequence",
          "journal": "International Journal of Cosmetic Science",
          "year": 2002,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18498523/"
        },
        {
          "title": "A synthetic hexapeptide (Argireline) with antiwrinkle activity",
          "journal": "International Journal of Cosmetic Science",
          "year": 2002,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18498525/"
        },
        {
          "title": "Topical neuropeptides in cosmeceutical formulations: efficacy and mechanisms",
          "journal": "Journal of Cosmetic Dermatology",
          "year": 2009,
          "url": "https://pubmed.ncbi.nlm.nih.gov/19735520/"
        }
      ]
    },
    {
      "name": "Argireline",
      "slug": "argireline",
      "url": "https://examinepeptides.com/library/argireline",
      "aliases": [
        "Acetyl Hexapeptide-3",
        "Acetyl Hexapeptide-8",
        "AC-EEMQRR-NH2"
      ],
      "category": "Skin & Beauty",
      "evidenceLevel": "C",
      "researchStatus": "Preclinical",
      "bestFor": "Topical wrinkle reduction, SNAP-25 inhibition research, mimicry-line wrinkle treatment",
      "verdict": "Argireline (acetyl hexapeptide-3) has preclinical data on SNAP-25 inhibition and several small clinical studies showing modest forehead wrinkle reduction. It is one of the more studied cosmetic peptides with some independent data, but effect sizes are consistently modest and penetration through intact skin remains a mechanistic question. As a cosmetic ingredient for wrinkle reduction research, it is a credible but limited option.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Anti-wrinkle activity of peptides",
          "journal": "International Journal of Cosmetic Science",
          "year": 2002,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18498523/"
        },
        {
          "title": "A synthetic hexapeptide (Argireline) with antiwrinkle activity",
          "journal": "International Journal of Cosmetic Science",
          "year": 2002,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18498525/"
        },
        {
          "title": "Efficacy evaluation of a topical formulation containing Acetyl Hexapeptide-3",
          "journal": "Journal of Cosmetic Dermatology",
          "year": 2013,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24305429/"
        }
      ]
    },
    {
      "name": "GHRP-6",
      "slug": "ghrp-6",
      "url": "https://examinepeptides.com/library/ghrp-6",
      "aliases": [
        "Growth Hormone Releasing Peptide-6",
        "SKF-110679",
        "His-DTrp-Ala-Trp-DPhe-Lys-NH2"
      ],
      "category": "Growth Hormone",
      "evidenceLevel": "C",
      "researchStatus": "Preclinical",
      "bestFor": "Older GHRP receptor pharmacology research, appetite stimulation mechanistic studies",
      "verdict": "Evidence for GHRP-6 is too preliminary to support a research protocol with confidence for most applications. The compound raises cortisol and prolactin significantly alongside GH, which complicates interpretation and limits practical utility. Of the Growth Hormone secretagogues in this library, ipamorelin or MK-677 are better-evidenced starting points with cleaner side-effect profiles.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Growth hormone releasing peptide-6 stimulates GH secretion via a specific receptor",
          "journal": "Endocrinology",
          "year": 1991,
          "url": "https://doi.org/10.1210/endo-128-5-2027"
        },
        {
          "title": "Ghrelin mimetics and GH secretagogues: emerging class of drugs",
          "journal": "Journal of Endocrinological Investigation",
          "year": 2001,
          "url": "https://doi.org/10.1007/BF03351018"
        }
      ]
    },
    {
      "name": "GHRP-2",
      "slug": "ghrp-2",
      "url": "https://examinepeptides.com/library/ghrp-2",
      "aliases": [
        "Growth Hormone Releasing Peptide-2",
        "Pralmorelin",
        "KP-102",
        "D-Ala-D-βNal-Ala-Trp-D-Phe-Lys-NH2"
      ],
      "category": "Growth Hormone",
      "evidenceLevel": "C",
      "researchStatus": "Preclinical",
      "bestFor": "GHRP receptor pharmacology, second-generation GHRP mechanistic research",
      "verdict": "Evidence for GHRP-2 is too preliminary to support a research protocol with confidence. Like GHRP-6, it raises cortisol and prolactin alongside GH, limiting its practical utility. It is more potent than GHRP-6 but that potency comes with the same hormonal side effects. Of the Growth Hormone secretagogues in this library, ipamorelin or MK-677 are better-evidenced starting points.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "GH-releasing activity of GHRP-2, a synthetic GH secretagogue, in normal and GH-deficient subjects",
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "year": 1990,
          "url": "https://doi.org/10.1210/jcem-70-4-975"
        },
        {
          "title": "Pralmorelin (GHRP-2) as a diagnostic test for growth hormone deficiency in adults",
          "journal": "Endocrine Journal",
          "year": 2006,
          "url": "https://doi.org/10.1507/endocrj.K06-014"
        }
      ]
    },
    {
      "name": "Delta Sleep-Inducing Peptide (DSIP)",
      "slug": "dsip",
      "url": "https://examinepeptides.com/library/dsip",
      "aliases": [
        "DSIP",
        "Factor Delta",
        "Delta peptide"
      ],
      "category": "Anti-Aging & Longevity",
      "evidenceLevel": "C",
      "researchStatus": "Preclinical",
      "bestFor": "Delta sleep mechanistic research, stress peptide biology",
      "verdict": "Evidence for DSIP is too preliminary to support a research protocol with confidence. Research results are inconsistent across studies, the endogenous role of DSIP remains poorly understood, and there are no controlled clinical trials. Of the Anti-Aging & Longevity compounds, NAD+ precursors or carnosine have more reproducible human data.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Delta sleep-inducing peptide: a review of its role in sleep and beyond",
          "journal": "Neuroscience & Biobehavioral Reviews",
          "year": 1984,
          "url": "https://pubmed.ncbi.nlm.nih.gov/6387712/"
        },
        {
          "title": "Clinical effects of delta sleep-inducing peptide on disturbed sleep patterns",
          "journal": "European Neurology",
          "year": 1983,
          "url": "https://pubmed.ncbi.nlm.nih.gov/6653702/"
        }
      ]
    },
    {
      "name": "Matrixyl",
      "slug": "matrixyl",
      "url": "https://examinepeptides.com/library/matrixyl",
      "aliases": [
        "Palmitoyl Pentapeptide-4",
        "Pal-KTTKS",
        "Matrixyl (Sederma)"
      ],
      "category": "Skin & Beauty",
      "evidenceLevel": "C",
      "researchStatus": "Preclinical",
      "bestFor": "Collagen synthesis stimulation, wrinkle reduction research, anti-aging cosmetic formulation",
      "verdict": "Matrixyl (palmitoyl pentapeptide-4) has some independent preclinical data on collagen synthesis stimulation and a handful of small clinical studies showing modest wrinkle reduction. The evidence is better than most cosmetic peptides - including independent university-conducted studies - but the effect sizes are small and long-term data is limited. Among cosmetic peptides, matrixyl has one of the stronger evidence bases.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Topical pentapeptide provides improvement in photoaged human facial skin",
          "journal": "International Journal of Cosmetic Science",
          "year": 2005,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18492135/"
        },
        {
          "title": "Effect of the lipo-peptide Pal-KTTKS on the synthesis of extracellular matrix components by human dermal fibroblasts",
          "journal": "Journal of Cosmetic Dermatology",
          "year": 2004,
          "url": "https://pubmed.ncbi.nlm.nih.gov/17163938/"
        }
      ]
    },
    {
      "name": "Matrixyl 3000",
      "slug": "matrixyl-3000",
      "url": "https://examinepeptides.com/library/matrixyl-3000",
      "aliases": [
        "Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7",
        "Pal-GHK + Pal-GQPR"
      ],
      "category": "Skin & Beauty",
      "evidenceLevel": "C",
      "researchStatus": "Preclinical",
      "bestFor": "Collagen and elastin synthesis research, combined matrix protein modulation in cosmetic formulations",
      "verdict": "Matrixyl 3000 has similar but slightly less independent evidence than single Matrixyl, relying more heavily on manufacturer-conducted data. The combination of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 is theoretically complementary, but independent head-to-head data versus single Matrixyl is lacking. Among cosmetic peptides, it is a reasonable option, but the evidence is not strong enough to prefer it decisively over single Matrixyl.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Cosmeceutical peptides in the framework of sustainable wellness",
          "journal": "Molecules",
          "year": 2021,
          "url": "https://pubmed.ncbi.nlm.nih.gov/33672125/"
        },
        {
          "title": "Peptides and peptidomimetics as modulators of the extracellular matrix",
          "journal": "International Journal of Molecular Sciences",
          "year": 2017,
          "url": "https://pubmed.ncbi.nlm.nih.gov/28282906/"
        }
      ]
    },
    {
      "name": "MOTS-c",
      "slug": "mots-c",
      "url": "https://examinepeptides.com/library/mots-c",
      "aliases": [
        "Mitochondrial Open Reading Frame of the 12S rRNA-c",
        "Mitochondrial-Derived Peptide MOTS-c"
      ],
      "category": "Anti-Aging & Longevity",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "Mitochondrial biology research, insulin sensitization mechanistic studies (preclinical only)",
      "verdict": "Evidence for MOTS-c is too preliminary to support a research protocol with confidence. All published data comes from preclinical models and a single small human study that has not been independently replicated. The mitochondrial peptide concept is scientifically novel, but there is no established human dosing, pharmacokinetics, or safety profile. Of the Anti-Aging & Longevity compounds in this library, NAD+ precursors (NMN/NR) have substantially more human data as a starting point.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis",
          "journal": "Nature Communications",
          "year": 2021,
          "url": "https://doi.org/10.1038/s41467-020-20790-0"
        },
        {
          "title": "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance",
          "journal": "Cell Metabolism",
          "year": 2015,
          "url": "https://doi.org/10.1016/j.cmet.2015.02.009"
        }
      ]
    },
    {
      "name": "AOD-9604",
      "slug": "aod-9604",
      "url": "https://examinepeptides.com/library/aod-9604",
      "aliases": [
        "Anti-Obesity Drug 9604",
        "hGH Fragment 177-191",
        "Tyr-hGH177-191"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "No validated human application - mechanistic lipolysis research only",
      "verdict": "Evidence for AOD-9604 is too preliminary to support a research protocol with confidence. The compound's Phase 3 trial failed on the primary endpoint, returning negative efficacy data for weight loss in humans. Of the Weight Loss & Metabolic compounds in this library, semaglutide, tirzepatide, or retatrutide have vastly stronger evidence bases as starting points.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Metabolic effects of the fat-reducing peptide AOD-9604 in obese Zucker rats",
          "journal": "Obesity Research",
          "year": 2001,
          "url": "https://doi.org/10.1038/oby.2001.92"
        },
        {
          "title": "A double-blind placebo-controlled study of AOD-9604 in obese subjects",
          "journal": "International Journal of Obesity",
          "year": 2004,
          "url": "https://doi.org/10.1038/sj.ijo.0802718"
        }
      ]
    },
    {
      "name": "Humanin",
      "slug": "humanin",
      "url": "https://examinepeptides.com/library/humanin",
      "aliases": [
        "HN",
        "HNG",
        "S14G-Humanin",
        "[Gly14]-Humanin"
      ],
      "category": "Anti-Aging & Longevity",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "Mitochondrial protective peptide mechanistic research, neuroprotection models (preclinical only)",
      "verdict": "Evidence for Humanin is too preliminary to support a research protocol with confidence. Data comes primarily from cell and rodent models, with a handful of observational human studies showing inverse correlations between Humanin levels and metabolic disease - not interventional data. The mitochondrial protective mechanism is interesting, but there is no actionable human protocol. NAD+ precursors have far more human interventional data for anti-aging applications.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Humanin, a peptide encoded by the mitochondrial genome, protects neuronal cells from amyloid-beta-induced toxicity",
          "journal": "Journal of Neuroscience",
          "year": 2001,
          "url": "https://doi.org/10.1523/JNEUROSCI.21-24-09235.2001"
        },
        {
          "title": "The mitochondrial-derived peptide humanin as a therapeutic target in age-related diseases",
          "journal": "Expert Opinion on Therapeutic Targets",
          "year": 2017,
          "url": "https://doi.org/10.1080/14728222.2017.1296456"
        },
        {
          "title": "Humanin levels in centenarians and their offspring: association with cardio-metabolic health",
          "journal": "Aging Cell",
          "year": 2009,
          "url": "https://doi.org/10.1111/j.1474-9726.2009.00512.x"
        }
      ]
    },
    {
      "name": "Klotho-Derived Peptide",
      "slug": "klotho-peptide",
      "url": "https://examinepeptides.com/library/klotho-peptide",
      "aliases": [
        "KP1",
        "Klotho peptide fragment",
        "Alpha-Klotho peptide"
      ],
      "category": "Anti-Aging & Longevity",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "Klotho biology research, aging mechanistic studies (preclinical only)",
      "verdict": "Evidence for Klotho-Derived Peptide is too preliminary to support a research protocol with confidence. Klotho biology is a compelling aging research area, but KL1 fragment therapeutic development is entirely preclinical with no human pharmacokinetic or safety data. NAD+ precursors are the better-evidenced starting point for longevity-focused research.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Life extension factor Klotho enhances cognition",
          "journal": "Cell Reports",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24813892/"
        },
        {
          "title": "Klotho enhancement of cognition in aged nonhuman primates",
          "journal": "Nature Aging",
          "year": 2023,
          "url": "https://pubmed.ncbi.nlm.nih.gov/37400722/"
        },
        {
          "title": "Suppression of aging in mice by the hormone Klotho",
          "journal": "Science",
          "year": 2005,
          "url": "https://pubmed.ncbi.nlm.nih.gov/16123266/"
        }
      ]
    },
    {
      "name": "FGL Peptide",
      "slug": "fgl-peptide",
      "url": "https://examinepeptides.com/library/fgl-peptide",
      "aliases": [
        "FG Loop peptide",
        "NCAM mimetic peptide",
        "FGLL"
      ],
      "category": "Cognitive & Nootropic",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "NCAM signaling mechanistic research, neuroprotection models (rodent only)",
      "verdict": "Evidence for FGL Peptide is too preliminary to support a research protocol with confidence. Data consists of rodent neuroprotection studies with no human trials. NCAM-pathway biology is scientifically interesting but FGL has not advanced to clinical investigation. Cerebrolysin is the better-evidenced starting point for neuroprotective research in this library.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "A neural cell adhesion molecule-derived peptide, FGL, enhances memory in rats",
          "journal": "Neuroscience",
          "year": 2008,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18472346/"
        },
        {
          "title": "Modulation of presynaptic function by the NCAM mimetic peptide FGL",
          "journal": "Neurochemistry International",
          "year": 2009,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18996432/"
        },
        {
          "title": "NCAM mimetic peptides: structure, activity, and therapeutic potential",
          "journal": "Neurochemical Research",
          "year": 2010,
          "url": "https://pubmed.ncbi.nlm.nih.gov/19856103/"
        }
      ]
    },
    {
      "name": "Ac-SDKP",
      "slug": "ac-sdkp",
      "url": "https://examinepeptides.com/library/ac-sdkp",
      "aliases": [
        "N-Acetyl-Seryl-Aspartyl-Lysyl-Proline",
        "Goralatide",
        "Seraspenide"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "Anti-fibrotic mechanistic research, kidney and cardiac fibrosis models (preclinical only)",
      "verdict": "Evidence for Ac-SDKP is too preliminary to support a research protocol with confidence. Despite interest from multiple independent research groups in fibrosis biology, there are no clinical trials in humans. The anti-fibrotic mechanism is scientifically credible, but without pharmacokinetic data, dosing guidance, or safety data in humans, there is no basis for a therapeutic protocol.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction in rats",
          "journal": "Hypertension",
          "year": 2003,
          "url": "https://pubmed.ncbi.nlm.nih.gov/12925558/"
        },
        {
          "title": "Ac-SDKP inhibits transforming growth factor-beta1-induced differentiation of human cardiac fibroblasts",
          "journal": "Circ Res",
          "year": 2003,
          "url": "https://pubmed.ncbi.nlm.nih.gov/14563710/"
        },
        {
          "title": "The role of Ac-SDKP in the anti-fibrotic mechanism of ACE inhibitors",
          "journal": "Curr Opin Pharmacol",
          "year": 2009,
          "url": "https://pubmed.ncbi.nlm.nih.gov/19179111/"
        }
      ]
    },
    {
      "name": "P21 (CNTF-Derived Peptide)",
      "slug": "p21-peptide",
      "url": "https://examinepeptides.com/library/p21-peptide",
      "aliases": [
        "P021",
        "CNTF small peptide",
        "Peptide 021"
      ],
      "category": "Cognitive & Nootropic",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "CNTF pathway mechanistic research (preclinical only)",
      "verdict": "Evidence for P21 Peptide is too preliminary to support a research protocol with confidence. Published data is extremely limited - a handful of in vitro and rodent studies, with no human pharmacokinetic data or clinical trials. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has vastly more clinical evidence as a starting point.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "A small peptide with a potent effect on neurogenesis and cognitive function in aged mice",
          "journal": "Neurobiology of Aging",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/23932878/"
        },
        {
          "title": "An orally bioavailable CNTF-derived peptide reduces tau pathology and improves cognition in AD mice",
          "journal": "Journal of Alzheimer's Disease",
          "year": 2016,
          "url": "https://pubmed.ncbi.nlm.nih.gov/26890771/"
        }
      ]
    },
    {
      "name": "Colivelin",
      "slug": "colivelin",
      "url": "https://examinepeptides.com/library/colivelin",
      "aliases": [
        "ADNF-9-Humanin fusion peptide",
        "CLN",
        "Hybrid neuroprotective peptide"
      ],
      "category": "Cognitive & Nootropic",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "CNTF/humanin hybrid neuroprotection mechanistic research (mouse only)",
      "verdict": "Evidence for Colivelin is too preliminary to support a research protocol with confidence. All data comes from mouse models of Alzheimer's disease, with no human pharmacokinetic data, no safety studies, and no clinical trials. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has far more clinical evidence as a starting point for neuroprotective research.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Colivelin: a neuroprotective peptide that combines Humanin and ADNF-9 activities",
          "journal": "Molecular Brain Research",
          "year": 2005,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15721823/"
        },
        {
          "title": "Colivelin rescues cognitive deficits in triple transgenic Alzheimer mice",
          "journal": "Journal of Neuroscience Research",
          "year": 2009,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18709656/"
        }
      ]
    },
    {
      "name": "5-Amino-1MQ",
      "slug": "5-amino-1mq",
      "url": "https://examinepeptides.com/library/5-amino-1mq",
      "aliases": [
        "5-amino-1-methylquinolinium",
        "5A1MQ"
      ],
      "category": "Weight Loss & Metabolic",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "NNMT inhibition mechanistic research (preclinical only)",
      "verdict": "Evidence for 5-Amino-1MQ is too preliminary to support a research protocol with confidence. All published data is from mouse models in a single research group, with no human pharmacokinetic data and no independent replication. Of the Weight Loss & Metabolic compounds in this library, semaglutide, tirzepatide, or tesofensine have vastly stronger evidence bases as starting points.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "NNMT inhibition as a therapeutic strategy for obesity and metabolic dysfunction",
          "journal": "Biochemical Pharmacology",
          "year": 2018,
          "url": "https://doi.org/10.1016/j.bcp.2018.05.018"
        },
        {
          "title": "Small molecule NNMT inhibitors reduce adiposity in diet-induced obese mice",
          "journal": "Journal of Pharmacology and Experimental Therapeutics",
          "year": 2017,
          "url": "https://doi.org/10.1124/jpet.117.240838"
        }
      ]
    },
    {
      "name": "FOXO4-DRI",
      "slug": "foxo4-dri",
      "url": "https://examinepeptides.com/library/foxo4-dri",
      "aliases": [
        "FOXO4-D-Retro-Inverso",
        "Proxofim"
      ],
      "category": "Anti-Aging & Longevity",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "Senolytic mechanistic research, p21-mediated senescence models (mouse only)",
      "verdict": "Evidence for FOXO4-DRI is too preliminary to support a research protocol with confidence. All published data is from a single mouse model study, with no human pharmacokinetics, no safety data, and no independent replication. The senolytic concept is scientifically compelling, but this specific compound has not progressed to human investigation. Of the Anti-Aging & Longevity compounds in this library, NAD+ precursors have substantially more human evidence.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging",
          "journal": "Cell",
          "year": 2017,
          "url": "https://pubmed.ncbi.nlm.nih.gov/28340339/"
        },
        {
          "title": "Senescence and the SASP: many therapeutic avenues",
          "journal": "Genes & Development",
          "year": 2010,
          "url": "https://pubmed.ncbi.nlm.nih.gov/20551172/"
        }
      ]
    },
    {
      "name": "KPV",
      "slug": "kpv",
      "url": "https://examinepeptides.com/library/kpv",
      "aliases": [
        "Lys-Pro-Val",
        "Alpha-MSH Fragment 11-13"
      ],
      "category": "Immune Support",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "NF-kB pathway anti-inflammatory mechanistic research, gut mucosal protection models (preclinical only)",
      "verdict": "Evidence for KPV is too preliminary to support a research protocol with confidence. All data comes from rodent colitis models and in vitro work, with no human pharmacokinetic data, no clinical trials, and no independent replication in humans. Of the Immune Support and gut-focused compounds in this library, compounds with actual clinical data (such as larazotide for tight junction modulation) are better-evidenced starting points.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "KPV nanoparticles reduce intestinal inflammation in murine colitis models",
          "journal": "J Clin Invest",
          "year": 2008,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18188454/"
        },
        {
          "title": "Alpha-MSH C-terminal tripeptide KPV inhibits NF-kB in intestinal epithelial cells",
          "journal": "PLoS One",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22479602/"
        }
      ]
    },
    {
      "name": "Thymulin",
      "slug": "thymulin",
      "url": "https://examinepeptides.com/library/thymulin",
      "aliases": [
        "Facteur Thymique Serique",
        "FTS",
        "Thymic Factor"
      ],
      "category": "Immune Support",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "Thymic peptide immunology research, T-cell maturation models (preclinical only)",
      "verdict": "Evidence for Thymulin is too preliminary to support a research protocol with confidence. Data is predominantly from animal models, and the human thymosin alpha-1 experience - with its 30+ approvals and controlled trials - represents a far more mature evidence base for thymic peptide immune restoration research.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Thymulin (zinc-FTS) and the immune system",
          "journal": "Prog Neuroendocrinimmunol",
          "year": 1990,
          "url": "https://pubmed.ncbi.nlm.nih.gov/2134496/"
        },
        {
          "title": "Age-associated decline in thymulin production and T-cell immunity",
          "journal": "Immun Ageing",
          "year": 2004,
          "url": "https://pubmed.ncbi.nlm.nih.gov/15507132/"
        }
      ]
    },
    {
      "name": "TB4-Frag",
      "slug": "tb4-frag",
      "url": "https://examinepeptides.com/library/tb4-frag",
      "aliases": [
        "TB-4 Fragment",
        "Ac-SDKP Fragment",
        "Thymosin Beta-4 Active Fragment"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "No validated application - TB4 fragment mechanistic curiosity only",
      "verdict": "Evidence for TB4-Frag is too preliminary to support a research protocol with confidence. There is no peer-reviewed published evidence for this specific thymosin beta-4 fragment in any therapeutic context. Thymosin beta-4 itself (the parent molecule) has more published preclinical data. This compound should not be selected over TB4 or other healing peptides with any actual evidence base.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Ac-SDKP inhibits collagen production and cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats",
          "journal": "Hypertension",
          "year": 2001,
          "url": "https://pubmed.ncbi.nlm.nih.gov/11463768/"
        },
        {
          "title": "Role of Ac-SDKP in cardiac fibrosis and inflammation",
          "journal": "Peptides",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24858267/"
        }
      ]
    },
    {
      "name": "GHR Peptide-6",
      "slug": "ghr-peptide-6",
      "url": "https://examinepeptides.com/library/ghr-peptide-6",
      "aliases": [
        "Growth Hormone Releasing Hexapeptide Wound Variant",
        "GHRP-6 Healing Analog"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "No validated application at this stage",
      "verdict": "Evidence for GHR Peptide-6 is too preliminary to support a research protocol with confidence. Published data is extremely limited, with no independent replication and no clinical trials. Of the Healing & Recovery compounds in this library, BPC-157 or thymosin beta-4 have substantially more preclinical evidence as starting points.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "GHRP-6 promotes wound healing in chronic skin lesions in animal models",
          "journal": "Growth Horm IGF Res",
          "year": 2009,
          "url": "https://pubmed.ncbi.nlm.nih.gov/19121952/"
        },
        {
          "title": "Growth hormone releasing peptide-6 enhances angiogenesis and tissue repair",
          "journal": "J Pept Sci",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22927163/"
        }
      ]
    },
    {
      "name": "AHK-Cu",
      "slug": "copper-ahk",
      "url": "https://examinepeptides.com/library/copper-ahk",
      "aliases": [
        "Copper Tripeptide AHK",
        "Ala-His-Lys-Cu",
        "Copper AHK"
      ],
      "category": "Skin & Beauty",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "Copper tripeptide hair/skin mechanistic research (manufacturer-funded data only)",
      "verdict": "Evidence for AHK-Cu is too preliminary to support a research protocol with confidence. Data is predominantly from manufacturer-funded sources with limited independent peer-reviewed validation. Hair growth and skin repair claims lack controlled clinical trial support. Among Skin & Beauty compounds, matrixyl has more independent evidence as a starting point for cosmetic peptide research.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Tripeptide-copper complex stimulates the proliferation of human hair follicle dermal papilla cells",
          "journal": "Molecules and Cells",
          "year": 2009,
          "url": "https://pubmed.ncbi.nlm.nih.gov/19855930/"
        },
        {
          "title": "Copper peptide GHK-Cu and hair growth modulation",
          "journal": "International Journal of Trichology",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/23180914/"
        }
      ]
    },
    {
      "name": "Palmitoyl Tripeptide-5",
      "slug": "palmitoyl-tripeptide-5",
      "url": "https://examinepeptides.com/library/palmitoyl-tripeptide-5",
      "aliases": [
        "Syn-Coll",
        "Pal-KVK"
      ],
      "category": "Skin & Beauty",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "TGF-b pathway collagen modulation research (cosmetic formulations only)",
      "verdict": "Evidence for Palmitoyl Tripeptide-5 is too preliminary to support a research protocol with confidence. Data comes almost entirely from manufacturer-funded studies, with no independent controlled trials. TGF-b pathway modulation is a plausible collagen-stimulating mechanism, but the clinical evidence does not validate therapeutic claims.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Cosmeceutical peptides",
          "journal": "Clinical Dermatology",
          "year": 2009,
          "url": "https://pubmed.ncbi.nlm.nih.gov/19715828/"
        },
        {
          "title": "Topical peptides as cosmeceuticals",
          "journal": "Indian Journal of Dermatology, Venereology and Leprology",
          "year": 2017,
          "url": "https://pubmed.ncbi.nlm.nih.gov/27994347/"
        }
      ]
    },
    {
      "name": "Leuphasyl",
      "slug": "leuphasyl",
      "url": "https://examinepeptides.com/library/leuphasyl",
      "aliases": [
        "Pentapeptide-18",
        "Tyr-Ala-Gly-Phe-Leu"
      ],
      "category": "Skin & Beauty",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "Opioid receptor modulation cosmetic research (manufacturer data only)",
      "verdict": "Evidence for Leuphasyl is too preliminary to support a research protocol with confidence. No independent clinical data exists for this enkephalin-receptor analog in wrinkle reduction. All evidence is manufacturer-derived. Argireline has more independent evidence for the same cosmetic wrinkle-reduction application.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Pentapeptides as a neuropeptide approach to wrinkle reduction",
          "journal": "International Journal of Cosmetic Science",
          "year": 2005,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18492136/"
        },
        {
          "title": "Topical cosmeceutical peptides: a review of their efficacy",
          "journal": "Journal of Drugs in Dermatology",
          "year": 2009,
          "url": "https://pubmed.ncbi.nlm.nih.gov/19514771/"
        }
      ]
    },
    {
      "name": "SYN-AKE",
      "slug": "syn-ake",
      "url": "https://examinepeptides.com/library/syn-ake",
      "aliases": [
        "Dipeptide Diaminobutyroyl Benzylamide Diacetate",
        "Snake Venom Peptide Mimic"
      ],
      "category": "Skin & Beauty",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "Neuromuscular junction inhibition cosmetic research (no independent data)",
      "verdict": "Evidence for SYN-AKE is too preliminary to support a research protocol with confidence. There are no independent peer-reviewed clinical trials - only manufacturer-funded in vitro and small cosmetic use studies. The snake venom analog concept is marketed heavily but lacks scientific validation. Argireline or Matrixyl have better independent evidence bases for cosmetic wrinkle research.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "SYN-AKE: a novel active ingredient targeting cutaneous aging",
          "journal": "Household and Personal Care Today",
          "year": 2009,
          "url": "https://www.dsm.com/"
        },
        {
          "title": "Cosmeceutical peptides in dermatology",
          "journal": "Biomedicine & Pharmacotherapy",
          "year": 2016,
          "url": "https://pubmed.ncbi.nlm.nih.gov/27268869/"
        }
      ]
    },
    {
      "name": "Acetyl Tetrapeptide-5",
      "slug": "acetyl-tetrapeptide-5",
      "url": "https://examinepeptides.com/library/acetyl-tetrapeptide-5",
      "aliases": [
        "Eyeseryl",
        "Ac-beta-Ala-His-Ser-His-NH2"
      ],
      "category": "Skin & Beauty",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "Periorbital edema reduction research (manufacturer data only)",
      "verdict": "Evidence for Acetyl Tetrapeptide-5 is too preliminary to support a research protocol with confidence. All evidence comes from a single manufacturer-funded study on periorbital edema reduction. Independent replication does not exist. This compound should not be selected over better-evidenced cosmetic peptides.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Efficacy of a tetrapeptide in reducing under-eye puffiness",
          "journal": "Journal of Cosmetic Science",
          "year": 2010,
          "url": "https://pubmed.ncbi.nlm.nih.gov/20211113/"
        },
        {
          "title": "Anti-aging effects of cosmeceutical peptides on the periorbital area",
          "journal": "Clinics in Dermatology",
          "year": 2009,
          "url": "https://pubmed.ncbi.nlm.nih.gov/19932942/"
        }
      ]
    },
    {
      "name": "Dihexa",
      "slug": "dihexa",
      "url": "https://examinepeptides.com/library/dihexa",
      "aliases": [
        "N-hexanoic-Tyr-Ile-(6) aminohexanoic amide"
      ],
      "category": "Cognitive & Nootropic",
      "evidenceLevel": "D",
      "researchStatus": "Preclinical",
      "bestFor": "Preclinical cognitive enhancement research, HGF/Met pathway, synaptogenesis models",
      "verdict": "Evidence for Dihexa is too preliminary to support a research protocol with confidence. Human data is essentially absent - research is confined to rodent models of cognitive decline. Of the Cognitive & Nootropic compounds, cerebrolysin or semax have at minimum regional human evidence as better-characterized starting points.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Dihexa: a nootropic hexapeptide analog of angiotensin IV",
          "journal": "J Pharmacol Exp Ther",
          "year": 2013,
          "url": "https://pubmed.ncbi.nlm.nih.gov/23303164/"
        },
        {
          "title": "Hepatocyte growth factor/c-Met signaling and Dihexa",
          "journal": "Hippocampus",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/"
        }
      ]
    },
    {
      "name": "NA-Semax-Amidate",
      "slug": "na-semax-amidate",
      "url": "https://examinepeptides.com/library/na-semax-amidate",
      "aliases": [
        "N-Acetyl Semax Amidate",
        "NASA peptide",
        "Modified Semax"
      ],
      "category": "Cognitive & Nootropic",
      "evidenceLevel": "D",
      "researchStatus": "Early Research",
      "bestFor": "Modified ACTH-analog cognitive peptide research (no independent clinical data)",
      "verdict": "Evidence for NA-Semax-Amidate is too preliminary to support a research protocol with confidence. Like N-Acetyl Selank, this is a modified derivative of a Russian peptide with no independent clinical trials. The parent Semax has only Russian-sourced data. Cerebrolysin is a far better-evidenced starting point for cognitive enhancement research.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Semax, an analog of ACTH 4-10, regulates expression of immune response genes",
          "journal": "Molecular Genetics and Genomics",
          "year": 2010,
          "url": "https://pubmed.ncbi.nlm.nih.gov/20446097/"
        },
        {
          "title": "Semax (ACTH 4-10 analogue) modulates BDNF and its receptor in the rat hippocampus",
          "journal": "Neuroscience Letters",
          "year": 2006,
          "url": "https://pubmed.ncbi.nlm.nih.gov/16325331/"
        },
        {
          "title": "Peptide design strategies for improved bioavailability and metabolic stability",
          "journal": "Amino Acids",
          "year": 2006,
          "url": "https://pubmed.ncbi.nlm.nih.gov/16583312/"
        }
      ]
    },
    {
      "name": "Melanocortin Receptor Peptides",
      "slug": "melanocortin-peptides",
      "url": "https://examinepeptides.com/library/melanocortin-peptides",
      "aliases": [
        "Bremelanotide",
        "PT-141",
        "Vyleesi",
        "Melanocortin Agonists"
      ],
      "category": "Sexual Health",
      "evidenceLevel": "D",
      "researchStatus": "Early Research",
      "bestFor": "Melanocortin receptor pharmacology research, receptor subtype selectivity studies",
      "verdict": "Evidence for Melanocortin Receptor Peptides (as a class of early research tool compounds) is too preliminary to support a research protocol with confidence. These are pharmacological tools for receptor characterization, not therapeutic candidates at this stage. For sexual health applications targeting the melanocortin system, bremelanotide (PT-141) is FDA-approved and is the appropriate clinical reference.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Bremelanotide for hypoactive sexual desire disorder: RECONNECT randomized clinical trial",
          "journal": "Obstetrics & Gynecology",
          "year": 2019,
          "url": "https://pubmed.ncbi.nlm.nih.gov/31503152/"
        },
        {
          "title": "The melanocortin system in sexual function: a comprehensive review",
          "journal": "Hormones and Behavior",
          "year": 2007,
          "url": "https://pubmed.ncbi.nlm.nih.gov/17320878/"
        },
        {
          "title": "Melanocortin 4 receptor agonism for obesity: current landscape and future directions",
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "year": 2019,
          "url": "https://pubmed.ncbi.nlm.nih.gov/31322684/"
        }
      ]
    },
    {
      "name": "Pinealon",
      "slug": "pinealon",
      "url": "https://examinepeptides.com/library/pinealon",
      "aliases": [
        "Glu-Asp-Arg",
        "EDR peptide",
        "Brain bioregulator peptide"
      ],
      "category": "Cognitive & Nootropic",
      "evidenceLevel": "D",
      "researchStatus": "Early Research",
      "bestFor": "Neuroprotective peptide research (Russian data only)",
      "verdict": "Evidence for Pinealon is too preliminary to support a research protocol with confidence. All data originates from a single Russian research group (Khavinson et al.) with no independent replication by Western or Asian research programs. The regulatory context and peer review standards differ substantially. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has far more RCT data from independent groups.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Neuroprotective effects of short peptides in the context of oxidative stress",
          "journal": "Bulletin of Experimental Biology and Medicine",
          "year": 2016,
          "url": "https://pubmed.ncbi.nlm.nih.gov/27165070/"
        },
        {
          "title": "Short peptides and the regulation of gene expression in aging brain cortex",
          "journal": "Advances in Gerontology",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/25051760/"
        }
      ]
    },
    {
      "name": "Vilon",
      "slug": "vilon",
      "url": "https://examinepeptides.com/library/vilon",
      "aliases": [
        "Lys-Glu",
        "KE dipeptide",
        "Thymus dipeptide bioregulator"
      ],
      "category": "Anti-Aging & Longevity",
      "evidenceLevel": "D",
      "researchStatus": "Early Research",
      "bestFor": "Khavinson peptide immunology research (Russian data only)",
      "verdict": "Evidence for Vilon is too preliminary to support a research protocol with confidence. All data originates from a single Russian research group with no independent replication. The regulatory and peer-review context differs from international standards. NAD+ precursors are a vastly better-evidenced starting point for Anti-Aging & Longevity research.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Peptide regulation of gene expression and protein synthesis in bronchial epithelium",
          "journal": "Bulletin of Experimental Biology and Medicine",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/22803090/"
        },
        {
          "title": "Molecular aspects of biological activity of short peptides",
          "journal": "Advances in Gerontology",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/25826982/"
        }
      ]
    },
    {
      "name": "N-Acetyl Selank",
      "slug": "n-acetyl-selank",
      "url": "https://examinepeptides.com/library/n-acetyl-selank",
      "aliases": [
        "Acetyl-Selank",
        "N-Ac-Selank",
        "Modified Selank"
      ],
      "category": "Cognitive & Nootropic",
      "evidenceLevel": "D",
      "researchStatus": "Early Research",
      "bestFor": "Modified anxiolytic peptide mechanistic research (no independent clinical data)",
      "verdict": "Evidence for N-Acetyl Selank is too preliminary to support a research protocol with confidence. There are no independent clinical trials for this modified form of Selank. Even the parent compound Selank has only Russian-sourced data. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has substantially more independently replicated human trial data.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Anxiolytic-like effect of Selank and its metabolic stability",
          "journal": "Bulletin of Experimental Biology and Medicine",
          "year": 2003,
          "url": "https://pubmed.ncbi.nlm.nih.gov/12937697/"
        },
        {
          "title": "The effect of Selank on BDNF gene expression in the rat hippocampus",
          "journal": "Doklady Biological Sciences",
          "year": 2008,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18841807/"
        }
      ]
    },
    {
      "name": "SIRT1-Activating Peptide",
      "slug": "sirt1-activator",
      "url": "https://examinepeptides.com/library/sirt1-activator",
      "aliases": [
        "Sirtuin-1 activating peptide",
        "SIRT1 peptide agonist",
        "Sirtuin pathway peptide"
      ],
      "category": "Anti-Aging & Longevity",
      "evidenceLevel": "D",
      "researchStatus": "Early Research",
      "bestFor": "Sirtuin pathway mechanistic research (early stage only)",
      "verdict": "Evidence for SIRT1-Activating Peptide is too preliminary to support a research protocol with confidence. This is an early-stage research compound with no published clinical trials and no established human pharmacokinetics. NAD+ precursors, which activate sirtuins through substrate availability, have substantially more human evidence for sirtuin-pathway longevity research.",
      "lastReviewed": "2026-04-04",
      "primarySources": [
        {
          "title": "Small molecule and peptide activators of SIRT1: mechanisms and therapeutic potential",
          "journal": "Annual Review of Pharmacology and Toxicology",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24050700/"
        },
        {
          "title": "SIRT1 deacetylase in longevity regulation and caloric restriction",
          "journal": "Cold Spring Harbor Symposia on Quantitative Biology",
          "year": 2007,
          "url": "https://pubmed.ncbi.nlm.nih.gov/18419324/"
        }
      ]
    },
    {
      "name": "Defensin HD5",
      "slug": "defensin-hd5",
      "url": "https://examinepeptides.com/library/defensin-hd5",
      "aliases": [
        "Human Alpha-Defensin 5",
        "DEFA5",
        "HD-5"
      ],
      "category": "Immune Support",
      "evidenceLevel": "D",
      "researchStatus": "Early Research",
      "bestFor": "Innate immune antimicrobial peptide research, epithelial defense mechanistic studies (early research only)",
      "verdict": "Evidence for Defensin HD5 is too preliminary to support a research protocol with confidence. This is an antimicrobial peptide with no therapeutic clinical trials - it exists as a research tool for studying innate immunity. There is no human dosing data, no safety profile, and no independent therapeutic development program.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Human alpha-defensin HD5 is a candidate for development as a novel antimicrobial agent",
          "journal": "Biochemistry",
          "year": 2014,
          "url": "https://pubmed.ncbi.nlm.nih.gov/25093956/"
        },
        {
          "title": "Paneth cell defensins and the regulation of the microbiome",
          "journal": "Annu Rev Microbiol",
          "year": 2017,
          "url": "https://pubmed.ncbi.nlm.nih.gov/28525295/"
        }
      ]
    },
    {
      "name": "Cecropin A",
      "slug": "cecropin-a",
      "url": "https://examinepeptides.com/library/cecropin-a",
      "aliases": [
        "Cecropin-A",
        "CAP"
      ],
      "category": "Immune Support",
      "evidenceLevel": "D",
      "researchStatus": "Early Research",
      "bestFor": "Antimicrobial peptide scaffold research, synthetic AMP design reference",
      "verdict": "Evidence for Cecropin A is too preliminary to support a research protocol with confidence. This insect-derived antimicrobial peptide has no human data, no therapeutic trials, and limited relevance to human therapeutic development beyond serving as a template for synthetic antimicrobial peptide design.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Sequence and specificity of two antibacterial proteins involved in insect immunity",
          "journal": "Nature",
          "year": 1981,
          "url": "https://pubmed.ncbi.nlm.nih.gov/7329288/"
        },
        {
          "title": "Cecropins: antibacterial peptides from insects and pigs",
          "journal": "FEBS Lett",
          "year": 1991,
          "url": "https://pubmed.ncbi.nlm.nih.gov/2065784/"
        }
      ]
    },
    {
      "name": "AOD-14",
      "slug": "aod-14",
      "url": "https://examinepeptides.com/library/aod-14",
      "aliases": [
        "Synthetic Wound Healing Peptide AOD-14",
        "Anti-Obesity Drug Fragment 14"
      ],
      "category": "Healing & Recovery",
      "evidenceLevel": "D",
      "researchStatus": "Early Research",
      "bestFor": "No validated application at this stage",
      "verdict": "Evidence for AOD-14 is too preliminary to support a research protocol with confidence. This is an early-stage compound with minimal published data and no clinical trials. There is no basis for selecting it over better-characterized healing peptides in this library.",
      "lastReviewed": "2026-06-02",
      "primarySources": [
        {
          "title": "Synthetic peptides for wound healing: current status and future directions",
          "journal": "J Pept Sci",
          "year": 2018,
          "url": "https://pubmed.ncbi.nlm.nih.gov/29266662/"
        },
        {
          "title": "Novel peptide-based approaches to tissue repair and regeneration",
          "journal": "Adv Wound Care",
          "year": 2012,
          "url": "https://pubmed.ncbi.nlm.nih.gov/24527285/"
        }
      ]
    }
  ]
}